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ABSTRACT

Objectives
The objectives were to 1) examine adherence to multiple medications prescribed for a
chronic disease (intra-disease multiple medication adherence) and that of multiple chronic
diseases (inter-disease multiple medication adherence); 2) determine appropriate measurement
paradigm from different intra-disease multiple medication adherence measurement approaches;
3) identify optimal cut-point for a dichotomized composite measure.

Methods
A retrospective study design was used. The subjects came from the MarketScan®
Commercial Claims and Encounters data 2002-2003 and filled both sulfonylurea (SU) and
thiazolidinedione (TZD). Adherence was measured by proportion of days covered (PDC) over
each period of 30 or 90 days and cumulatively. Random components from multivariate
multilevel models were analyzed to examine multiple medication adherence relationships,
including associations of evolutions of adherence. Survival analysis was performed on anycause or diabetes-related emergency services (ER) utilization. Concordance statistics were
computed to compare different measurement approaches.
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Results
Intra-disease multiple medication analysis demonstrated strong and significant (p<0.05)
relationships between overall adherence estimates for SU and TZD and changes in adherence
estimates over time. Patients who were receiving lipid or hypertension medications, or both in
addition to SU and TZD showed strong and significant (p<0.05) relationships between overall
adherence to cross-disease medications or cross-disease adherence slope estimates. However,
such results were not observed in diabetic subjects who were prescribed nitrates for angina.
Each of six composite measures of intra-disease multiple medication adherence
significantly predicted hazard (hazard ratio <1.0) of all-cause or any diabetes-related ER
utilization. Although each concordance statistic was significant (p<0.05), there were no
differences among concordance statistics produced by these measurement approaches. The
average and all approach showed some superiority. The optimality of cut-point for categorizing
adherence based on a composite measure of intra-disease multiple medication adherence ranged
from 75-85%.

Conclusion
The study population demonstrated good but not optimal levels of adherence to multiple
chronic disease medications. Factors that affect adherence to individual medications appear to
be related and should be targeted for intervention. Efficacy of a composite measure of intradisease multiple medications may depend on intervention goals. Further research needs to
identify a composite measurement approach that demonstrates superiority in predictive and
discriminatory power consistently.
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CHAPTER 1
INTRODUCTION
Chronic Diseases and Its Implication
The disease-related pharmaceutical market landscape has been evolving for the last few
decades. This evolution is characterized primarily by marked changes in incidence and
prevalence, and thus importance, of chronic diseases. According to the Centers for Disease
Control and Prevention (CDC), chronic diseases such as cancer, diabetes, heart disorders, stroke,
and arthritis are among the most common, expensive, and preventable of all health problems in
the U.S. The number of patients with at least one chronic disease is growing in America and
projected to rise to 164 million by 2025 (Wu and Green, 2000). Chronic diseases have
associated with them significant implications. For example, seven out of 10 deaths annually
among Americans occur from chronic diseases; heart disease, cancer, and stroke account for
more than 50% of all deaths each year (Kung et al., 2008). Moreover, chronic disease patients
are likely to consume health care resources frequently because of the nature of care they require.

Chronic comorbidities
It is undeniable that the situation facing the healthcare system today is dire because of the
increasing prevalence of chronic diseases in the U.S. population. However, the chronic disease
crisis looms even larger for tomorrow. It is imperative that chronic diseases be managed
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appropriately. Additionally, the challenge associated with the management of chronic disease is
compounded because many of these patients experience two or more chronic diseases
simultaneously (multiple comorbidities). In fact, a consistent pattern has been found currently
such that many individuals present to the healthcare system with multiple coexisting diseases
(Starfield, 2006). In the U.S., the number of patients with multiple comorbidities has been
estimated to increase from 60 million in 2000 to 81 million by 2020 (Mollica and Gillespie,
2003). This growth in comorbidities is not confined to any specific segment of population or
geographic region. The National Center for Health Statistics (NCHS) reported that 7% of adults
of 45–54 years of age, 30% of low income adults of 55–64 years of age, and 37% of adults of 75
years of age and over had three or more chronic conditions in 2005 (NCHS, 2007). Moreover,
not all chronic disease necessarily have symptoms associated with them and they may remain
undiagnosed. Approximately 10% and 8% of U.S. adults of 20–64 years of age were reported to
have undiagnosed high cholesterol and elevated blood pressure, respectively in 1999–2004
(NCHS, 2007). Thus, it is possible that many chronic disease patients, at some point in time,
may be suffering from comorbidities the number of which may exceed current estimates.
The impact of chronic disease and multiple morbidities on the U.S. healthcare system is
not trivial. This is so partly because of an increase in number of the elderly population apart
from some of the reasons discussed above. In the U.S., about 80% of Medicare spending is
devoted to patients with four or more chronic conditions and costs increase exponentially as
number of chronic conditions increases (Wolff, Starfield, and Anderson, 2002). Health care
managers increasingly have had to deploy additional resources toward the management of
chronic diseases and specifically, multiple comorbidities. This confluence of events has led to a
growing interest on the part of researchers and practitioners in the impact of comorbidity on
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health outcomes, including mortality, health-related quality of life, and quality of health care
(Fortin et al., 2007; Ritchie, 2007).

Chronic Disease Treatment and Outcomes
Treatment Trend
Prescription drug utilization in the U.S. has experienced a significant change over the last
decade. Lundy (2010) reported that from 1999 to 2009, the number of prescriptions dispensed
increased by 39% compared to a U.S. population growth of only 9%.In addition, the average
number of retail prescriptions per capita grew by approximately 25% during the same period.
These findings, at a minimum, suggest that prescription medications are being utilized for the
treatment of diseases at an increasing rate.
In addition to an overall increase in medication use, the pattern of medication use unfolds
an interesting trend. Physicians frequently recommend multiple therapies for the treatment of
chronic disease. This trend – oftentimes described by treatment intensification or therapy
augmentation – is prevalent largely in chronic disease management and has been facilitated by
the availability of new products and product classes. Until the early 1990s, U.S. prescribers had
only two anti-diabetic drug classes (i.e., insulins and sulfonylureas (SU)) to treat hyperglycemia
associated with type 2 diabetes. Several new classes of oral anti-diabetic medications (OAD)
such as metformin, acarbose, thiazolidinediones (TZD) (pioglitazone and rosiglitazone)were
introduced to the U.S. market from 1995 to 1999. The availability of multiple therapeutic
options gave physicians the opportunity to manage diabetes in ways that directly influenced
glycemic control and the underlying disease pathophysiology. The CDC estimated that 14% of
adult diabetes patients were using insulin and at least one oral medication for diabetes (CDC
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National Diabetes Fact Sheet 2011). Other anti-diabetic medications that were introduced
relatively recently, including glucagon-like peptide-1 (GLP-1) analogues, dipeptidyl peptidase-4
(DPP-4) inhibitors, and lispro insulin are gaining in popularity and more importantly, many
products including new product classes are currently under development (Nguyen et al., 2011).
Thus, it is not surprising that antihyperglycemic prescription patterns in the U.S. have changed in
the last decade. The trend has included an increasing use of multiple medication regimens
(Cohen et al., 2003).
The practice of intensive treatment is advocated in other chronic diseases. For example,
an aggressive management of hypertension has been recommended for some patients in the U.S
(Leeper 2005; Mustone-Alexander, 2006). As a result, multiple medication regimens are
prescribed initially or in response to poor outcomes. This practice may have provided the
impetus for two-medication combination products; in fact, a combination product of three antihypertensive drugs exists in the market (e.g., Exforge HCT). Interestingly, the use of
combination of antihypertensive therapies (i.e., use of ≥2 antihypertensive medication classes)
was higher in the U.S. when compared against European countries (Wang et al., 2007).
Similarly, multiple medication regimens are the treatment norm in other chronic conditions
including those in which multiple classes of medications are prescribed. For example, a number
of pharmacological agents are prescribed to treat the underlying causal factors, including
hypertension, coronary artery disease, and dyslipidemia in patients with heart failure. Wong et
al. (2011a) reported that there has been a significant change in heart failure patient characteristics
over the last two decades; along with an increasing number of comorbidities, the mean number
of prescription medications has grown from 4.1 to 6.4 prescriptions. Similarly, a U.K. study of
patients suffering from diabetes, hypertension, and lipid disorder reported that approximately

4

50%, 20%, and 30% of subjects were receiving 3, 4-5, and 6 or more medications, respectively
(Stack et al., 2010).

Medication Adherence and Its Implications
Appropriate medication consumption behavior is critical to chronic disease management.
In general, rates of adherence to medication regimens are low in patients with chronic conditions.
An estimated 33-50% of all patients do not take their medications as prescribed (Horne, 1999;
Osterberg and Blaschke, 2005). Likewise, persistence with chronic disease medications is also
low as many patients with chronic conditions oftentimes discontinue treatment within a few
months of initiation. One study found that while adherence was approximately 80% in the first 3
months of treatment, the adherence rate to anti-hyperlidemic medications reduced to 56% within
6 months and only one in four patients showed an adherence level of 80% or more after 5 years
(Benner et al., 2002). Among a large cohort of patients who were suffering from coronary artery
disease, over 25% of patients discontinued their medication within 6 months and only 74% of
patients were adherent to all prescribed medications just 120 days after an acute myocardial
infarction (MI) (Jackevicius, Mamdani, and Tu, 2002). In spite of evidence supporting the use of
pharmacotherapy, patients do not appear to demonstrate appropriate medication use behaviors.
Large-scale studies have confirmed repeatedly that pharmacological treatment can reduce
adverse outcomes associated with chronic diseases. However, the reduction of the occurrence of
potential adverse outcomes depends on patients’ ability to follow their prescribed medication
regimens. The relationships between poor adherence and desirable treatment outcomes have
been examined. Various outcomes that have been studied include clinical parameters (e.g.,
systolic or diastolic blood pressure, HbA1c, or lipid profile) or adverse events (e.g.,
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hospitalizations or emergency room visits). Patients who were highly adherent to
antihypertensive therapy (AHT) were more likely to achieve blood pressure control than those
with medium or low adherence (Chapman et al., 2005). Similarly, ‘good’ adherence to
pharmacotherapy was associated with a host of positive health outcomes. A study investigating
the relationship between antihypertensive therapy use and the risk of MI/stroke reported that
patients who stayed with the therapy were at significantly lower risk of myocardial infarction
(MI) or stroke than who did not (Charles et al., 2003). Additionally, adherence to medication
regimens has been shown to reduce the risk of hospitalization or emergency room (ER) visits.
Sokol et al. (2005) examined the relationship between adverse health outcomes and poor
adherence in patients with diabetes, hypertension, high cholesterol, and congestive heart failure
to examine the relationship between poor adherence and adverse health outcomes. In all four
conditions, hospitalization rates were significantly higher for patients with low medication
adherence and there were 26% and 18% reductions in hospitalization or ER visits over a 2-3 year
period among diabetes patients and hypertension patients, respectively, who were adherent to
treatment. A negative association between adherence and mortality has also been reported (Ho
et al., 2006a; Rasmussen, Chong, and Alter, 2007; Simpson et al., 2006). For example, one-year
mortality was significantly higher in patients who were taking only some of their medications
compared to those adherent to all medications (Jackevicius, Li, and Tu, 2008). More
importantly, similar associations, including those against all-cause mortality, hold for different
medication classes (e.g., statins and β-blockers) (Rasmussen, Chong, and Alter, 2007; Wei et al.,
2002).
In spite of the strong association of adherence with positive outcomes, nonadherence to
medication remains a significant public health problem. A report by the World Health
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Organization (WHO) states that nonadherence to medications for chronic disorders such as
hypertension, dyslipidemia, and diabetes leads to reduced health benefits and serious economic
consequences in terms of wasted resources including time and money (WHO, 2003). Poor
medication adherence is a source of waste in health care systems or avoidable medical spending
in the U.S. because it gives rise to unnecessary health risks, particularly for patients with chronic
illnesses (New England Healthcare Institute (NEHI), 2009).For a typical, mid-sized employer
that spends $10 million in medical claims, poor adherence is associated with avoidable
healthcare expenditures of about $1 million annually (NEHI, 2009). Poor adherence or
nonadherence has been shown to result in $100 billion each year in excess hospitalizations alone
(Osterberg and Blaschke, 2005). In addition to poor health outcomes that translate into societal
costs, overall health care costs are much higher for patients with poor adherence. The annual
healthcare costs were estimated to be $8,886 for diabetes patients with high levels of adherence
as compared to $16,498 for those with low levels of adherence (Sokol et al., 2005).
Additionally, a 10% increase in adherence was associated with 2% and 4% decrease in total
health care costs and diabetes-related medical care costs respectively (Shenolikar et al., 2006).
However, the association between costs and adherence is not clear. Medication adherence was
positively associated with lower disease-related medical costs in chronic conditions such as
diabetes and hypercholesterolemia (Sokol et al., 2005); however, evidence contrary to what
mentioned above exists also (e.g., Karve et al., 2008). Because 75% of U.S. health care spending
is used for the treatment of chronic disease (CDC, 2009), the role of adherence in chronic disease
management, improving the efficiency in the health care system, and achieving desired health
outcomes cannot be overemphasized.
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Need for the Project
Decades of research has advanced our understanding of patient adherence to medication.
A range of perspectives including medicine, pharmacology, psychology, and nursing (Russell et
al., 2003) have been employed to examine adherence behavior. A host of factors, both internal
(e.g., personality) and external (e.g., socio-cultural), (see Cameron, 1996 for a review) have been
implicated. Some of these factors offer a simplistic but, to some extent, successful model
explaining patient adherence. Other approaches emphasize the complex, dynamic, and
reciprocal nature of relationships among the factors affecting adherence including how patients
cognitively interpret and act on their illness and associated symptoms (Bishop, 1991; Leventhal,
Diefenbach, and Leventhal, 1992). In spite of these effects, several questions related to
adherence remain unanswered. Specifically, there is a dearth of understanding about the
consistency of adherence behavior within a disease and across diseases and the state of change of
such behaviors in patients over time.
Multiple therapies are often prescribed for patients suffering from chronic diseases.
Indeed, treatment intensification is advocated and advised earlier in the patient’s treatment for a
chronic condition (Grant et al., 2011). Thus, multiple medication regimens may occur because of
multiple medications intended to treat a single disease or because of the need to treat
comorbidities. While treatment intensification and treatment of comorbidities have become the
norm, new issues arise as a result of such practices. Further examination of intra-disease and
inter-disease multiple medication adherence are warranted. Another important issue is the
measurement of intra-disease multiple medication adherence, including the selection of right
measure. These issues seem relevant and merit empirical exploration.
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Study Aims:
The present study has several aims. The hypotheses and objectives associated with these
aims are discussed in Chapter 2. Specifically, this study:
1. examined adherence to multiple medications prescribed for the treatment of a chronic
disease (intra-disease multiple medication adherence behavior);
2. examined adherence to multiple medications prescribed for the treatment of different but
related chronic diseases (inter-disease multiple medication adherence behavior);
3. proposed a composite measure for the estimation of adherence to multiple medications
prescribed for the treatment of a chronic disease;
4. compared the existing methods and the proposed method of estimating adherence to
multiple medications prescribed for the treatment of a chronic disease;
5. calibrated the intra-disease multiple medication adherence measurement approaches
including the composite measure.

Significance
The rising prevalence of chronic disease, including diabetes, hypertension, and
hyperlipidemia is a recognized public health concern. For patients on intensified treatment
regimens or multiple medications, the concern is increased due to the risk of adverse
consequences associated with inadequately controlled or uncontrolled disease. The practice of
prescribing multiple medications for a chronic disorder has increased recently and is expected to
continue in the future due to the aging U.S. population, increase in knowledge of disease, and the
availability of newer classes of medications. Although chronic disease patients may be managed
with a single fixed-dose combination medication, this option is not always available for all
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patients. Thus, the importance of understanding multiple medication adherence within a disease
or across diseases is and remains an important issue facing the healthcare system. It is believed
that this information on multiple medication adherence may act as trigger to providers and will
guide clinicians, pharmacists, healthcare managers, and policy makers to formulate strategies to
improve medication adherence and design interventions to promote health behaviors. As various
suggestions (e.g., synchronization and scheduling) (Agarwal et al., 2009) have been made to
improve medication adherence, the applicability of these strategies will be strengthened by the
knowledge about intra-disease and inter-disease multiple medication adherence behavior.
Indeed, profiling patients based on adherence patterns will help with designing subsequent
interventions.
Assessing or measuring medication adherence is the first step in order to understand
nonadherence and lay the groundwork for interventions for improving adherence (Morisky et al.,
2008). Although many measures of adherence exist (see McCaffrey, 2011 for a review), most
were developed to evaluate adherence to individual medications or medication classes. Thus, an
examination of these measures in situations where patients are prescribed multiple medications
for a disease is important. In a market where implementation of quality initiatives and
performance-based incentives are increasingly advocated and emphasized (Lee, 2007), the
question about measuring multiple medication adherence occupies a central position. The lack
of informed thought, as it is now, is going to constrain the appropriate assessment of adherence
to multiple medications and hamper the quality of patient care. Moreover, the effect of metric
choice must be known in order to provide guidance and consistency in the adherence literature.
In particular, an empirical rationale about measure choice while examining multiple medication
adherence is needed for practitioners, researchers, and policy makers alike.
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CHAPTER 2
LITERATURE REVIEW
Adherence Research
Adherence to medication has been a focus of much research for, at least, the last five
decades. Apart from a nearly uncountable number of primary studies that have been conducted
on adherence/compliance, the number of reviews and meta-analyses of studies on the same topic
is not small. The breadth and depth of past research on adherence is extremely large and a
thorough discussion is beyond the scope and objective of this chapter. It is well known that
many factors affect adherence. Researchers have attempted to categorize these factors into
different dimensions deemed to be most important. For example, the WHO (2003) describes five
sets of factors as being influential on medication-taking behaviors of patients. These are
socioeconomic, patient-related, therapy-related, condition-related, and healthcare team-related
factors of adherence. However, there is little consensus regarding the optimal categorization of
factors that influence adherence.

Adherence to Chronic Disease
Given the prevalence and overarching impact of chronic diseases, adherence to chronic
disease medications has been extensively investigated empirically. In general, these studies are
conducted within a disease category such as diabetes (Adams et al., 2008), hypertension (Morrell
et al. 1997), dyslipidemia (Huser, Evans, Berger, and 2005), heart failure (Dunlay et al., 2011),
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ischemia (Carney et al., 1998), myocardial infarction (Maio et al., 2011), stroke (Khan et al.,
2010), and so on. While some studies focused on a single class of medications or a single
product within a disease (e.g., Kogut et al., 2004; Pladevall et al., 2004; Shenolikar et al., 2006),
others focused on multiple medications, including multiple therapeutic classes within a disease
(e.g., Alvarez Guisasola et al., 2008; Dunlay et al., 2011; Guillausseau, 2003) or on a single
medication across diseases (e.g., Thavendiranathan et al., 2006).
On average, there is not much difference in adherence estimates among different chronic
disease categories. A meta-analysis concluded that adherence rates, measured by 12-month
medication possession ratio (MPR), in antihypertensive, anti-diabetic, and anti-hyperlipidemic
medication(LIP) categories varied between 67% and 76% and were not significantly different
(Cramer et al., 2008). However, it is not uncommon to find individual studies reporting lower
rates of adherence to pharmacotherapy. For example, one U.S. study reported that the average
antihypertensive adherence was 49% among elderly patients initiating therapy (Monane et al.,
1996). Likewise, a systematic review of studies reported that adherence rates in diabetes varied
widely among oral agent-only (36%-87%) versus concomitant or insulin-only (54%-81%)
regimens (Lee et al., 2006). Adherence within a disease may vary depending on therapeutic
class or subclass. For example, Wogen et al. (2003) compared adherence rates of amlodipine,
lisinopril, or valsartan. These medications belong to three different pharmaceutical subclasses
calcium-channel blocker (CCB), angiotensin-converting enzyme inhibitor (ACEI), and
angiotensin receptor blocker (ARB), respectively and were found to exhibit significantly
different average MPRs (75% for valsartan, 67% for amlodipine, and 65% for lisinopril). Other
studies have examined different measurement approaches to examine adherence. One such
method is analyzing dichotomized adherence rates. Dunlay et al. (2011) investigated 6-month
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adherence rate among community dwelling heart failure patients; proportions of patients who
had poor adherence based on medication possession (proportion of days covered (PDC)< 80%)
to β-blockers, ACEIs/ARBs, and statins were 19%, 19%, and 13%, respectively. Monane et al.
(1996) reported only 23% of hypertension patients showed adherence levels of 80% or greater
measured over a year.
Alternatively, studies have examined persistence with therapy or duration with therapy
before discontinuation. Unlike adherence rates, persistence rates were somewhat similar for
different product categories. An analysis of 139 studies that focused on diabetes, hypertension,
dyslipidemia, and other cardiovascular diseases revealed that only 63% of patients continued
with their medication for one year (Cramer et al., 2008). Persistence appears to have strong
relationship with time; in general, persistence decreases over time. A systematic review reported
that treatment persistence with OAD ranged from 16 to 80% in patients who continued their
treatment for 6-24 months and discontinuation time ranged from 83-300 days (Cramer, 2004).
Approximately 10-30% of type 2 diabetes patients enrolled in a Medicaid population were found
to withdraw from SU regimens within one year of diagnosis (Sclar et al., 1999). Persistence fell
less sharply from 97% at 1 year to 82% at 4.5 years for patients with established hypertension
compared to that of 78% and 46% over the same period for those with newly diagnosed disease
(Caro et al., 1999). Persistence with anti-hyperlipidemic medications is lower in primary
prevention than in secondary prevention. Perreault et al. (2005) observed that persistence with
statin fell from 71% after 6 months of treatment to 45% after 3 years in the secondary prevention
cohort, while the corresponding values in the primary prevention cohort were 65% and 35%
respectively. Ho et al. (2006b) evaluated the early discontinuation of β-blockers, aspirin, and
statins among acute myocardial infarction patients. One month after treatment initiation, the
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authors reported, 12.1%, 3.7%, and 17.9% of patients discontinued all three drugs, two out of
three drugs, and one drug, respectively, while approximately 66% of patients continued taking all
three medications. Likewise, persistence to medications has been examined across disease
states. In elderly patients (≥ 65 years) the two-year adherence rate (measured as medication
being dispensed at least every 120 days) to statin treatment was about 40% in patients with a
recent diagnosis of acute coronary syndromes (ACS), 36.1% in patients having chronic coronary
heart disease (CHD), and 25.4% in primary prevention patients (Jackevicius, Mamdani, and Tu,
2002). Interestingly, the average persistence rate across the studies conducted in Europe was
61.7% over an average observation period of 17 months, while that of the U.S. studies was
51.1% observed over a mean period of 21 months (Cramer et al., 2008). Hudson, Richard, and
Pilote (2007) investigated the patterns of prescription and discontinuation of anti-platelet agents,
β-blockers, ACE inhibitors and/or ARBs, and statins in all post-AMI (acute myocardial
infarction) patients; the rates of discontinuation increased significantly during follow-up and had
a parabolic shape with the youngest and oldest patients having the highest rates.
Medication adherence in different chronic conditions has been studied together within a
sample (i.e., within a single study). Usually, these studies have shown modest variation in
adherence across different chronic disease categories. For example, Briesacher et al. (2008)
compared drug adherence rates among patients with hypercholesterolemia, hypertension,
hypothyroidism, seizure disorders, and type 2 diabetes mellitus (T2D) in a commercially insured
population. Approximately 72% of subjects with hypertension achieved adherence rates of 80%
or better compared with 68.4%, 65.4%, 60.8%, or 54.6% for those with hypothyroidism, type 2
diabetes, seizure disorders, and hypercholesterolemia, respectively. Khanna et al. (2012)
compared population adherence rates in a Medicaid population across different diseases,

14

including diabetes, hypertension, and dyslipidemia. On average, adherence rates were poor in
the population such that approximately 35-42% patients showed adherence rate ≥ 80%.

Adherence and Demography
Medication adherence is a function of several factors, including individual characteristics.
Early research on determinants of adherence focused primarily on demographic factors, not to
say that such studies are not carried out any more. Indeed, many investigations were conducted
within specific demographic segments such as age (e.g., Benner et al., 2002), gender (e.g., Khan
et al., 2010), and race (e.g., Adams et al., 2008). In the classic review by Sacket and Haynes
(1976), no clear relationship emerged between adherence and demography, including gender,
race, ethnicity, education, marital status, and income. Many studies included specific age groups
that ranged from a relatively young group of patients of 20-49 years (Okano et al., 1997) to
elderly cohort aged 65 years or older (Monane et al., 1997). Patient age has been found to
predict adherence more consistently than other demographic characteristics. Yet, some studies
reported positive association of adherence to medication (e.g., AHTs or OADs) and age (Ren et
al., 2002; Venturini et al., 1999) while other studies failed to do so (Coons et al., 1994;
Evangelista et al., 2003). The relationship between age and adherence, however, may not be
linear. Morrell et al. (1997) reported that the younger old, (e.g., 60-70 years), demonstrated the
highest levels of adherence to AHTs, whereas the adherence levels of those over 75 years were
the lowest. Indeed, the study concludes, adherence was problematic for those over 75 years. In
light of such finding, it appears that the differential impact of age on medication adherence may
be affected by some other factors. Park (1999) argued such effects may be mediated by
cognitive changes or other age-related factors.
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Adherence: Trait and Intention
Researchers have searched for stable characteristics that affect adherence. Dispositional
characteristics that affect general behaviors have been examined. Specifically, associations have
been examined between personality factors and adherence to medications in chronic diseases,
including diabetes and hyperlipidemia (Axelsson et al., 2009; Christensen and Smith, 1995;
Stilley et al., 2004). Past research has shown that conscientiousness, a personality trait reflecting
methodical and industrious behavior, is associated with treatment adherence (Christensen and
Smith, 1995; Stilley et al., 2004). However, the associations with personality traits have not
been supported consistently. Using a medication events monitoring system (MEMS), Insel,
Reminger, and Hsiao (2006) investigated the association between personality and adherence in
older community dwelling adults who were using chronic medications, including AHT and LIP.
The study found no association with conscientiousness but it did found negative associations
with other personality factors, namely self-reliance and independence. Recently, an
observational study found that no personality traits except neuroticism were associated with
medication nonadherence over 6 years of follow-up in a sample of elderly patients receiving an
alternative (herbal) medication (Jerant et al., 2011). It is possible that these characteristics work
in conjunction with other factors. For example, the interaction between conscientiousness and
health beliefs was found to predict adherence among hemodialysis patients (Wiebe and
Christensen, 1997). Thus, the influence of personality factors may be less clear or conditional on
other variables. In addition, with evidence showing that there may be marked inter-individual
and intra-individual variation in adherence to different medications or different aspects of
treatment over time (Cleary et al., 1995; Kruse and Weber, 1990), defining patients by stable
characteristics, which could be speculated to constitute ‘compliant patient’ or ‘noncompliant
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patient’ is not practically sensible or theoretically tenable. At most, as suggested by Horne
(1998), they can influence some but not others and this has led to exploration of the interaction
of patients with their disease and treatment.
A patient may make decision, consciously or subconsciously, about adherence to
medications. It has been argued that such decision-making is related broadly to distinct types of
medication nonadherence – intentional nonadherence and unintentional nonadherence – and
potentially contribute to observed patterns of adherence behaviors (Clifford, Barber, and Horne,
2008; Johnson 2002; Morisky, Green, and Levine, 1986; Stack et al., 2010). While intentional
nonadherence describes an active process in which the patient makes a conscious decision about
deviating from a medication regimen, unintentional nonadherence represents a passive process in
which the patient may deviate from appropriately following the treatment regimen because of
carelessness or forgetfulness (Morisky, Green, and Levine, 1986). Past research has examined
these mechanisms empirically in chronic care management. Using a self-report measure, Lowry
et al. (2005) examined adherence to antihypertensive medications among veterans and found that
approximately 9% of the study subjects reported intentional nonadherence and 31% reported
unintentional nonadherence. Stack et al. (2010) measured self-reported intentional and
unintentional nonadherence to differing numbers of medicines prescribed in type 2 diabetes
patients and found no difference in intentional nonadherence. Among patients receiving OADs,
AHTs, and statins; the authors noted, while intentional nonadherence to statin significantly
increased with number of medicines prescribed, unintentional nonadherence was higher for some
medicines than for others (e.g., OAD adherence < AHT or statin). Similarly, Wroe (2002) found
that different reasons or beliefs with regard to utility were associated with intentional adherence
as opposed to unintentional adherence among asthma patients. Other researchers examined a
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number of other factors including complexity, type, and knowledge of medication regimens and
presence of co-morbid conditions (Barr et al., 2002; Horne, 1998; Lehane and McCarthy, 2007)
to explore the unintentional nonadherence. Thus, it appears that varying levels of both the
intentional and the unintentional dimensions of medication taking may occur simultaneously. It
is recommended that simultaneous examination of the intentional and unintentional dimensions
of nonadherence be considered for the sake of comprehensive understanding of the factors of
nonadherence (Lehane and McCarthy, 2007; Johnson, 2002), although these dimensions may
have varied motivational or psychosocial factors associated with them.

Psychological Factors in Adherence: Health and Disease Beliefs and Attitudes
Several theoretical models in social psychology have been adapted to explain variations
in adherence to treatment. These theories can be broadly categorized into two groups: Social
Cognition Models (SCM) and Self-regulatory Theory. The social cognitive perspectives focus
on attitudes and beliefs or expectancies as major determinants of health behavior (Conner and
Norman, 1996). They assume that patients undertake cost/benefit analyses as a motivating factor
to act. Subjective weighting of the benefits, barriers, and consequences of behaviors provide the
motivation for actions. Several theoretical models fall under this group(e.g., the Health Belief
Model (HBM), the Theory of Reasoned Action (TRA), the Theory of Planned Behavior (TPB),
and the Social Learning Theory). The HBM has been utilized in studies of medication adherence
across several diseases including hypertension (Cronin, 1986) and diabetes (Brownlee-Duffeck
et al., 1987). The TRA and TPB constructs have been useful in predicting adherence to
prescription medications (Miller, Wikoff, and Hiatt, 1992; Reid and Christen, 1988). The
concept of locus of control - more specifically, multidimensional health locus of control (HLC)
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(Wallston, Wallston, and Devellis, 1978) - has been applied in the health care context. The HLC
beliefs provide inconclusive or inconsistent evidence and remain fairly weak predictors of
adherence behavior (see Horne and Weinman, 1998 for a discussion). Disease-specific HLC
beliefs have also been advanced. The use of condition-specific HLC measures appears to
improve the utility of the framework. For instance, disease-specific locus of control measures
have been associated with adherence to diabetes care and hypertension (Bradley et al., 1990;
Kohlman et al., 1993; Stanton, 1987). Several studies have combined constructs from different
theories were combined to examine patients’ adherence behavior. For example, Reid et al.
(1985) used the HBM and the TRA to examine intention to comply with antihypertensive
regimens. Efficacy beliefs (e.g., outcome efficacy and self-efficacy) and HBM constructs were
examined among patients who were compliant or noncompliant to tuberculosis treatment
(Barnhoorn and Adriaanse, 1992) or for predicting adherence with an over-the-counter acne
medication (Flanders and McNamara, 1984). Wang et al. (2002) used health beliefs based on the
TRA and LOC beliefs to examine medication nonadherence in hypertension patients.
Although Social Cognitive Models have been extensively used, they are not devoid of
criticism. Rationality of health-related behavior, a fundamental premise of SCMs, is questioned.
Indeed, some health behaviors appear to be habitual or routine and may not always be
characterized by rational decision-making. Moreover, the dynamic nature of health behavior is
often ignored. In an attempt to explain the dynamic relationships among cognitions, motivations,
and behaviors, Leventhal and colleagues developed the Self Regulatory Model (SRM) - a selfregulatory framework for understanding illness perceptions (Leventhal, Diefenbach, and
Leventhal, 1992; Leventhal et al., 1997). The fundamental premise of the SRM is that patients
are active problem solvers who respond to illness in a dynamic and specific fashion based on

19

their interpretation and evaluation of illness and its symptoms (more discussion follows). The
role of illness representation in explaining adherence decisions have been examined empirically
and illness representations (i.e., patient’s own beliefs about illness) were associated with
treatment adherence among chronic disease patients (Bane, Hughes, and McElnay, 2006;
Gonder-Frederick and Cox, 1991; Meyer et al., 1985).

Patient-Provider Interaction and Associated Impacts on Adherence
Chronic disease care requires a long-standing interaction between a patient and a health
care provider. Thus, the patient-provider relationship is important for the success of chronic
diseases management. Researchers have recognized factors that characterize the quality of
patient-provider interactions as important determinants of medication adherence. Interaction
quality, including the state of collaboration between a provider and a patient, behaviors and
attitudes of healthcare professionals, and amount of time spent with patients in a supportive
environment discussing medications or diseases (Arbuthnott and Sharpe, 2009; Cameron, 1996;
Kiortsis et al., 2000) have been examined for their effect on medication adherence. A specific
aspect of the patient-physician interaction that has been extensively investigated is the role of
communication. A meta-analysis of 106 studies found a positive relationship between physician
communication and adherence (Zolnierek and Dimatteo, 2009). Piette et al. (2003) examined
dimensions of communication; both general communication and diabetes-specific
communication were correlated independently with patients’ self-reported adherence to
hypoglycemic medications. Thus, it is believed that an appropriate collaborative relationship
between a patient and a provider may improve medication adherence. As may be expected, one
of the basic communication goals is to improve patient’s knowledge about various aspects of
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disease or treatment. Numerous studies have been conducted to examine the effects of
knowledge of disease and medication on adherence. Although there is some conflicting
evidence, in general, a positive correlation has been found between knowledge and adherence to
chronic disease medications (Cuspidi et al., 2001; McDonald, Garg, and Haynes, 2002). In
addition, patient-centered, communication-driven interventions, such as disease management
programs, are thought to facilitate the management of chronic care and help patients in their
effort to self-care. In fact, disease management has been implemented to educate chronic
disorder patients and support self-management skills and reported to improve adherence to
treatment recommendations (Fitzner et al., 2005; Thiebaud et al., 2008). Indeed, disease
management is widely recommended for patients on multiple medications.

Adherence and Treatment Intensification
Adherence to medication assumes importance because of its profound role in achieving
desired therapeutic benefits. In other words, that nonadherence to medications may potentially
lead to adverse consequences is of great public health concern and reasons for such concerns
have been discussed in the previous chapter. Thus, adherence enhancement occupies a central
role in chronic disease management in that it helps achieve treatment goals. Another potential
way to achieve treatment goals is through intensification of therapy. Specifically, therapy
intensification (TI) can occur through an increase in dosage of a medication that is already being
consumed by the patient for a disease, an addition of a medication or multiple medications to the
patient’s prescribed regimen intended for the disease, or switching to a new class of medication
(Rodoni et al., 2006; Schmittdiel et al., 2008). As such, the relationship between adherence and
treatment intensity is important for research purposes due to its clinical implications. A survey
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of physicians reported that those who intensified therapy in patients with type 2 diabetes were
more likely to consider issues such as patient adherence and medication costs (Grant et al.,
2009). Some researchers have addressed whether physicians are likely to increase therapy
depending on patient adherence (Grant, Singer, and Meigs, 2005; Heisler et al., 2008).
Nonadherence was not related to the subsequent addition of a second drug in diabetes patients
(Kogut et al., 2004). Others suggest that there may be an interaction between adherence and
disease. Poor adherence was reported to inhibit intensification of diabetes therapy but not that
for antihypertensive medications in diabetes patients (Voorham et al., 2011). The extent of lack
of therapy intensification among adherent patients has also been investigated. Among diabetes
patients with no evidence of poor adherence, the lack of treatment intensification was found in
30% , 47%, and 36% of patients for hyperglycemia, hyperlipidemia, and hypertension treatment,
respectively (Schmittdiel et al., 2008). On the contrary, Grant et al. (2007) reported that diabetes
patients with poor adherence were less likely to have their regimen increased and time to
intensification was negatively associated with adherence in poorly controlled patients.
Researchers have examined the relationship between TI and adherence in achieving desired
control over time. Rose et al. (2009) observed that treatment intensification was associated with
improvement in blood pressure regardless of the patient’s level of adherence. However, other
researchers have concluded that achieving desired treatment goals is a function of a combination
of intensification and adherence; therapy intensification must be coupled with interventions to
improve medication adherence (Ho et al., 2008). Although no consensus exists regarding the
role of adherence in intensification of therapy, it can be posited at a minimum that the full benefit
of therapy intensification cannot be realized without adequate adherence.
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Adherence to Multiple Chronic Disease Medications
It has been well established that underutilization of medications is a major problem in
health care. In general, studies on medication utilization focus on a single therapeutic class of
medications. A meta-analysis undertaken to examine studies related to adherence to diabetes,
hypertension, and dyslipidemia medications concluded that over 80% of the 139 studies that
were reviewed investigated only one therapeutic class (Cramer et al 2008). Although a few
studies exist that have compared adherence rates across different disease categories in a single
study (e.g., Khanna et al., 2012), they did not analyze simultaneous adherence to multiple
medication regimens. This approach (i.e., considering adherence within a single disease
category) is not much insightful because it is well known that the presence of multiple chronic
comorbidities is now more of a norm than an exception. Moreover, this approach is not
consistent with the recommendation of aggressive treatment of comorbidities.
Only a few published studies have examined concomitant adherence to medications
prescribed for multiple chronic diseases. Chapman et al. (2005) investigated patterns and
predictors of simultaneous adherence to newly initiated antihypertensive and anti-hyperlipidemic
therapies. Using a dichotomized measure of adherence, the researchers concluded that 44.7%
and 35.8% of the patients were adherent with both antihypertensive (AH) and antihyperlipidemic (LIP) medications at 3 and 12 months after medication initiation respectively;
however, at each time, approximately an additional 25%-29% of the subjects demonstrated PDC
≥ 80% to either AHT or LIP. Concomitant medication consumption behavior has been
examined, although less explicitly, in other disease conditions. For example, patients receiving
long-term dialysis demonstrated higher adherence to antihypertensive and calcitriol therapies
than their phosphate binder regimens (Cleary et al., 1995). Preferential or selective adherence
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was shown to be prevalent in kidney transplant patients. A cross-sectional study of kidney
transplant patients compared adherence rates over a month for nonimmunosuppressive
medications (i.e., AHT, LIP, and anti-diabetic agents) and immunosuppressive medications;
more patients were reported to be selectively more adherent to immunosuppressive medications
and nonadherent in the former therapeutic category were more likely to have diabetes (Terebelo
and Markell, 2010). A study was conducted to examine medication use in patients who were
discharged from hospital after acute myocardial infarction with prescriptions for aspirin, statin,
and β-blockers; while 34% of the patients discontinued at least one medication, 12% stopped all
three medications within a month of hospital discharge (Ho et al,. 2006b). A small study with
diabetes patients who had asthma reported that the pattern of diabetes and asthma medications
had a similar dispensation interval among 52% of the patients (Krigsman, Nilsson, and Ring,
2007). However, the refill adherence rate for diabetes medication was higher than that for
asthma medication with no correlation between adherence levels. Adherence to medication for
one disease has been examined as predictor of adherence for another disease. Diabetes
medication adherence, for instance, was associated positively with odds of being adherent to
statin medication in a university employee population (Kumar and Holiday-Goodman, 2010).
Simultaneous adherence across therapeutic classes has been examined among patients with
psychiatric as well as physical comorbidities. A study with patients who were using medications
for schizophrenia, diabetes, and hypertension examined differential medication adherence (Piette
et al., 2007). Intra-patient adherence rates as measured by MPR across therapeutic classes, the
authors noted, were correlated modestly; while the correlation of MPRs for hypertension and
diabetes was the highest, there were weak but significant correlations between MPR for
antipsychotic medications and MPR for each of the two physical conditions. MPR for
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antipsychotic medications explained only 13% and 16% of the variance in that for
antihypertensive and hypoglycemic medications, respectively. In addition, patients were more
likely to show poor adherence for antihyperglycemic and antihypertensive therapies than for
antipsychotic therapy (Piette et al., 2007).
Relatively few studies have examined selective adherence over a long period of time.
Indeed, such research is insightful in that it has the ability to guide in understanding changes
within an individual. Nichol et al. (2009) examined the transition probabilities of patients
receiving both LIP and AHT therapies among different adherence categories (i.e., fully adherent,
partially adherent (0.2 ≤ PDC < 0.8), and nonadherent) over a period of six years. The study
reported that patients showing full adherence to both medications at the beginning were more
likely to maintain their adherence status and patients who were partially adherent to one and
fully adherent to the other were more likely to elevate to the adherent status for both
medications. The results of the study are interesting in that they suggest the presence of an
adherence trait. However, other variables (e.g., comorbidity profile, beliefs, etc.) that were not
evaluated may explain further the results. The study found an association between type of
medication and transition to nonadherence. Interestingly, this finding is also supported by
another study despite methodological differences. Grant et al. (2003) interviewed diabetic
patients to examine 7-day adherence to multiple medications; patients with overall suboptimal
adherence appeared to have issues with one specific medication and similar observation was
made in patients who showed suboptimal adherence and were consuming three or more antidiabetic medicines although no association with number of medications was found.
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Adherence and Burden of Consuming Multiple Medications
From the above discussion, it is apparent that chronic disease patients are likely to
experience multiple medication regimens. As such, the burden may occur because of multiple
chronic diseases, aggressive treatment (e.g., therapeutic intensification), or a combination
thereof. The relationship between number of medications being taken and adherence has been
the focus of many studies including those of concomitant adherence. Chapman et al. (2005)
observed a negative relationship between number of other prescription medications taken in the
year before initiating concomitant antihypertensive and anti-hyperlipidemic medications and the
likelihood of adherence with concomitant therapy. Similar relationships have been observed by
other studies examining joint adherence (Benner et al., 2009; Terebelo and Markell, 2010).
Interestingly, Benner et al. (2009) noted a significant curvilinear relationship indicating a decline
in change in adherence to concomitant AHT and LIP with increase in number of prescriptions.
The relationship within the context of adherence to a single medication or a class of medications
has also been examined. For example, statin adherence in an elderly population was negatively
associated with number of total prescriptions for other medications (Benner et al., 2002;
Jackevicius, Mamdani, and Tu, 2002). However, evidence contradicting the relationship as
discussed above also exists. Grant et al. (2004) examined the impact of concurrent medication
use on statin adherence and refill persistence; number of concurrent medications, including
statin, measured at initiation of statin therapy as well as at last recorded fill of statin was
positively associated with statin adherence and persistence. In a study of predictors of
suboptimal adherence in diabetes patients, Grant et al. (2003) observed that total number of
medications prescribed was not associated with self-reported medication adherence measured
over seven days. Similarly, Piette et al. (2007) found that number of drug classes was associated
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with a slight decrease in odds of being nonadherent. The relationship may vary by disease.
Briesacher et al. (2008) found that add-on drug therapies enhanced adherence among subjects
with hypertension, type 2 diabetes, hypothyroidism but not with hyperlipidemia; although burden
was generally small, the association of comorbidity with adherence varied across disease. Thus,
the relationship between the burden of prescription medications and adherence appears to be
intriguing. Patients’ overall comorbidity profile and medication beliefs may be the potential
reasons for the discrepancy. However, methodological issues (e.g., method to sum up all
prescriptions) may also explain such results.

Measurement of Adherence
Precise and appropriate measurement of medication use behavior has been an important
topic in the realm of adherence research. Adherence/compliance and persistence are commonly
chosen to present medication utilization patterns although terminology, definitions, and methods
of assessment vary widely in the published literature. Several different ways to measure
adherence exist (see Fairman and Motheral, 2000 for a review). A review of studies of patient
adherence with cardiovascular medications and anti-diabetic medications showed that
administrative claims data were used in the greatest number of studies, followed by
questionnaires, MEMS, ‘other’ sources, and pill counts (Cramer et al., 2008). Retrospective
pharmacy and medical claims data, although not devoid of limitations, offer several advantages,
including relative efficiency. A set of diverse measures of medication adherence (e.g., MPR,
discontinuations, refill adherence, medication gaps, etc.) have been used in studies using claims
data; interestingly, variations in operational definition were observed within subgroups (see
Andrade et al., 2006; Vik, Maxwell, and Hogan, 2004 for a review). In recent years, there has
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been an increase in the trend in use of continuous measures of adherence that are based on days’
worth of medication dispensed or related measures and this trend seems be driven by the
propensity to analyze longitudinal observations using pharmacy claims data (Cramer et al.,
2008).

Comparison of Adherence Measurement
Given that several operationalizations of adherence exist, the interpretation of research
findings, if required, becomes difficult. In addition, the disparate use of adherence measures
creates challenges to researchers about the appropriateness of measures to be used in adherence
studies. As such, the task of selecting an appropriate measure is critical. Fortunately, some
efforts have been made to compare different measures of adherence. Hansen et al. (2009)
assessed the agreement among different adherence measurement methods – patient self-report,
pharmacy refills, and electronic adherence measures and compared the sensitivity and specificity
of different cut-off points for classifying nonadherence in a sample of hypertensive or heart
failure patients. Hess et al. (2006) compared 11 measures of refill adherence that include
Continuous Measure of Medication Acquisition (CMA); Continuous Multiple Interval Measure
of Oversupply (CMOS), MPR, Medication Refill Adherence (MRA), Continuous Measure of
Medication Gaps (CMG), Continuous Single Interval Measure of Medication Acquisition (CSA),
PDC, Refill Compliance Rate (RCR), Medication Possession Ratio, modified (MPRm), Dates
Between Fills Adherence Rate (DBR), and Compliance Rate (CR); while six measures(CMA,
CMOS, MPR, MRA, CMG, and PDC) provided similar values, the others yielded higher values.
Karve et al. (2008; 2009) compared the abilities of eight different measures of adherence to
predict all-cause or disease specific hospitalization in a state Medicaid population; PDC and
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MPR emerged as the best predictors of hospitalization in different disease cohorts such as
diabetes, hypertension, hyperlipidemia, and congestive heart failure.
A practice that is common in the adherence literature is the dichotomization of
continuous adherence estimates to categorize patients as adherent or nonadherent. Most often,
the 80% cut-point is used to classify a patient as adherent or nonadherent. However, different
cut-points for an operational definition of adherence have been used in past studies; such
differences exist not only across studies that employed different methods but also across studies
that used the same method. Maenpaa et al. (1987) defined good adherence as consuming 85% by
pill count in a study of adherence in heart disease patients. Irvine et al. (1999) classified cardiac
patients as poorly adherent when they had an average pill count below the 20th percentile of the
pill count distribution in which the 20th percentile point represents those taking lesser than 66%
of doses dispensed. Granger et al. (2005) used a complex method of estimation of adherence; the
proportion of time patients took more than 80% of their study medication by pill count was
determined first and then those demonstrating proportion of time greater than 80% were
classified as adherent. In a study of ambulatory patients with stable coronary heart disease,
nonadherence was defined as self-reported consumption of medications 75% of the time or less
(Gehi et al., 2007). There are many examples of similar variations in the literature (see Vik,
Maxwell, and Hogan, 2004).
Apart from using different thresholds for categorization, differences in number of
categories also exist. Some studies had grouped patients into multiple categories based on
adherence. For example, Bramely et al. (2006) examined the relationship between adherence
and blood pressure control in patients with essential hypertension and categorized patients into
three adherence groups: high (80%-100%), medium (50%-79%), and low (< 50%). In a study
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exploring the relationship between drug adherence and mortality, adherence estimates, measured
by PDC, were subdivided a priori into three categories: high (≥ 80%), intermediate (40%-79%),
and low (< 40%) (Rasmussen, Chong, and Alter, 2007). Likewise, Nichol et al. (2009) used
three adherence categories while examining adherence rates in patients who were prescribed
concomitant AHT and LIP; however, different labels were used with different cut-points: fully
adherent (PDC ≥ 0.8), partially adherent (0.2 ≤ PDC < 0.8), and nonadherent (PDC < 0.2).
Furthermore, other researchers have used four categories to classify adherence to chronic
medications (Mason et al., 2011).
Classifying patients into different categories according to their adherence behavior may
be appropriate when it is consistent with the goal of research. In fact, categorization offers
efficiency from the perspective of healthcare providers, including practicing pharmacists.
However, the practice is not without limitations. Given a lack of uniform method, it becomes
difficult to compare results, if needed. Oftentimes, the rationale behind such classification
schema decisions is not explicitly stated; however, some researchers perform sensitivity analysis
to examine the susceptibility of results to different classification schema. Recently, Karve et al.
(2009) attempted to validate the optimality of cut-points for adherence measure for classifying
patients as adherent or nonadherent. Using retrospective claims data for patients in five disease
cohorts, the authors observed that the optimal cut-point of the PDC measure that predicted
disease-specific hospitalization varied from 0.58 to 0.85 depending on disease. However, the
predictive power of the study models was only modest as was evident from weak c-statistics. In
addition, by excluding patients who were prescribed two or more drug classes for a disease the
study limited its applicability in that the result may not be generalizable to patients on
concurrently advised multiple medication regimens.
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Measurement of Adherence to Multiple Medication Regimens
Measurement of adherence to multiple medications has been and remains a complex
issue. The level of complexity may vary in situations in which the issue of measurement of
adherence arises: multiple medication regimens for a single disease (i.e., therapy
intensification/augmentation) and multiple medication regimens used to treat two or more
diseases. Although adherence to multiple medications has been examined in few studies, the
question of measurement has not been discussed explicitly. Indeed, this issue has not received
the critical deliberation that it deserves. Currently, there is no consensus or published guideline
for measuring adherence to multiple medications. Quite understandably, a set of varied practices
exists.
Several approaches are followed for the measurement of adherence to multiple
medications concurrently consumed for a single disease. These include 1) average of adherence
(PDC) to each medication (henceforth, termed as ‘average’), 2) adherent only if ≥ 80% PDC,
measured separately for each medication, on each concurrent medication (termed as ‘all’), and 3)
adherent if ≥ 80% PDC measured as proportion of days when at least one medication was
available, i.e., a patient is adherent on a day if he possesses at least one medication on the day,
(termed as ‘at least one’) (see Choudhry et al., 2009 for further illustration). These estimation
approaches are further complicated depending on the definition of individual intervals, i.e.,
denominators of adherence measures. Specifically, the interval of individual medications can be
based on the entire observation period or prescription period for each drug. However, because
medications are to be continued, the prescription period-based interval may not be important for
most chronic disease medications except for situations when physician-recommended switches
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occur. Several studies can be cited in which adherence to multiple medications was computed
based on one of these approaches or some variants of them. Khanna et al. (2012) adopted the ‘at
least one’ approach in the study of adherence to medications although the objective was not to
examine multiple medication adherence. Yu, Yu, and Nichol (2010) averaged adherence of
multiple medications for diabetes. Studies focusing on adherence to multi-disease medications
adopted one of the above approaches. Piette et al. (2007) employed a weighted average,
analogous to the average measure, in the calculation of intra-disease adherence to two
medications; weight was based on the adjustment (of days supply needed) made in the
denominator of the MPR estimator and weighted average MPR was then dichotomized. A
similar method was employed by Schmittdiel et al. (2008) in which each drug class adherence,
measured by CMG, was combined into a single estimate for all drugs for a chronic disorder; the
summary measure was computed by weighting the estimate for each class by the number of days
from the first to last fill in the observation period and then the single estimate was dichotomized.
It is not surprising that different measurement methods result in different estimates, at least in
some cases. For example, Choudhry et al. (2009) reported concurrent medication adherence
estimates that ranged from 35% to 95% depending on different measurement approaches
followed in patients receiving oral hypoglycemic agents. Martin et al. (2009) used a restricted
definition of PDC for quarters in which multiple medications were recommended such that a
patient was considered adherent on a day when he possessed all medications concurrently
recommended and categorized as adherent if he had 80% or higher PDC as estimated by the
method during the observation period (herein, termed as ‘both’). It can be noted here that this
definition (‘both’) will not yield any estimate greater than that of the all approach as described
above. For example, if a patient is prescribed two medications concurrently and he is adherent to
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the first medication for the first 16 days (80%) of a 20-day period but possesses the second
medication for the last 16 days, then he will be categorized as adherent according to the ‘all’
measure (80% on each) but not according to the ‘both’ method (60%). Because of such
complexities of estimation of multiple medication adherence, patients taking two or more
medications for a disease are typically excluded from subsequent analyses (e.g., Karve et al.,
2008; 2009; Piette et al., 2007).
As discussed above, few studies have examined joint adherence to medications for
multiple conditions. While classifying patients as adherent or nonadherent based on joint
adherence behavior, researchers have followed a dichotomized adherence measurement approach
that is, in principle, identical to the both approach (e.g., Chapman et al., 2005). In other words,
patients were considered adherent with concomitant therapy if 80% or more days are
simultaneously covered by each therapy. In contrast, Nichol et al. (2009) defined fully adherent
to concomitant antihypertensive therapy and anti-hyperlipidemic medications as those
demonstrating ≥ 80% adherence (PDC) on each medication where adherence was estimated
separately for each medication (the ‘all’ approach). Other researchers adopted an average-based
approach for estimating overall adherence to multiple medications prescribed for different
diseases. Ho et al. (2006a) examined the relationship between mortality and overall adherence to
multiple medications in a cohort of diabetes patients who were prescribed one or more classes of
medications that included oral hypoglycemics, antihypertensives, and statins; for patients who
were prescribed medications from multiple categories, a summary PDC measure was calculated
as the average of PDC of any one or more categories of medications. The study might have
applied the same principle while estimating adherence to multiple medications intended to treat a
single disease although it was not explicitly explained. Interestingly, different approaches were
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adopted simultaneously for estimating adherence to multiple medications – one for a disease and
another for two different diseases. In the case of estimating adherence to medications for a
disease, Benner et al. (2009) noted, a patient was considered covered if he was adherent with at
least one AH medication on a given day; for different diseases, however, patients with a PDC of
≥ 80% for both AHT and LIP were considered adherent.

Limitations of Research Related to Adherence to Multiple Medications
Adherence to Multiple Medications
Patients for whom intensified treatment regimen is advised may be at high risk for
experiencing adverse consequences if the disease is not adequately controlled. However, studies
on adherence have focused largely on understanding consumption of any single medication
prescribed for a disease or collective consumption patterns in which all medications for a disease
are considered together. In addition, failing to establish adherence as a universal trait
characteristic (Horne, 1998) leaves us with a critical knowledge gap about whether individual
adherence patterns of a multiple medication regimen for a disease duplicate or closely follow one
another. In other words, what happens to adherence behavior for each medication in patients on
multiple medications for a single disease? What is the relationship between adherence values
estimated for different medications taken concurrently for a single disease? While the roles of
illness perceptions (Leventhal et al., 1997) may suggest concurrent adherence, the burden of
taking more medications may attenuate adherence although the effect of prescription burden on
adherence is not consistent. Thus, further research is needed to explore adherence to multiple
medications taken concurrently for a disease or intra-disease multiple medication adherence.
Specifically, there is much to learn about the covariation of adherence behavior, including the
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extent of covariation, effect of demography on covariation, and relationships between individual
change patterns over time.
Similarly, there is a dearth of empirical knowledge about covariation in adherence among
medications prescribed for multiple diseases (i.e., inter-disease multiple medication adherence)
in patients suffering from multiple chronic diseases simultaneously and where fixed combination
(single) dosage are not available. Although there have been some attempts to examine cross
disease adherence behaviors (e.g., Chapman et al., 2005; Stack et al., 2010), several issues,
including those raised above, however, remain to be solved. While some studies do not answer
long term association or change in trends regarding joint adherence behaviors because of the
study design (cross-sectional), others are limited to specific populations (e.g., newly initiated
therapy, mental disorder, etc.). It is known that some patients suffer simultaneously from more
than two chronic diseases some of which are more symptomatic than others. In addition, an
overarching situation arises when therapy intensification occurs in some of these diseases. It is
not known how inter-disease and intra-disease adherence covariations emerge, if any, in complex
therapeutic situations in patients having multiple morbidities.

Measurement of Adherence to Multiple Medications
Assessing adherence accurately is crucial for many reasons including identifying
opportunities for intervention. Although many measures of adherence exist, these measures were
developed specifically for the measurement of adherence to individual medications or
medication classes. The applicability of these measures in a multiple medications situations is
not known. Thus, there is a global need to revisit the issue of measuring adherence to multiple
medications. Currently, the operationalization of joint adherence to multiple medications is
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borrowed from the definition of adherence to a single drug. That is, a patient is adherent if he or
she is ≥ 80% (in general) on all or some medications simultaneously taken for a disease.
Empirical work is required to determine the optimality of cut-points or threshold when
researchers choose to use nominal measure of intra-disease multiple medication adherence,
including those in which an average-based estimate is dichotomized. Another important issue,
particularly because of the absence of evidence for optimal thresholds for joint adherence, is the
selection of a method (e.g., ‘all’, ‘average’, ‘at least any’ etc.) that results in the best prediction
of outcomes. In other words, benchmarking the measurement practices within the domain of
intra-disease multiple medication adherence has not yet happened.
Intra-disease multiple medication adherence entails a situation that is conceptually
distinct form that of single drug adherence. The situation occurs because of prescriptions of two
different chemical entities intended to treat the same disease. In other words, the issue is to
devise a measure that represents clinically meaningful summary adherence by virtue of its focus
on the disease and treatment outcomes but not on individual medication adherence estimates. In
their pursuit to improve quality of care, several organizations (e.g., the National Committee for
Quality Assurance (NCQA), the Agency for Healthcare Research and Quality (AHRQ), and the
Pharmacy Quality Alliance (PQA)) emphasize the need for developing measures including
healthcare quality indicators. As a result, there exist composite measures of clinical quality
indicators (e.g., Shwartz et al., 2008). However, the development of appropriate composite
measures for joint adherence is still lacking. In summary, the issue of appropriately
operationalization of the measure of multiple medication adherence is very consistent with
contemporary thoughts in the measurement literature (e.g., Reeves et al., 2007; Shwartz et al.,
2008) but has not been addressed yet.
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CONCEPTUALIZATION
Adherence to Multiple Medications
Adherence to Multiple Medications Taken for a Single Disease
Chronic disease management requires at least continual and effective
pharmacotherapeutic intervention. The patient remains always at the center of and is a crucial
partner in disease control efforts that take place in social and physical environments. Despite the
advancement of knowledge and the availability of advanced pharmacotherapies, significant
barriers to treatment appear to reside in the psychological and behavioral domains (Rosenstock,
1985).
Health psychologists have advanced different theoretical approaches in their attempt to
understand various determinants of health behavior, including adherence to medications. One of
such approaches emphasizes on the dynamic, iterative, and reciprocal nature of such behaviors
and adopts a system theory view that is oftentimes governed by goals or feedback processes
(Bishop, 1991). Fundamental to this approach is the understanding of how patients assess and
interpret their illness. According to the Common Sense Model of Self-Regulation (CSM)
(Leventhal, Brissette, and Levethal, 2003), adherence behavior represents an effort on the
patient’s end to cope with a disease that results from cognitive and emotional appraisals of
illness. The theory postulates that a patient is likely to exhibit adherence behavior if adherence
makes sense within his concept of the illness, taking into account his experience with the illness
and medications, potential outcomes of adherence behavior, and individual beliefs about the
illness. Indeed, as changes in cognitive pathways are accompanied by befitting coping attempts,
medication adherence will be affected accordingly. The CSM has been further extended to
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incorporate medication beliefs into the cognitive mechanisms of the CSM (Horne, 2003). The
extended framework contends that medication adherence is related to specific beliefs about
beneficial effects (necessity beliefs) and worries about detrimental effects (concern beliefs) of
medications. In addition, the extended framework includes two general beliefs: general harm
beliefs – general mistrust about medications and general overuse beliefs, which describe a
patient’s concern that physicians prescribe too many medications. This framework has been
applied to medication adherence in different chronic diseases (diabetes and cardiovascular
diseases) (Bane, Hughes, and McElnay, 2006; Tibaldi et al., 2009). It should be noted here that
there is a distinction (see Helman, 1981 for a discussion) between illness and disease. However,
the propositions advanced by the framework seem to make sense regardless of such distinctions,
as adherence behavior is largely patient driven and based on a determination of health status or
perception of illness. Empirical evidence from studies (BaneHughes, and McElnay, 2006;
Tibaldi et al., 2009) suggest that specific necessity and concern beliefs consistently predict
intentional medication adherence and are indeed better predictor than general beliefs. Allen
LaPointe et al. (2010) reported a significant association between nonpersistent use of antihyperlipidemic medications and decrease in perceived necessity of cardiac medications. Schuz
and colleagues (2011) applied the framework in a longitudinal study to examine the role of
beliefs about medication ‘as a whole’ without regard to specific illnesses. Elderly patients’
necessity beliefs about medication were associated with intentional nonadherence and general
overuse beliefs with unintentional nonadherence. Interestingly, a positive association between
number of medications and adherence was found after controlling for past adherence. However,
these findings are difficult to interpret adherence because of a lack of focus on illness in the
study. Specifically, adherence may be driven by beliefs in individual medications or subsumed
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under overall illness beliefs to seek protections from the illness. The later argument is consistent
with illness perceptions under the CSM and may be relevant for understanding intra-disease
multiple medication adherence. In other words, it may be that cognitive perceptions or
representations of medications along with that of the disease play a pivotal role in adherence
behavior and affect adherence behavior to multiple medications prescribed for a disease. Again,
this argument is founded on a cogent theoretical rationale that is based on the role of illness
representation in adherence behavior (Leventhal, Difenbach, and Leventhal, 1992).
Empirically, self-regulatory perspective or illness representation has been applied to
examine adherence in multiple chronic disease categories (e.g., hypertension, diabetes) (Meyer,
Leventhal, and Gutmann, 1985; Gonder-Frederick and Cox, 1991). It is important to note that it
is unlikely for a patient to understand the necessity of individual medications within a disease
category. However, it is not unlikely to have distinct concerns (e.g., side effects) for individual
medications. As such, these concerns may be addressed appropriately (e.g., therapy
modification, counseling, subsidence of symptoms gradually etc.) at the provider level during
subsequent pharmacy or clinic visits. If addressed, it may rather enhance patient convictions
about the medications. In addition, empirical findings suggest that compared to necessity,
concern beliefs play a minor role in affecting adherence (Schuz et al., 2011). This argument
about adherence to multiple medications for a disease rests on the premise of patients’
knowledge of the indications of their prescription medications. Only 13% of patients in a
primary care practice reported not knowing the indication of at least one of their prescription
medications, which constituted 6.3% of all prescription medications that were studied (Persell et
al., 2004). A small survey at an academic primary care clinic reported that patients identified a
correct indication for nearly 80% of their medications (Marks et al., 2010). While impressive, it
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is important to note that the extent of understanding may vary for different diseases. For
example, lack of knowledge was only 3% for diabetes medications (5% for oral anti-diabetic
medicines and none for insulin) and most prevalent for cardiovascular medications with 11% in
hypertensive and anti-hyperlipidemic medications (Persell et al., 2004). Another study
conducted among dialysis patients reported that a significantly larger number of patients knew
the indication for their antihypertensive drugs and calcitriol than for their phosphate binder
(Cleary et al., 1995).
Several other variables, including demography, have been examined as determinants of
adherence. However, as discussed previously, conclusive evidence relating demography to
adherence does not exist. It is not an exception even when the studies that used the selfregulatory framework are considered. For example, Wroe (2002) reported unintentional
nonadherence was less strongly associated with decision balance, and more so with demography,
age in particular. In contrast, Schuz et al. (2011) found no association of demography with
adherence while Horne and Weinman (1999) reported only age affecting adherence. At a
minimum, it can be posited that illness and medication beliefs may have an independent effect on
joint adherence behavior that cannot be explained by other factors. Indeed, adherence may be
primarily driven by illness perceptions. Therefore, the following hypotheses are presented with
regard to adherence to multiple medications taken for a disease:

H1:

Overall, there will be a positive covariation between adherence behaviors related to
two medications taken concurrently for the same chronic disease.

H1a:

Overall, the covariation of adherence between behaviors related to two medications
taken concurrently for the same chronic disease will persist after controlling for
gender.
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H1b:

Overall, the covariation of adherence between adherence behaviors related to two
medications taken concurrently for the same chronic disease will persist after
controlling for age.

H 2:

In general, patients will demonstrate a positive relationship between changes in
adherence behaviors related to two medications taken concurrently for the same
chronic disease over a period. In other words, the slope of adherence to each
medication over time will be positively related (‘association of the evolutions’).

H2a:

The ‘association of the evolutions’ will persist after controlling for gender.

H2b:

The ‘association of the evolutions’ will persist after controlling for age.

Adherence to Multiple Medications Taken for Concordant Diseases
Many patients suffer from multiple chronic diseases. Chronic disease patients have a
higher propensity to suffer from multiple morbidities. For instance, according to the Medical
Expenditure Panel Survey, most adult diabetics have at least one comorbid chronic disorder
(Druss, 2001). Other studies reported that as many as 40% of diabetics had more than two
chronic diseases (Maddigan, Feeny, and Johnson, 2005; Wolff, Starfield, and Anderson, 2002).
However, not all chronic comorbidities are necessarily similar in terms of having underlying
relationships among them. Piette and Kerr (2006) provided a useful yet broad typology for
classifying chronic conditions. They outlined three general dimensions or features of comorbid
conditions: clinically dominant comorbid conditions, concordance of conditions, and
symptomatic/asymptomatic conditions. Most relevant for the purpose of this study is the
concordance feature. As defined by Piette and Kerr (2006), concordant diseases are those that
“represent parts of the same overall pathophysiologic risk profile and are more likely to be the
focus of the same disease and self-management plan” (p. 727). In contrast, discordant
comorbidities do not directly share either pathogenesis or management characteristics. For
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example, hypertension, coronary artery disease, and diabetes are considered concordant while
diabetes and cancer or irritable bowel syndrome would be defined as discordant conditions.
Moreover, it is thought that concordant diseases are likely to be managed by a single provider.
Clinical practice guidelines help shape the management of chronic concordant comorbidities.
For example, diabetes guidelines oftentimes make specific recommendations for the
management of concordant conditions such as hyperlipidemia and hypertension (Boyd et al.,
2005). In other cases, treatment management plans for concordant diseases follow specific
patterns. For example, treatment of hypertension and dyslipidemia may be initiated together or
within a short interval of each other. These patterns (e.g., treatment synchronization) may have a
positive influence on adherence (Agarwal et al., 2009).
Patients may hold different beliefs about illnesses and associated medications.
Medication use for individual medications may vary because of differential perceived risks and
benefits attributed to each medication (McHorney and Gadkari, 2010). Similarly, illness
perceptions may or may not vary depending on disease. For instance, it was reported that while
perceptions of diabetes were different from hyperlipidemia and hypertension, the latter two
demonstrated similarity on many components of illness perceptions (Stack et al., 2008; 2011);
however, self-reported intentional nonadherence did not vary between OADs, AHT, and statins
(Stack et al., 2010). Such a relationship between adherence and beliefs is counterintuitive.
Methodological issues and a lack of distinction between dimensions (e.g., intentional) of
adherence may explain some difference. It may also be such that even if perceptions (e.g.,
necessity) vary across some diseases, patients may still demonstrate adherence to all (e.g.,
varying degrees of necessity for all) but strengths of associations between medication use may be
attenuated. Thus, a latent influence may be conceived that ties along concordant chronic disease
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care. While Nichol et al. (2009) reported the likelihood of transition to full adherent status over
time of those who showed selective adherence to one drug but not the other, Ho et al. (2006b)
reported that some patients chose to continue with only one therapy or more. These results
provide mixed evidence for associations of adherence across medication categories.
Patients may possibly exhibit different behaviors across diseases when one of disease is
symptomatic in nature. Inferences derived from perceived symptoms play a very important role
in patient-driven management of chronic diseases (Gonder-Frederick and Cox, 1991). Although,
in general, adherence to treatment regimens tends to be lower in patients whose illnesses are
asymptomatic, contrary evidence also exists. Symptom status did not predict adherence among
ischemia patients (Carney et al., 1998). Haynes, Taylor, and Sackett (1979) concluded that the
association between symptoms and adherence was not very consistent. However, recognition,
interpretation, and inferences made about symptoms may influence behavior in every aspect of
medical decision-making and disease management. Piette and Kerr (2006) argued that
physicians might view managing bothersome symptoms as greater concerns for patients and
focus on treating symptoms to improve patients’ functioning and quality of life as well as
prevent poor long-term outcomes.
Different factors are likely to affect adherence behavior across different concordant
diseases. Some factors (e.g., medication-specific beliefs) may not favor associations of
adherence across such diseases. Another factor that has been examined in studies of adherence is
prescription burden; however, the relationship is not very clear (Benner et al., 2002; Grant et al.,
2004). In contrast, treatment focus or clinician priority related to concordant disease
management during clinical encounters, if any, may alter patient perceptions about respective
medications or illness leading to associations. It is contended that there will be, at least weak,

43

associations of adherence across concordant diseases. Therefore, the following hypotheses were
proposed:
H 3a:

For patients suffering from multiple concordant chronic diseases, there will be a
significant covariation of adherence behaviors related to medications taken
concurrently for an index chronic disease and another asymptomatic chronic disease.

H 3a1:

For patients suffering from multiple concordant chronic diseases, there will be a
significant covariation of adherence behaviors related to medications taken
concurrently for an index chronic and another asymptomatic chronic disease
regardless of disease.

H 3b:

For patients suffering from multiple concordant chronic diseases, there will be a
significant covariation of adherence behaviors related to medications taken
concurrently for an index chronic disease and another asymptomatic chronic disease
even when number of chronic diseases increases.

H 3c:

For patients suffering from multiple concordant chronic diseases, there will be a
significant covariation of adherence behaviors related to medications taken
concurrently for an index chronic disease and another symptomatic chronic disease.

Measurement of Intra-disease Multiple Medication Adherence
While deliberating on the issue of intra-disease multiple medication adherence, an issue
that remains is the determination or development of an appropriate composite measure of
adherence. Currently, several approaches are used for measuring joint adherence. These
measurement approaches are grounded in the definition of adherence to a single drug. That is, a
patient is adherent only if he is 80% (in general) or more on all simultaneously taken medications
intended to treat a disease or some other variant of this approach. Another way to measure
multiple medication adherence is averaging individual medication adherence estimates of all
simultaneously taken medications intended to treat a disease. An assumption made by these
approaches is that all medications are created equal. This assumption is questionable for several
44

reasons. First, some medications are more “forgiving” – a drug attribute, which dictates that the
duration of action significantly exceeds the dosing interval – of poor adherence compared to
others (Urquhart, 1998). Thus, the impact of nonadherence is likely to differ based on this
characteristic. This, of course, needs to be emphasized that even the most forgiving medication
cannot be effective if not taken for a long time. Second, physicians intensify therapy with a
purpose such as controlling different biomarkers representing different pathways (e.g., fasting
serum insulin or glucose) or aggressively controlling a single end-point (e.g., blood pressure).
The mechanistic approach of drug action dictates that there are differential effects of medications
on individual disease markers (de Winter et al., 2006). Indeed, medication consumption affects
one intermediary outcome or more that are considered to cause observable outcomes such as
hospitalizations or death. It is sensible to think of medications in terms of preventing such
outcomes. This thought is consistent with clinical practice that oftentimes emphasizes achieving
targeted intermediary outcomes (e.g., HbA1c). Finally, pathophysiology of chronic disease is
not yet fully understood. However, it is generally accepted that chronic disease may progress at
a certain rate and individual medications are likely to have different impact on that rate. For
example, de Winter et al. (2006) compared disease progression rates representing change in βcell function and change in insulin sensitivity over time in patients receiving gliclazide,
metformin, and pioglitazone; apart from differential symptomatic short-term effects, different
disease progression rates for each parameter were observed among these treatment groups. In
fact, drug treatment for a chronic disease only slows down the process, which will continue to
progress at a specific rate. For example, it was found that even when patients’ adherence with
diabetic medications was nearly 100%, the disease was found to progress over time (Charbonnel
et al., 2004; de Winter et al., 2006). Thus, the overall impact of noncompliance may be further
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complicated when the effect, likely to be different for individual medications, on disease
progression rate is considered. Although these effects cannot be accurately captured without
pharmacokinetic-pharmacodynamic (PK-PD) modeling, potentially differential effects should be
considered in some way while conceptualizing a summary measure of joint adherence. One
plausible way is to derive weights based on a medication’s comparative effectiveness with
respect to some outcome. Precisely, the weight represents adherence driven efficacy,
conceptually analogous to what is termed as ‘use-effectiveness’ by Hughs and Walley (2003), as
it is practically very difficult or infeasible to tease out pure efficacy from the impact of
adherence. Thus, weights can be determined by estimating the impact of adherence on
intermediate clinical markers, composite outcomes such as QALY, or adverse consequences,
including hospitalization. Furthermore, weights may be based on short-term or long-term
outcomes as deemed appropriate.
Over the last few years, there has been an increasing emphasis on developing composite
measures of quality indicators. This wave has been seen in the domain of hospital and clinical
quality indicators. However, the definition of composite indicators varies across studies. While
some researchers define composite measure as weight-based average (Geppert, 2011; Shwartz et
al., 2008), others define it as dichotomized measure (Reeves et al., 2007). Geppert et al. (2011)
operationalized a complex formula of AHRQ quality indicator (QI) composite measure as
weighted average of risk-adjusted ratio and the reference population ratio from which weight is
determined empirically. In contrast, Reeves et al. (2007) defined ‘all or none’, conceptually
equivalent to ‘all’ or ‘both’ measures as described previously, as composite measure. In this
study, the composite measure was defined in the spirit of Geppert et al. (2011). The proposed
new measure representing composite adherence is defined below. The formula is presented for
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two medications; however, it can be extended to accommodate more medications. This is an
empirical regression weight-based composite average measure, henceforth termed as ‘composite’
measure. By definition, the composite measure allows for the benefits of individual medications
based on partial adherence, if any.
Adhcom =

W1 . A1 + W2 . A2
W1 + W2

where Adhcom = empirical regression weight-based composite adherence estimate,
Adhi = estimated adherence to drug i ,
wi = outcome-based regression weight for drug i;
•

Assuming all drugs do NOT have equal effectiveness/ efficacy

•

Assuming a joint additive effect

•

Assuming trivial effects of disease progression and disease status at baseline
As stated before, apart from developing a summary measure, there is a need to determine

which one constitutes an appropriate method among several measurement approaches for intradisease multiple medication adherence. In other words, the performance of these measurement
approaches must be compared in order to select the most appropriate measure. In most studies,
adherence measures are dichotomized including categorization of an average-based measure
(e.g., Piette et al., 2007) although wide variability occurs. From the perspective of calibration,
such approaches for categorization suffer from limitations and make some assumptions that do
not appear to be grounded theoretically or empirically. Therefore, the following objectives will
be examined:
1. To examine the effectiveness of the composite measure,
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2. To compare the performance of the existing measurement approaches with the composite
measure,
3. To determine the optimal cut-point of the composite measure,
4. To determine the optimal cut-point of the average measure and other continuous measures.
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CHAPTER 3
METHODOLOGY
This chapter will discuss the methodology used to examine the study hypotheses and
objectives. The study has two major focuses: adherence behavior to multiple medications and
multiple medication adherence measurement. The methodology addressing the hypotheses and
objectives associated with these two substantive areas are organized separately whenever
appropriate. In addition, the data analysis plan to examine the hypotheses and objectives are
discussed.
The study was approved by Thompson Reuters and compliant with the protocol specified
in the Data User Agreement (DUA) between the company and The University of Mississippi.
The study was compliant with the Health Insurance Portability and Accountability Act (U.S.
Department of Health and Human Services). In addition, approval was obtained from the
Institutional Review Board (IRB) at The University of Mississippi.

Research Design
A longitudinal observational study design was employed for this study. Using
retrospective administrative claims data, study subjects were identified. Medication and health
service utilization of these patients were determined as described below. However, for the
comparative validation and calibration of the measurement approaches a prospective study
design was conducted utilizing the same data source.
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Description of Data Source
This study utilized the MarketScan® Commercial Claims and Encounters database
(MCCED) for 2002 and 2003 from Thomson Reuters (Healthcare) Inc. The MCCED is a large
and comprehensive relational database that represents millions of individuals and consists of
medical and prescription claims of private sector employees and their dependents. This multisource database is constructed through submissions of health insurance data. Collectively, the
database incorporates data from a large number of payers, including commercial insurance
companies, Blue Cross and Blue Shield plans, and third-party administrators (TPAs). The fullyintegrated data can track patient information across sites, types of providers, all claims types
including medical/surgical and outpatient pharmaceutical claims, and over a number of years.
Rigorous validation methods, as stated by the company, ensure the completeness, accuracy, and
reliability of data. The data appear robust and reflect a continuum of care provided to patients
that allows analysis of utilization patterns and the subsequent outcomes associated with medical
care and medication use.
The Commercial Claims and Encounters Database has the following structure:
1. Annual Enrollment file
2. Aggregated Populations file
3. Medical/surgical Claims files:
•

Inpatient Admissions file

•

Inpatient Services file
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•

Facility Header file

4. Outpatient Services file
5. Outpatient Pharmaceutical Claims file
The enrollment files include information about demography (e.g., age, gender,
geographic region of residence), plan, and enrollment history. The prescription claims files
include national drug codes (NDC), therapeutic class, dates of purchase, quantities of medication
dispensed, days’ supplies, refill indicator, and plan and cost related information. The Inpatient
Admissions files contain records that summarize information about a hospital admission. These
files are constructed after identifying all of the encounters or claims (service records) associated
with an admission (e.g., claims from hospital, physician and/ or surgeon, and independent labs).
Information in the Inpatient Admission claims files includes hospital stays, including length of
stay, date of admission or discharge, diagnosis (ICD-9 ) and procedure codes (CPT-4 or
HCPCS), diagnosis related group (DRG), and provider type. The Inpatient Services files contain
the individual facility and professional encounters and services associated with the inpatient
admission record. An identifier that exists in both the Inpatient Admissions and the Inpatient
Services files identifies the individual service records that come from each admission record.
The outpatient services claims files include services that were rendered in a doctor’s office,
hospital outpatient facility, emergency room, or other outpatient facility. Some of the
information, aggregated to the level of each outpatient visit, are diagnosis codes, treatment
procedures, place of outpatient service (e.g., emergency room, office). A few claims in the
outpatient claims files may represent inpatient services because the claim could not be
incorporated into an inpatient admission (e.g., no room and board charge was found); generally,
place of service is coded as inpatient. For the study, the Enrollment files, Inpatient Admission
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files, Inpatient Services files, Outpatients Services files, and Outpatient Pharmaceutical claims
files were utilized to create a longitudinal panel of observations for each subject.

Disease State Selection
Primary Disease Context of the Study
In recent years, physicians have been found to prescribe multiple medications
concurrently for the treatment of a single disease. Such multiple medication regimens occur in
many diseases, including hypertension, diabetes, heart failure, and so on. Thus, a number of
diseases are available, in which the objectives of this research can be studied empirically. In
fact, two or more diseases can be selected for empirical work. For the sake of parsimony,
however, only one disease was selected. Diabetes was chosen as the primary disease state. Such
a selection was deemed appropriate for several reasons.
Diabetes has been and continues to be a concern in the U.S. The recently published
National Diabetes Fact Sheet 2011 estimated that the number of diabetes patients including those
undiagnosed was at 25.6 million or 11.3% of all people in the age group of 20 years or older.
The report revealed that diagnosed and undiagnosed diabetes patients comprised 13.7% of
individuals who were 45-64 years old and 26.9% of 60 years or older in 2010. In addition,
according to the fact sheet, 1.9 million new cases of diabetes were diagnosed in people aged 20
years and older in 2010; the extent of newly diagnosed cases varied by age group. Among
diagnosed new cases in 2010, over one million patients were between 45 and 64 years old (CDC
National Diabetes Fact Sheet 2011). However, a great concern implied in the report could be
that the number of patients estimated to have pre-diabetes (i.e., serum glucose levels higher than
normal but not yet high enough to be classified as diabetes) was reported to be 79 million in
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2010. Pre-diabetes was also reported to affect patients across all ages. Not all pre-diabetes
individuals develop diabetes but a large proportion do over time. Estimates provided by
different studies widely vary depending on methods and definitions (e.g., impaired glucose
tolerance vs. impaired fasting glucose levels, population, follow-up time) (see Nichols, Hillier,
and Brown, 2007 for a discussion). The Diabetes Prevention Program revealed that 11 cases per
100 person-years progressed from pre-diabetes to type 2 diabetes over about three years of
follow-up and many people with pre-diabetes develop type 2 diabetes within 10 years (Knowler
et al., 2009).
Diabetes patients often suffer from a number of comorbidities. CDC estimates that 67%
of adults aged 20 years or older with self-reported diabetes in 2005–2008 had high blood
pressure or used prescription medications for hypertension. Mykkanen et al. (1993) reported that
70% of the adults with type 2 diabetes also had hypertension or hyperlipidemia. As such, many
diabetes patients are prescribed multiple medicines to improve metabolic control, serum glucose
and cholesterol level, and blood pressure (Morris, 2001; Rosenstock, 2001). Indeed, intensive
disease management is often advocated for diabetes patients. The American Diabetes
Association (2004) recommends aggressive management of hypertension in adult diabetes
patients and the use of multiple (two or more at proper doses) medications to achieve blood
pressure targets. Improper or poor management of diabetes has been associated with deaths and
several secondary complications, including heart disease, stroke, kidney disease, blindness, and
amputation. Diabetes was the seventh leading cause of death in 2007 and the risk for stroke is 2
to 4 times higher among people with diabetes (CDC National Diabetes Fact Sheet 2011).
Understandably, the cost of diabetes is enormous. The total cost of diagnosed diabetes in the
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United States in 2007 was estimated to be $174 billion, including $116 billion for direct medical
costs (CDC National Diabetes Fact Sheet 2011).
Apart from adverse outcomes that may be attributed to the fact that patients fail to
achieve treatment goals (Saydah et al., 2004), the treatment pattern in diabetes has undergone a
significant change over the last couple of years. Specifically, the trend of using multiple
medication regimens has increased considerably. Nau, Garber, and Herman (2004) examined the
use of multiple medication therapies in a managed care population and reported that the
percentage of diabetes patients who were receiving multiple medications for diabetes increased
to 43% in 2001 from 27% in 1997. Similarly, Alexander et al. (2008) found that the average
number of diabetes medications per treated patient increased from 1.14 in 1994 to 1.63 in 2007
and monotherapy declined by approximately 40%. This trend could be attributable partly to
pharmaceutical innovation. A number of new medication classes (e.g., TZD, DPP-4 inhibitors)
have been introduced over the past two decades. More importantly, a number of new medication
classes are in the development pipeline (Nguyen et al., 2011) and expected to be introduced to
the U.S. market in the future. Thus, it does not appear likely that multiple medication regimens
use for the treatment of diabetes will decrease in the future. Conversely, the continuing trend of
more aggressive pharmacotherapeutic management coupled with the availability of innovative
therapies makes multiple medication therapies more likely in diabetes. Thus, diabetes appears to
be an appropriate disease category for examining the effect of polypharmacy on adherence and
polypharmacy adherence on health outcomes.
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Selection of Concordant Diseases
Effective disease management for patients with multiple medications or chronic
conditions may pose an overwhelming challenge to providers and patients alike. Piette and Kerr
(2006) provided a useful and intuitive framework that might facilitate such efforts. The authors
provided several examples to outline the concordant-discordant as well as the symptomaticasymptomatic framework. Although the orthogonality of boundaries may be blurred, it is
undeniable that some examples make more intuitive sense than do others. Following the
authors’ proposition, hypertension, dyslipidemia, and diabetes are considered concordant
asymptomatic diseases whereas angina is considered symptomatic. Applying the principle,
angina can also be considered concordant with the aforementioned diseases.

Identification of Study Subjects
Selection of Multiple Medication Regimens within the Primary Disease
As was presented previously, the major focus of the study lies on those patients who have
been prescribed multiple medications for a disease (i.e., diabetes). Several classes of
medications are available for the treatment of diabetes, including sulfonylureas (SU), metformin,
insulins, thiazolidinediones (TZD), alpha-glucosidase inhibitors, meglitinide, glucagon-like
peptide-1 (GLP-1) analogues, and dipeptidyl peptidase-4 (DPP-4) inhibitors. Diabetic patients
who are prescribed multiple medications may receive two or more classes of medications
described above. Thus, a number of different combinations exist and some combinations of
medications occur more frequently than do others. For example, insulin and metformin are
oftentimes prescribed together. TZDs are added often to metformin or SU. For this study,
patients who were prescribed TZDs and SUs concurrently were included. These two classes are
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frequently used but not, usually, as fixed-dose combinations. Although insulins are frequently
used, adherence to insulin is difficult to measure from administrative claims data. Metformin is
widely used but oftentimes prescribed as fixed-dose combination product that restricts its
variability in usage. Other medications (e.g., DPP-4 inhibitors) are relatively new and their
usage patterns are still evolving.

Selection of Medications for Concordant Diseases
Two asymptomatic diseases concordant with diabetes were considered in this study:
dyslipidemia and hypertension. Commonly used medications for the treatment of dyslipidemia
include fibrates and statins. Other classes include bile acid sequestrants (cholestyramine,
colesevelam, and colestipol), niacin, and ezetimibe. Two classes of anti-hyperlipidemic
medications are seldom prescribed together and medications under the other classes are
prescribed generally as adjunct to statins. In instances where patients were found to be on more
than one medication, statin adherence was considered for the sake of simplicity of calculation of
adherence. Many medications are available and indicated for the treatment of hypertension.
Angiotensin II receptor blockers (ARB) or Angiotensin I converting enzyme inhibitors (ACEI),
generally in combination with a thiazide diuretic, are considered as initial therapy for diabetic
hypertensive patients while β-blockers and calcium channel blockers (CCB) are add-on therapies
(Whaley-Connell and Sowers, 2005). As such, these five classes of AHTs were considered.
Moreover, such an approach is consistent with a previously published study of adherence to
medications among diabetes patients suffering from multiple comorbidities (Stack et al., 2010).
An attempt was made to confirm diagnoses of hypertension (ICD-9 codes 401 - 405) from
medical services records. Unlike dyslipidemia and hypertension, angina is symptomatic and
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concordant with diabetes. While many medication classes including antihypertensives are
prescribed for angina pectoris, nitrates are the core pharmacotherapeutic treatment for angina
(Parker and Parker, 1998). In addition, past adherence/persistence research has examined
nitrates for the treatment of angina (Grant et al., 2004; Kardas, 2004; Poluzzi et al., 2006). Only
di-nitrate, mono-nitrate and nitroglycerin (not sublingual) tablets and capsules were considered
as these medications are expected to be consumed at regular intervals (at least once daily). In
addition, an effort was made to confirm from medical services utilization data whether they had
any diagnosis of angina. Consistent with past research, the ICD-9 codes 413.x (angina pectoris),
414.0, 414.8, 414.9 (ischemic heart disease), and 786.5 (chest pain) were selected to
operationalize “ICD angina” such that it includes all conditions most likely representing chronic
angina (Pakhomov et al., 2007). Medications, including those for diabetes, were selected based
on literature (Parker and Parker, 1998; Wang, 2006) (Appendix A).

Figure 3.1: Illustration of Subject Identification to Examine Adherence
Identification period
Index date
TZD
Qtr 1 2002

Qtr 2 2002

Eligible observation period

SU
Qtr 3 2002

Qtr 4 2002

Qtr 5 2003

Qtr 6 2003

Qtr 7 2003

Qtr 8 2003

Selection of Subjects and Observation Periods
For this study, the identification of subjects occurred from January 1, 2002 through
September 30, 2002 (Figure 3.1). Patients who filled at least one prescription for each
medication (i.e., SU and TZD) were identified from the prescription claims records. Such a
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filling pattern would provide an indication that the patient was prescribed both medications.
Furthermore, the earliest (or later of two initial fills) fill date indicating that patient was
prescribed both medications served as the index date. For example, if a patient filled a
prescription for a SU on March 23, 2002 and a prescription for a TZD on September 29, 2002,
the index date for the patient would be September 29, 2002. Because of their complementary
mechanisms of action, it was assumed that physicians were unlikely to replace one medication
with the other even when the latest fill date for one and the earliest fill date for the other occur at
widely-apart temporal distance. However, the order of prescription was not considered for this
project. The observation period started 90 days after the index date. The 90-day limit was
chosen to allow for any physician-driven therapy modification. Thus, the latest date on which an
observation can start for a patient was January 1, 2003 and continued through December 31,
2003. It can be noted here that subjects were likely to have variable observation periods
depending on respective index dates.

Primary Inclusion Criteria
Subjects identified thus far were considered for inclusion in the study if they met a set of
additional requirements. First, subjects were required to be 18 years or older on the index date.
Second, they must have been continuously enrolled in MCCED with pharmacy and medical
benefits for at least 15 months starting from their respective index date. The 15-month period
included 90 days (approximately, 3 months) of pre-observation period and 12 months of
observation period. It can be noted here that the choice of the duration is consistent with the
literature. A review of studies on adherence with AHT, OAD, and LIP reported that the mean
duration of studies were 30, 18, and 15 months for LIP, OAD, and AHT, respectively (Cramer et
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al., 2008). Anti-diabetic prescription trends using the data source suggested that a large
proportion of these diabetes patients were prescribed the combination of SU and TZD before
January 1, 2002 (Cohen et al., 2003). Thus, many patients who continued to fill during the preindex period had been filling the scripts for at least a year. In addition, it was required to ensure
that failing to refill was not driven by physician decisions. In other words, the lack of filling was
not due to a decision to modify therapy on the part of the prescriber. Especially for those new to
treatment, early modification of therapy is likely to occur because of many issues (e.g., side
effects) within a first few months of treatment. Third, patients must not have records of filling
other anti-diabetic medications including insulin after the respective index date and during the
study period; however, patients were included if they filled a prescription for insulin or other
anti-diabetic medicines than SU and TZD only after the minimum 15-month period. In such
cases, patients were not followed after they had started such fills. In other words, the period in
which only the two study medications were filled were considered for analysis for these patients.
Because anti-diabetic therapies are to be continued life long, this criterion together with some
others as described above would, as best as can be determined, ensure that any lack of filling is
because of nonadherence and not because of physician-driven treatment modifications. Finally,
study subjects who were less than 65 years at all time during the observation period were
selected. Elderly (≥ 65 years) patients suffer from multiple diseases including diabetes - the
disease of interest for the study. Because of their age, oftentimes a disease might have advanced
to a point when clinician might find it a clinical necessity to prescribe multiple medications for
the disease. However, prescription drug coverage of all elderly may not be uniformly captured
in the database (i.e., MCCED). In addition, Medicare beneficiaries’ inpatient and outpatient
medical services utilization might not be completely captured in this commercial claims database
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and such information is very critical for examining the measurement-related objectives. Those
patients who met all the above criteria constituted the general pool of eligible subjects. It is
noted here that additional criteria are required to be met prior to examining some hypotheses and
objectives and are discussed in appropriate sections below.

Inclusion Criteria for Examining Inter-disease Medication Adherence
Subjects for examining inter-disease medication adherence were selected from those
identified as described above by imposing additional requirements. Dyslipidemia, hypertension,
and angina were considered as concordant diseases in conjunction with diabetes. Statins or
fibrates were considered for dyslipidemia, any of ACEI, ARB, CCB, diuretics, and β-blockers
for hypertension, and nitrates (oral nitroglycerin, di-nitrates, and mono-nitrates) for ischemia.
Patients were required to show at least two fills for medications for the respective diseases. For
example, patients with diabetes and dyslipidemia must be filling statins or fibrates in addition to
a SU and a TZD; patients with diabetes, dyslipidemia, and hypertension must fill any AHT as
described above and any anti-hyperlipidemic medications in addition to a SU and a TZD. A
similar process was followed for patients on angina medications. The two fills criterion for
concordant disease medications was consistent with that of intra-disease (diabetes) medications
adherence. In addition, having the subjects demonstrate that they had filled concordant disease
medications before the observation period started ensured at least one year of observation.
Again, this was consistent with intra-disease medications adherence criteria.
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Inclusion Criteria for Examining Measurement Approaches
Patients who were included for examining intra-disease multiple medication adherence
constituted the general pool of patients. In addition, subjects were excluded from analysis if they
had experienced within the first 90 days of observation any adverse outcome events (i.e.,
hospitalization or ER visits) against which measures were to be compared. This step was
adopted to avoid measurement problems and potential confounding. A similar exclusion
criterion was used while examining the effect of adherence on health outcomes in diabetes
patients (Yu, Yu, and Nichol, 2010).

Variables and Measurement
Periods of Observation
The observation period for each patient was divided into several quarters or 90-day
periods. Each patient was observed for at least four quarters. Duration of three months as the
unit of observation was chosen because some patients might obtain their prescription
medications from mail-order pharmacies and received 90 days’ worth of medication supply. In
addition, such a time period is, to an extent, consistent with reality such that chronic disease
patients may visit a pharmacy or a physician once in three months. Whenever a patient entered
the study, the first quarter for the patient is started. Thus, first quarters for different patients may
represent different calendar time points.
The selected patients were followed until one of the following events happened: 1)
disenrollment; 2) patients started filling insulins or any other OADs than SUs and TZDs; or 3)
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the end of the year 2003. An additional criterion was imposed for comparing the measurement
approaches. Subjects were followed until the event occurred.

Measurement of Adherence
Various measures of adherence can be computed using administrative claims data. These
measures use different formulas to estimate adherence (see Hess et al., 2006 for a discussion).
Mathematically, these formulas are closely related and yield similar values. Past research has
attempted to compare the values estimated by different measures. Karve et al. (2008) compared
the predictive validity of eight different measures that are generally used in studies that utilize
administrative claims data. The authors concluded that PDC provided the most conservative
estimate of adherence. Similarly, Hess et al. (2006) examined several measures and reached a
similar conclusion. Martin et al. (2009) compared adherence estimates measured by PDC, MPR,
and truncated MPR (MPRt) in psychiatric disorder patients, including those who were prescribed
multiple therapies because of therapeutic duplication; the authors recommended using PDC as
measure of adherence. Interestingly, the authors discussed a variant of PDC (i.e., the both
approach) that can be considered a conservative estimate of adherence when applied in the (intradisease) multiple medications context such as this study. Considering only the overlapped
period, the ‘both’ approach inherently assumes that effects of simultaneously-prescribed
medications occur only when taken together. It is very likely that best plausible outcomes can be
achieved if consumed together as deemed by prescribers. Nonetheless, effects of individual
medications cannot be, in general, denied regardless of whether one is taken or both are taken
concurrently. PDC appears to demonstrate better or equivalent predictive ability of outcomes
when compared against other measures suitable for use in research with claims data. For
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example, PDC showed the highest c-statistic reflecting its superior ability of health care
utilization in patients suffering from diabetes (Karve et al., 2008).

Table 3.1: Intra-disease Multiple Medication Adherence Measurement Approaches
Measure
Composite

Operational Definition
1.

Average*
At least
one*

ℎ

+
ℎ

ℎ≥1

ℎ

/( 1 + 2)
/2
≥ 80%

ℎ≥1
ℎ

ℎ

Min***
All*

ℎ

+

Max**
Both

ℎ

2.

ℎ
ℎ

ℎ

ℎ

≥ 80%

ℎ

X 100%
ℎ

≥ 80%

X 100% ≥ 80%

Note: Qtr: quarter; SU: sulfonylureas; TZD: thiazolidinediones; w1 and w2: weights;
*
adapted from Choudhry et al., 2009;
**
and *** continuous estimate of the ‘at least one’ and ‘both’ approaches respectively

For this study, adherence was measured as PDC and estimated based on days supply for
each patient for each class of medications in each quarter. As noted above, days supply data
were available in the pharmacy claims data. The value of the days’ supply was truncated in case
the supply extended beyond the observation period. Thus, for some patients who were found to
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be suffering from multiple chronic diseases, more than two PDC were calculated in some
quarters. Any switches between different therapeutic agents (molecules) were not carried
forward but that between equivalent agents (e.g., different brands of the same molecule) were
carried forward. For instance, if a patient was switched from glyburide to glipizide, then
glyburide on hand, if any, on the day of filling of glipizide was not carried forward for
calculating PDC for SU. While the assumption in case of the former was that the physician
modified the therapy for some reasons and the patient was not supposed to consume those extra
medications on hand, the assumption in the latter (i.e., between brands) was that the patient
continued taking the medication from previous refills as part of the same regimen. Similarly, in
case of dosage modification, adjustments were made based on recommendations occurring at a
later point in time.
Anticipating the plausibility of multiple medications prescribed for hypertension, an a
priori method was adopted for calculating adherence to antihypertensives after considering
several alternative options. One possibility was to consider each PDC separately. However, it
could add complexity to statistical analysis and cause potential modeling problems because of an
increase in number of DVs. Second, it was possible to estimate PDC in a manner analogous to
the both approach. If a therapy augmentation for AHT occurs after observation starts, adherence
estimates can be weighted by days’ supply. However, it would be difficult to distinguish
nonadherence episodes from physician-driven switch or discontinuation for some reasons (e.g.,
side effects). In such cases, it would further underestimate adherence of these patients.
Therefore, it was decided that adherence to multiple antihypertensive medications would be
measured based on the ‘at least one’ approach, i.e., proportion of days covered by at least one
AH therapy. This is essentially a single medication adherence estimation approach. This was

64

thought appropriate because it consistently measured adherence for all hypertension patients
regardless of numbers of AH medications.
Four different measurement approaches exist in the literature for estimating adherence in
situations of multiple medications use for a single disease. In addition, a composite measure was
conceived and empirically tested. Three of these measurement methods (average-based,
composite, and all) utilized the values of PDC estimated individually for each medication for
diabetes. Although the other two methods (i.e., at least one and both) of PDC estimates are
generally dichotomized for analysis, they can be used as continuous measures as well (termed
here as ‘max’ and ‘min’ respectively) following the operational definition described in Table 3.1.
These seven PDC estimates of adherence to multiple medications were computed for each
patient for each quarter for intra-disease adherence measurement comparisons.

Measurement of Outcome Variable
The outcome variable was meant to assess the potential impact of nonadherence to
medications. The outcome was used for assessing comparative performance of the various
measures of intra-disease multiple medications adherence. In other words, the variable was used
only for examining issues related to the measurement of combined adherence. Several clinical
outcomes are available of which one may be chosen for the effectiveness of diabetes treatment.
HbA1c, fasting serum insulin level, fasting plasma glucose (FPG), and post-prandial blood
glucose (PPG) are frequently used for monitoring patients for clinical purposes. However, these
variables cannot be measured from administrative claims data. Several variables have been used
as proxy measures for clinical effectiveness in research related to adherence. Some of them are
quality adjusted life years (QALY) (Martinez et al., 2008) and health service utilization such as
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hospital service utilization or ER visits (Balkrishnan et al., 2007). Two utilization outcomes are
generally assessed in studies on adherence to diabetes medication: 1) diabetes-related health
services utilization (DSU), and 2) all-cause health services utilization (Balkrishnan et al., 2007;
Karve et al., 2008; Sokol et al., 2005). Outcomes frequently encountered by diabetes patients
can also be considered. Smith and Maynard (2004) reported cardiovascular hospitalizations,
primarily coronary in origin, accounted for approximately 50% of all hospitalizations in persons
with diabetes within VA and non-VA medical care systems. Lau and Nau (2004) reported an
increased likelihood of a diabetes-, cardiovascular-, or cerebrovascular-related hospitalization
among diabetes patients with poor adherence (≤ 80%). It is easy to understand such an outcome
(i.e., cardio- or cerebrovascular related) lies in the middle of the conceptual continuum on which
more extreme points are occupied by any-cause hospitalization and DSU. Yu, Yu, and Nichol
(2010) examined the association between adherence and microvascular complications of diabetes
using office-based diagnosis of complications. A number of chronic complications of diabetes
and their association with medical costs have been identified (American Diabetes Association,
2002). This report considered a diverse set of clinical conditions such as cardiovascular diseases,
neurological symptoms, renal complications, endocrine/metabolic complications among others.
In contrast, a study conducted in Europe examined eight conditions, including myocardial
infarction, heart failure, stroke, ischemic heart diseases, while estimating diabetes-related
hospitalization costs (Gerdtham et al., 2009). While it may be logical to focus on macrovascular
diseases, including heart attack, chest pain, coronary heart disease, heart failure, and stroke, as
they are among major complications in diabetes patients (Deshpande, Harris-Hayes, and
Schootman, 2008), diabetes-specific outcomes encompassed in past research has varied from
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being very specific to very broad. Even within specific events, the focus has been laid on
microvascular complications or macrovascular events.
Diagnoses of microvascular complications (DSU) and macrovascular events appeared as
suitable outcome measures for this project. Cohen et al. (2003) reported that approximately 29%
of diabetes patient population enrolled in the MarketScan database suffered from diabetes
complications in 2000 at which time the number of diabetes population was growing at an
approximate rate of 10%. Although, microvascular complications lie closer to medication
consumption in the causal chain of medication effect, it was not selected because of possibility of
difficulty in finding a sufficient number (expected to be about 5%) of outcome events in a
relatively short time-frame of this study. Similarly, it was difficult to determine if a patient had a
preexisting diagnosis (for exclusion purposes) if they did not make a physician’s office visit
within three months or even six months, which might leave even a shorter window for analysis.
It is further complicated by an inherent limitation in the database that includes only two
diagnosis options for outpatient services. Similarly, because of the availability of only 2 years of
data it would be difficult to find enough subjects having DSU. Furthermore, any-cause inpatient
hospitalizations or those occurred primarily because of medical reasons was not chosen because
of anticipation of insufficient number of events required for a robust analysis.
Any-cause ER service utilization (ERSU) was chosen as the primary outcome variable to
examine the measurement issues-related objectives. ERSU is defined as any ER visits occurring
after at least 90 days since the beginning of observation. Existing evidence support that anycause ER visits can be used as an indicator for quality of diabetes care (Stern et al., 2009).
Although objectives in this study are different from Stern et al., yet the adaptation of the concept
seemed reasonable. In addition, ERSU as outcome variable may have practical implications
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given high cost of management associated with them. ERSU was identified from the outpatient
services claims file used for comparing the utility of different measures. ER service utilization
was identified based on the procedures followed by a previously published study (Margolis et al.,
2010), which used the MarketScan data. ERSU was dummy coded where 1 indicated occurrence
and 0 nonoccurrence of events.

Measurement of Covariates
As discussed previously, chronic diseases often co-occur. As such, the comorbidity
profile of these patients was measured. Several measures of comorbidity exist that were
developed for different purposes and applied in different population (see de Groot et al 2003 for
a review). For this study, the Charlson Comorbidity Index (CCI) (Deyo, Cherkin, and Ciol,
1992) was used as the measure of comorbidity. The CCI demonstrates good reliability and
validity across studies (de Groot et al., 2003). As correlations between the CCI and adherence is
generally weak (Sokol et al., 2005), it is less likely to cause multicollinearity. The CCI was
measured based on medical claims until the end of first quarters. Patient demographic
characteristics (age and gender) were obtained from the enrollment file. Patients’ age as
mentioned in the annual enrollment summary file 2002 was used in the analysis. Other variables
recorded for descriptive purposes include pharmacy type, insurance type, and geographic region.

Data Analysis
The study has several broad aims. Data analysis plans for these aims are organized for
these aims and discussed below. Apart from hypotheses testing, descriptions of study population
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and estimates of adherence for different diseases and those based on different measurement
methods will be provided.

Intra-disease Multiple Medication Adherence Behavior
It can be recalled that the substantive points that were to be examined included
relationship between adherence to multiple medications for a disease and that of the evolutions
of adherence behaviors. These relationships are outlined by hypotheses 1 through 2b (Table
3.2). These hypotheses were tested in the longitudinal analysis framework using a multilevel
approach. This analytical approach offers sophisticated modeling appropriate to the discretetime longitudinal structure of the data and concurs with Fitz-Simon, Bennett, and Feely (2005)
who argued to model random effects that incorporate intra-patient variability in prescription refill
patterns.

Table 3.2: Statement of Hypotheses
H1:

Overall, there will be a positive covariation between adherence behaviors related to
two medications taken concurrently for the same chronic disease.

H1a: Overall, the covariation of adherence between behaviors related to two
medications taken concurrently for the same chronic disease will persist after
controlling for gender.
H1b: Overall, the covariation of adherence between adherence behaviors related to two
medications taken concurrently for the same chronic disease will persist after
controlling for age.
H 2:

In general, patients will demonstrate a positive relationship between changes in
adherence behaviors related to two medications taken concurrently for the same
chronic disease over a period. In other words, slope of adherence to each
medication over time will be positively related (‘association of the evolutions’).

H2a: The ‘association of the evolutions’ will persist even after controlling for gender.
H2b: The ‘association of the evolutions’ will persist even after controlling for age.
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H 3a: For patients suffering from multiple concordant chronic diseases, there will be a
significant covariation of adherence behaviors related to medications taken
concurrently for an index chronic disease and another asymptomatic chronic
disease.
H
3a1:

For patients suffering from multiple concordant chronic diseases, there will be a
significant covariation of adherence behaviors related to medications taken
concurrently for an index chronic and another asymptomatic chronic disease
regardless of disease.

H 3b: For patients suffering from multiple concordant chronic diseases, there will be a
significant covariation of adherence behaviors related to medications taken
concurrently for an index chronic disease and another asymptomatic chronic
disease even when number of chronic diseases increases.
H 3c: For patients suffering from multiple concordant chronic diseases, there will be a
significant covariation of adherence behaviors related to medications taken
concurrently for an index chronic disease and another symptomatic chronic
disease.

The multilevel modeling approaches are one of the frequently employed statistical
methods to analyze longitudinal data. Specifically, multilevel modeling has been widely used by
education psychologists for years to investigate contextual effects for a variety of outcomes
including educational performance, instructional effectiveness, and change in attitudes over time
(Fraine, Van Damme, and Onghena, 2007; Marsh, 2007). Multilevel modeling has also been
applied in the context of health and health behavior. For example, researchers have examined
the association between various contextual factors and disease morbidity rates in many diseases,
including asthma (Juhn, 2005), coronary heart disease (Diez-Roux et at., 1997), and
cardiovascular diseases (Leyland, 2005). These approaches account for the hierarchical or
clustered nature of data. Hierarchy occurs because units are grouped or clustered at different
levels. Multilevel modeling considers information from all levels simultaneously and is able to
assess the variation in a particular response attributable to each level (Goldstein, 1991).
Certainly, for clustered data multilevel approaches may offer advantages including chance of
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drawing correct inferences over traditional methods (Hox 2002; Snijder and Bosker, 1999) and
allow for, most importantly, micro-level and cross-level analyses including modeling changes as
a function of time.

Table 3.3: Multilevel Approach to Longitudinal Data Analysis

Unconditional Means Model
Yij = M0j + Rij, where M0jis the mean of subject j and Rij is deviation of Y for subject j at
occasion i from the mean
M0j = M0 + U0j , where U0j is deviation of subject j from the population mean M0
Alternatively, Yij = M0 + U0j + Rij
Unconditional Growth Model
Yij = M0j + M1j.Time + Rij , where M0jand M1jare the intercept and slope (or growth rate)
of subject j respectively and Rij is deviation of Y for subject j’s at occasion i from his or her
true change trajectory
M0j = M0 + U0j , where U0j is deviation of subject j from the population intercept M0
M1j = M1 + U1j , where U1j is deviation of subject j from the population slope M1
Alternatively, Yij = M0 + M1.Time + U0j + U1j.Time + Rij
Variance components can be computed for each of U0j, U1j, and Rij
Adapted from Singer and Willet (2003)

Multilevel growth curve modeling can be extended to incorporate multiple dependent
variables (DV) that are collected longitudinally. Such an approach, also known as multivariate
multilevel regression modeling (Snijder and Bosker, 1999), was used to assess the hypothesized
relationship between the two DVs (i.e., adherence to SU and adherence to TZD) including the
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trend parameters of them. More specifically, the association of the evolutions (i.e., changes)
over time was examined. In the multivariate model that was used in the study, the dependent
variables were nested within the measurement occasions, which were nested, in turn, within the
subjects. The multiple outcome variables were combined through proper specification at the
lowest level. Thus, the dependent variables form level 1, measurement quarters form level 2,
and patients form level 3.
First, the unconditional means (or, random intercept) model was fitted (Table 3.3). It can
be noted here that hypothesis testing (for intra-disease medication adherence) that was followed
in the study is consistent with the approach suggested by Singer and Willet (2003) who
recommend fitting the unconditional (i.e., without predictors) means model followed by
unconditional growth (or, random slope) model. The unconditional means model implies that a
specific observed value of y (i.e., Ytj or in this analysis, a person’s PDC at a specific quarter) at a
point t is a deviation from a person j’s true mean (i.e., Y0j) and thus, the actual individual change
trajectory is flat as represented by person-specific mean. In other words, under this model such
deviations or level 2 residuals (as level 1 contains multiple DVs in this study) are within-person
distance from respective individual means. Thus, variance component of level 2 under
unconditional means model is the population variability in an average person’s outcome
estimates around his or her own mean. Similarly, level 3 (for this study) residuals represent
between-person deviations from the population mean because a person individual mean is a
deviation from the population mean (Singer and Willet, 2003). The statistical models for
examining hypotheses associated with intra-disease multiple medication adherence were adapted
from the literature (Fieuws and Verbeke, 2004; Snijder and Bosker, 1999) and are presented
below.
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Random intercept model
Yhtj = M10.d1 + M20.d2 + U10j.d1 + U20j.d2+ R1tj.d1 + R2tj.d2 --------------- (1)
Random intercept with fixed covariates model
Yhtj = M10.d1 + M20.d2 + C1.d1.Cov + C2.d2.Cov + U10j.d1 + U20j.d2 + R1tj.d1 + R2tj.d2----- (2)
Random slope model
Yhtj = M10.d1 + M20.d2 + M11.(t-t0)d1 + M21.(t-t0).d2 + U10j.d1 + U20j.d2 + U11j.(t-t0).d1 + U21j.(tt0).d2 + R1tj.d1 + R2tj.d2--------------- (3)
Random slope with fixed covariates model
Yhtj = M10.d1 + M20.d2 + C1.d1.Cov + C2.d2.Cov + M11.(t-t0)d1 + M21.(t-t0).d2 + U10j.d1 + U20j.d2 +
U11j.(t-t0).d1 + U21j.(t-t0).d2 + R1tj.d1 + R2tj.d2--------------- (4)
where h=1 for adherence to SU and h=2 for adherence to TZD;
d1=1 when h=1; d1=0 otherwise, and d2=1 when h=2; d2=0 otherwise;
M10 and M20 are population mean for random intercepts model (eq. 1 and 2) but population
intercepts for random slope models (eq. 3 and 4);
M11 and M12 are population mean slope;
Ch (h=1,2) are coefficients for fixed covariates Cov;
Uh0j (h=1,2) are individual-dependent random components for jth individual that affect all values
Yhtj in the same way;
Uh1j (h=1,2) are individual-dependent random components indicating rate of change for jth
individual where t0 is the reference point;
Rhtj (h=1,2) are random deviations from individual mean for jth individual at time t.
Random effects, not parameters in a statistical sense but latent variables (Snijder and
Bosker, 1999), were the effects of interest. Under the assumption of normal distribution, there
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are two major estimation methods for measuring random effects: maximum likelihood (ML) and
residual (or restricted) maximum likelihood (REML). However, the REML method is useful for
testing overall model fit only when two models have the same fixed parameters but differ in
random effects. Random intercepts or random slopes were fitted first. Then sequentially
covariates (gender and age) were introduced in each model to examine whether effects would
persist after the effects of covariates were controlled. It should be noted here that while residual
variance components U10 and U20 (estimated from deviations U10j and U20j, respectively) for eq. 1
and 2 represent between-person variability around grand mean, those for eq. 3 and 4 represent
between person variability in initial estimate and U11 and U21 estimate between-person variability
in rates of change. Similarly, R1 and R2 (estimated from deviations R1tj and R2tj, respectively) for
eq. 1 and 2 estimate within-person variance or the pooled scatter of each individual’s data around
his or her individual mean and those for eq. 3 and 4 measure the scatter of each individual’s
values around his or her linear growth trajectory (Singer and Willet, 2003). Covariances related
to level 3 (i.e., inter-individual) random components between two dependent variables (i.e.,U10
and U20 for eq. 1 and 2; U11 and U21 for eq. 3 and 4) were examined for significance. In addition,
the goodness of fit test was conducted for covariate models. To examine the association of the
evolutions, methods suggested by Fieuws and Verbeke (2004) were followed. The correlation
between changes in adherence was given by

=

.

( 11
( 11).
.

21)
… … … … … … … … (5)
( 21)
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Inter-disease Multiple Medications Adherence Behavior
The random intercept model (described by equation 1) employed for hypothesis 1 was
adapted to examine hypothesis 3a through 3c. Specifically, hypertension, dyslipidemia, and
angina medication adherence were added in the model in addition to diabetes medication
adherence for hypothesis 3a, 3a1, and 3c, respectively, whereas adherence to anti-hyperlipidemic
medications was added in the model for hypothesis 3a to test hypothesis 3b. It can be understood
that the number of DVs in each of these models are either three or four. Thus, random intercept
model for intra-disease adherence is extended for inter-disease adherence by addition of extra
DVs. Notations are extended accordingly to incorporate additional random intercept components
due to additional DVs. Covariances/correlations between these random intercepts were the
effects of interest and tested for significance.
Random Intercept Model for Inter-disease Multiple Medications Adherence
Yhtj = ∑ Mi0.di + ∑ Ui0j.di + ∑ Ritj.di, where h =1, 2 or 3; di=1 if i=h, otherwise di=0.---- (6)

Measurement of Intra-disease Medication Adherence
The new composite measure that was described in Chapter 2 is a weighted average-based
measure. Conceptually, each adherence estimate can be weighted to form a formative scale of
composite value based on their relative contribution to patient health or treatment outcomes.
Deriving appropriate weights is critical to the success of any composite measures. Thus,
important issues include but not limited to which parameters and how such weights should be
derived. Some directions can be provided from the medical risk assessment literature. Several
risk evaluation models have been proposed to stratify risks systematically (see Gale et al., 2009
for a review). These models estimate risk of an event based on weights of individual factors
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derived from regression. For example, the EMMACE risk model predicts the risk of 30-day
mortality where age, blood pressure, heart rate are weighted (Gale et al., 2009). Similarly, the
TIMI risk score for the prediction of mortality in ST- elevation myocardial elevation is computed
as the simple arithmetic sum of factors of mortality weighted according to the adjusted odds
ratios (e.g., 1 point for 1 < OR < 2; 2 points for 2 < OR < 2.5 and so on) from logistic regression
analysis (Morrow et al., 2000). Calvin et al. (2000) cited the RUSH model where the risk of
sustaining a major cardiac complication is computed as weighted average; two medication
histories (0.85 for IV nitroglycerine required on admission and 1.34 for receiving neither βblocker nor CCB at admission) were weighted differentially. Indeed, weighting individual risk
factors by odds ratio, Calvin et al. (1995) argued, does provide a reasonable approach to risk
stratification for major complications.
The Cox proportional hazards model was used to derive weight estimates. This model
provides a semiparametric regression technique to discriminate risk factors, including those
varying with time, associated with the occurrence of events (e.g., ER visits) during a specific
interval (Singer and Willet, 2003).Advantages of the Cox method to model the time until an
event of interest occurs are that it makes no assumption about the shape of the underlying hazard
function, but identifies determinants of risks and estimates multipliers of the baseline hazard and
the relative risks(hazard ratios) associated with the risk factors(Singer and Willet, 2003). The
analysis of Cox regression is based on number of events per variable (EPV), not number of
patients or patient-years. Thus, a sufficient number of events is required to enable accurate
estimates. A general rule of a minimum of 10-20 EPV has been advocated for Cox regression
(Concato et al., 1995; Peduzzi et al., 1995) although Vittinghoff and McCulloch (2007) argued
that analysis with 5-9 EPV might be comparable with 10-16 EPV in some situations. In cases of
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fewer events per independent variable, resampling techniques can be used to test model validity
(Akins et al., 2008). In the Cox model for weight derivation, ERSU was the outcome measure
and adherence estimates were treated as time-varying covariates. Adherence measured as PDC
was computed for each quarter for each medication for diabetes. Comorbidity (CCI), gender,
and age were treated as fixed (i.e., time-invariant) covariates. However, as mentioned before,
patients were followed until the first occurrence of event. This analysis strategy was consistent
with a previous study (Yu, Yu, and Nichol, 2010) that examined the effect of adherence on
health outcomes. Hazard (parameter) estimates derived from Cox regression were used
subsequently as weights.
Following the effort of computation of weights, a series of analysis were performed to
compare the predictive ability of medication adherence as measured by different measurement
techniques available in the literature and the one proposed in this study. The seven PDC
measures of adherence (see Table 3.1) were calculated for each quarter for each patient. The
Cox regression analysis as described above was repeated in which ERSU was used as outcome
measure and one of the seven adherence estimates was used as risk factor in different models
while keeping the same covariates. Then the next step is to characterize the performance of the
models in which adherence was operationalized differently or measured by different
mathematical formulas. Two types of measures are used for such purposes while modeling
dichotomous outcomes: calibration and discrimination (Pembina and D’Agostino, 2004).
Calibration, as defined by the authors, describes how closely the probabilities predicted by the
model correspond with the observed outcomes. Discrimination is a measure of a model’s ability
to classify subjects correctly into one of the binary outcome categories (e.g., events vs. noevents). Although calibration and discrimination may be related, good discrimination does not
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automatically confer the ability of good calibration and vice versa (Pencina and D’Agostino,
2004); demonstration of a model’s ability to discriminate well should be of primary importance
(Harrell, Lee, and Mark, 1996).
C-statistic – equivalently, area under the Receiver Operating Characteristic (ROC) curve
– computed from a logistic regression analysis determines the predictive accuracy or
discrimination ability of the model and is one of the most popular measures of model
discrimination for binary outcomes (Hanley and McNeil, 1982). Unlike logistic regression, the
measurement of predictive accuracy in survival analysis is more complex because of censoring.
Harrell, Lee, and Mark (1996) introduced c-statistic as a natural extension of the ROC curve
analysis and suggested plotting the predicted probability of surviving until each time point tj
(j=1,2..) against the actual proportion of subjects surviving beyond tj. An overall C index,
conceptually based on the measure of c-statistic in logistic regression, has been proposed to
describe the performance of a survival analysis model (D’Agostino and Nam, 2004; Pencina and
D’Agostino, 2004). D’Agostino and colleagues outlined the steps of computation of C-index as
follows. From a time-to-event model, three sets of comparison groups can be identified: those
who experience event against those who do not (event vs. non-event), those developing event
against those also developing event (event vs. event), and event group against those censored
(event vs. censored). For the sake of computing C-index, event vs. event and event vs. non-event
comparisons are considered as usable pairs; in other words, if two individuals are randomly
drawn at least one must have an event while the other may or may not develop so. Given all
usable pairs, the C-index is computed based on the proportion of concordance such that a subject
with a lower predicted probability of event experiences event later than does another with a
higher probability or vice versa. Several variants of this conceptualization (Gonen and Heller,
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2005; Kremers, 2007) and implementation in statistical software exist (e.g., Liu, Forman, and
Barton, 2009). The modified definition advanced by Kremers (2007) was used in the study as it
is suitable for time-dependent covariates and adjusts for ties of events, if any. Unlike
D’Agostino and colleagues’, Kremers’ definition is indexed by event times and counting occurs
with respect to each event time. For example, if an individual i experiences event at time ti, it
counts all other individuals (Ci) except i not having event at ti but with predictor score lower than
that of i, those with greater score at ti and no-event at ti as Di, those (Pi) with equal score but noevent at ti, and those (i.e., ties) with event at ti as Ti. Then Ci, Di, Pi, and Ti represent the count of
useable pairs that can be formed with individual i at time ti and can be termed as concordant,
discordant, tied in prediction, and tied in time, respectively. Concordance (or, C-index)
quantifies the proportion of all useable pairs of subjects such that a subject with the higher
model-predicted risk of event experiences event earlier and vice versa. Kremers’
conceptualization of concordance has been used in empirical studies (Fang et al., 2011; Wong et
al., 2011b) to examine the accuracy of risk predictions and implemented in SAS by the author.
Concordance values and their confidence intervals estimated for models with different adherence
measures were compared.
Analysis was undertaken to determine the optimal cut-off point for dichotomization of
the four continuous adherence (i.e., composite, average, min, and max) measures. Unlike data
dependent methods (e.g., median-split), outcome-based methods for dichotomization of
continuous variables rely on statistical criteria that best separate groups with regard to the
outcome. ROC curve analysis is generally used to determine the optimal threshold of continuous
or ordinal variables that differentiates binary outcomes and is a popular method in diagnostic
medicine (Begg et al., 2000; Hanley and McNeil, 1982; Harrell, Lee, and Mark, 1996). Unlike
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in logistic regression, ROC curves appear to vary as a function of time when derived from
survival analysis (Heagerty, Lumley, and Pepe, 2000). Therefore, deriving optimal threshold
based on ROC curves is difficult. Moreover, time-dependent optimal threshold may not be
appealing conceptually. Another approach to dichotomization is based on maximization of
appropriate test statistics. In the case of censored data, several statistics that are routinely
reported by statistical software can be utilized for such purposes, including log-rank test
(Williams et al., 2006), concordance statistic, Wald statistic, and partial likelihood ratio statistic
(Gonen and Sima, 2008; Hollander, Sauerbrei, and Schumacher, 2001). Mazumdar and
Glassman (2000) outlined the steps required to derive an optimal cut-off value. This approach,
known as maximally selected statistic, is based on a series of two sample tests such that models
are run with each of the potential candidate cut-off values and the cut-off value for which the
respective model generates the maximum test statistic (or, minimum p-value) is chosen as
optimal threshold. In general, such models are run in a unavailable setting although
recommendations for multivariable model also exist (Mazumdar and Glassman, 2000;
Mazumdar, Smith, and Bacik, 2003). In order to manage potential inflation of type I error due to
multiple tests, several approaches have been recommended. The methods to address such
problems include: (1) significance level (α) adjustment (e.g., Bonferroni adjustment or some
variants), (2) p-value adjustment based on mathematical functions or distribution (e.g., adjusted
p-value of 0.002 is equivalent to unadjusted p = 0.05 while examining all values within the inner
80% distribution of the variable), and (3) cross-validation/ split sample approach (Altman et al.,
1994; Faraggi and Simon, 1996; Hilsenbeck and Clark, 1996; Lausen and Schumacher, 1996;
Mazumdar and Glassman, 2000; Mazumdar, Smith, and Bacik, 2003; Miller and Siegmand,
1982). In an unpublished study, Gonen and Sima (2008) contrasted the utility of five different
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statistics in deriving optimal cut-point with censored data and the partial likelihood ratio statistic
based method emerged as the best strategy that performed consistently. The partial likelihood
ratio statistic based minimum p-value approach was employed in the study. A set of candidate
values (65, 70, 75, 80, and 85) were chosen a priori. These points are somewhat consistent with
existing evidence (e.g., Karve et al., 2009; Hansen et al., 2009 for a single medication adherence)
and clinical expert opinion and may be useful for implementation purposes. Bonferroniadjustment was made for p-value and such adjustment may not result in underpowered analysis
because of relatively small number of tests.
Data were analyzed in SAS software, version 9.3 (SAS Institute, Inc., Cary, North
Carolina). Relevant SAS codes for multilevel modeling and SAS macros were obtained from the
literature and past research (Kremers 2007; Thorp, 2007).
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CHAPTER 4
RESULTS
Of all subjects whose data were available in the MarketScan 2002-2003 commercial
claims database, 32,400 enrollees had filled at least one prescription for a SU and TZD by
September 30, 2002. After the application of study inclusion criteria, 6922 subjects were eligible
for subsequent analysis. These subjects were between18 and 62 years old as of 2002,
continuously enrolled for at least 15 months from their index date (i.e., earliest date indicating
filling of both SU and TZD), and either did not fill any diabetes medications other than SU and
TZD after the respective index date or did not begin filing other diabetes medications until at
least 15 months after their index date.
Note on Study Subject Selection
All prescription claims records for 2002 and 2003 of the selected subjects were extracted.
NDCs from prescription (RX) claims files were merged with their respective active ingredient
(or drug) name and strength using the Multum Lexicon Drug Data Table (Cerner Multum, 2011).
Some enrollees filled nonzero quantities of a NDC more than once on one day. As such,
duplicate fillings occurred for both SU and TZD. Subjects associated with duplicate fillings of
medications were excluded from subsequent analysis. It was observed in the dataset that some
subjects had a record of filling multiple SU (e.g., Amaryl and glipizide) or multiple TZD and
others filled multiple strengths of a SU or a TZD (e.g., Avandia 2 mg, 4 mg, or 8 mg). For
subjects displaying prescription fillings of multiple medications or strengths of SUs or TZDs, it
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was observed that some patients filled multiple classes or strengths somewhat regularly while
others switched from one strength to another within a medication. It is conceivable as to why a
patient might be filling multiple strengths of medications. One potential reason may be that a
physician might advise his patient to take different strengths of medication at different times in
order to achieve desired therapeutic outcomes (e.g., 2 mg at morning and 4 mg at night).
However, it is difficult to differentiate instances of nonadherence from physician-driven
medication consumption decisions in cases of lack of regular filling patterns. Similarly, in cases
of patients filling multiple medications, it cannot be clearly determined whether or not a change
was made because of some legitimate medical reasons such as side effects. Thus, it is not
possible to determine accurately the state of adherence for a patient who filled multiple
medications. Because of indeterminacy a criterion was imposed for inclusion. That is, subjects
were restricted to any molecule switch and/or strength switch once only. This would ensure that
if subjects switched from one strength to another of the same medication or one medication to
another they would not be filling two strengths or two classes of medications simultaneously as
switches of each type were constrained to once or less. Thus, these subjects will be on two
diabetes medications, a SU and a TZD, at any point in time consistent with the objective of
examining simultaneous medication adherence for two diabetes medications.

Demography of Study Subjects
A total of 6043 subjects were available for final analysis and constituted the general pool
of study participants. The demographic characteristics of the subjects are described in Table 4.1.
On average, these subjects were available for observation for over 600 days. There were 55.5%
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male and the average age of the subjects was nearly 54 years. The subjects were located across
different geographic regions as determined from the enrollment summary file in 2002; however,
the majority of the subjects came from the South and north central regions. The subjects were
enrolled in different types of health benefit plans. PPO and comprehensive type of plans were
predominantly chosen ones. However, few subjects appeared to have changed their plan types
over their enrollment period. Approximately, 19% subjects filled prescriptions of SU and/or
TZD from both community and mail order pharmacies. However, the majority of the subjects
appeared to patronize community pharmacies only when prescription fills for SU and TZD were
considered jointly.

Table 4.1: Demography of the Study Subject Pool
Variable
Age
Gender (male)
Geographic Region#
Northeast
North Central
South
West
Plan type
Comprehensive
EPO
HMO
POS
PPO
POS with capitation
Number of Plan type
One type
Two or more
Pharmacy Patronage*
Community Pharmacy only

N
6043
3356

Mean (std. dev) /Frequency %
53.86 (6.67)
55.54%

523
2442
2580
488

8.65%
40.41%
42.69%
8.08%

1862
161
588
883
2789
462

27.61%
2.39%
8.72%
13.09%
41.35%
6.85%

5359
684

88.68%
11.32%

3776

62.49%
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Mail-order only
Either type
Number of Days of Observation
Number of Comorbidities
Charlson Comorbidity Index (CCI)

893
1135
6043
6043
6043

14.78%
18.78%
636.21 (79.01)
1.06 (0.31)
2.08 (0.42)

* Based on filling patterns for SU and TZD and other medication fills were not
considered; # there were 10 subjects from unknown regions:

INTRA-DISEASE MULTIPLE MEDICATION ADHERENCE
Overall, the subjects demonstrated good levels of adherence (about 74%) for both SU and
TZD and maintained consistency in adherence over time (Table 4.2). With regard to population
level estimates, the adherence levels of SU measured at each quarter closely followed the
adherence levels of TZD for the respective quarters. All subjects had 90-day observation periods
at least until the fifth quarter but the number of available days of observation in their last quarter
varied among subjects. For example, if a person was observed for seven quarters, he has six 90day observation periods and the last (i.e., seventh) quarter with 90-days or less. For the sake of
estimation of last quarter PDC, two options were available: keeping the 90-day denominator for
everyone or using subject-specific variable denominators based on availability. For the last
quarter, the number of available days of observation for a subject was entered in the respective
denominator as a wide variety of available days of observation were found (e.g., less than 10
days to 90 days). In addition, more than 1000 subjects had a last quarter such that the number of
days available for observation in the quarter was less than 30. As expected, adherence rates
continuously declined, although slightly, over time until quarter 6. However, the rates increased
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slightly for the last two quarters when number of patients who were available for observation
continued to decrease.

Table 4.2: PDC Estimates for SU and TZD
Quarter
1
2
3
4
5
6
7
8
Weighted Average#

N
6043
6043
6043
6043
6043
6043*
4979*
3752*

SU
Mean
84.19
75.00
73.81
72.90
71.70
69.76
70.00
72.18

TZD
Std. dev.
23.87
32.78
34.00
35.15
36.06
37.79
38.18
38.46

73.86

Mean
85.64
75.79
73.98
72.52
70.31
69.04
69.36
70.77

Std. dev.
22.52
33.13
34.82
36.42
37.86
39.38
39.58
40.02

73.66

* Numbers of days of observation in these quarters are not 90 days for all subjects
# Weighted by N
SU: Sulfonylureas; TZD: Thiazolidinediones

Examination of Hypotheses: Intra-disease Multiple Medication Adherence
A total of 6043 subjects were available initially for the examination of intra-disease
multiple medication adherence (Hypotheses 1 through 2b. Only full-quarter observations were
included in these analyses. For example, if a person had 7 full quarters of observations and one
incomplete quarter, his incomplete quarter PDC was dropped when analysis was performed on
the 8th quarter. The number of persons available in the 6th, 7th, and 8th quarter were 4996, 3772,
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and 447, respectively. Although random intercept models were run successfully, growth models
could not be run on the entire set of subjects because of computation limitations when the SAS
default method for the estimation of denominator degree of freedom (ddf) was used. However,
by limiting the analysis to subjects having at least 6 full quarters of observation, both models
could be run successfully. Another alternative option was to choose other methods for
estimation of ddf. Estimation of ddf is concerned primarily with fixed effect tests, which were
not the objective of this research. SAS offers many approximate ddf estimation methods. The
Kenward and Roger method (i.e., ddfm=KR on the PROC MIXED model statement) was used in
this study. The Kenward and Roger method requires less memory than the default method in
SAS and is thought to perform reasonably well when complicated covariance structures are
present, sample sizes are moderate to small, and the design is moderately balanced (Schaalje,
McBride, and Fellingham, 2001). Unconditional and conditional random intercept models and
growth models using the KR method were run for examining the hypotheses. The results are
summarized in Table 4.3.

Table 4.3: Multilevel Model Analysis – Intra-disease Multiple Medication Adherence
Model
Unc. Mns
Con. Mns1
Con. Mns2
Con. Mns3
Unc. Grt
Con. Grt1
Con. Grt2
Con. Grt3

Parameter
Int-SU/Int-TZD
Int-SU/Int-TZD
Int-SU/Int-TZD
Int-SU/Int-TZD
Slp-SU/Slp-TZD
Slp-SU/Slp-TZD
Slp-SU/Slp-TZD
Slp-SU/Slp-TZD

Covariance
Estimate
420.71
394.94
416.79
391.77
17.4088
17.4006
17.4111
17.4027

Std. error Z value
11.7966
35.66
11.3517
34.79
11.7301
35.53
11.2982
34.68
0.6031
28.87
0.6030
28.86
0.6031
28.87
0.6031
28.86
87

Correlation
P
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001

0.5665
0.5509
0.5641
0.5488
0.6209*
0.6207*
0.6209*
0.6207*

Unc. Mns: Unconditional Means model; Con. Mns: Conditional Means model; Unc. Grt:
Unconditional Growth Model; Con. Grt: Conditional Growth Model;
Int: Random intercept; Slp: Random slope;
1: mean centered age as covariate; 2: gender as covariate; 3: mean centered age and gender
as covariates; * Represents the association of evolutions
SU: Sulfonylureas; TZD: Thiazolidinediones

For the examination of hypothesis 1, a random intercept model was analyzed on quarterspecific PDC estimates. PDC estimates for different medications can be identified by a dummy
variable indicating different medications (i.e., SU and TZD). The covariation between random
intercepts of SU and TZD was estimated at 420. 71 and it was significant (p<0.001). Thus, H1
was supported. The corresponding correlation between random intercept for SU and that of TZD
was 0.5665. For examining Hypotheses 1a and 1b, age (mean centered) and gender was entered
one at a time in the above model. The effects were significant (Appendix). After controlling for
age and sex, the covariations remained significant at the level of 0.001. The correlations
between random intercepts of SU and TZD in the model with age and with gender were 0.5509
and 0.5641, respectively, providing support for H1a and H1b were confirmed.
Growth models were used to examine Hypotheses 2 through 2b. Two random
components were added to the slopes of PDC estimates for SU and TZD. Thus, the growth
models contained four random components – one component for the intercept and one for the
slope for each of the two adherence estimators. For the examination of hypothesis 2, covariation
between random slopes was examined. The results are described in Table 4.3. The covariation
between random slopes of SU and TZD was estimated at 17.41 and it was significant (p<0.001).
Thus, H2 was confirmed. The corresponding correlation (i.e., the association of evolutions)
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between random slopes for SU and that of TZD was found to 0.62. When Hypotheses 2a and 2b,
age (mean centered) and gender was entered respectively in the model specified for H2. After
controlling for the effect of age and gender, the covariation remained significant at the level of
0.001. The associations of evolutions of SU and TZD in the model with age and with gender
were 0.62. Thus, the results supported H2a and H2b, respectively.

INTER-DISEASE MULTIPLE MEDICATION ADHERENCE
In addition to using multiple diabetes medications, diabetes patients may use medications
for the treatment of one or more different chronic disorders. Hypotheses 3a through 3c were
meant to examine simultaneous adherence behaviors for medications prescribed for different
additional chronic diseases. Subjects were selected from the general pool with an additional
restriction that subjects must have at least four full quarters of observation beginning from the
inter-disease index date. The index date for inter-disease medication adherence may be different
from index date for intra-disease medication adherence. Inter-disease index date was determined
by the first fill for a medication intended for the asymptomatic chronic disease of interest; the
inter-disease index date could occur on or later than the index date. For example, in case of
examining adherence relationships between diabetes medications and an anti-hyperlipidemic
medication (asymptomatic chronic disorder), if a patient filled an anti-hyperlipidemic medication
before his index date for SU and TZD, the inter-disease index date took the value of the diabetes
index date. Similarly, for a patient on two diabetes medications, antihypertensives, and antihyperlipidemic medications the earliest date indicating the patient filled all requisite medications
at least once was considered as the index date for subsequent analysis. Four inter-disease index

89

dates were computed for a patient who was eligible for inclusion in all analyses associated with
Hypotheses 3a through 3c. Only those patients who demonstrated at least one prescription fill
for chronic disease of interest and had at least four quarters of observation following respective
inter-disease index dates were included in hypotheses testing.

Table 4.4: Demography of the Inter-disease Multiple Medication Adherence Subjects
Analysis
SU + TZD + LIP
(H3a)

SU + TZD +
AHT (H3a1)

SU + TZD + LIP
+ AHT (H3b)

SU + TZD +
ANG (H3c)

Variable
Age
Gender (male)
Number of Days of
Observation
Age
Gender (male)
Number of Days of
Observation
Age
Gender (male)
Number of Days of
Observation
Age
Gender (male)
Number of Days of
Observation

N*
2360

Mean (std. dev) /Frequency (%)
54.92 (6.02)
1387 (58.77)
609.95 (92.38)

2444

53.70 (6.57)
1316(53.85)
578.57 (162.81)

860

54.60 (94.15)
462 (55.66)
601.87 (6.13)

300

56.46 (4.73)
187 (62.33)
559.92 (101.74)

* Subjects who had at least four 90-day quarters of availability starting from analysis-specific
index dates
SU: Sulfonylureas; TZD: Thiazolidinediones; LIP: anti-hyperlipidemic medications; AHT:
hypertension medications; ANG: Anti-anginal medications
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Table 4.4 describes the demographic profile of the subjects included in inter-disease
multiple medication adherence analyses. Subjects were about 55 year old and had, on average,
560 days of observation following the start of the analysis-specific (e.g., SU + TZD + AHT +
LIP for H3b) index date. With regard to gender, subjects consuming multiple asymptomatic
chronic disorder medications were evenly split except for those having angina in which 62%
were male.

PDC Estimates for Different Chronic Diseases
The population PDC estimates for different asymptomatic chronic disorders were about
70% (Table 4.5). Subjects may have had incomplete observation periods from quarter 5 onward.
The PDC denominator for any incomplete quarters was based on available days of observation.
Patients receiving anti-hyperlipidemic medications had slightly lower average adherence rates on
those medications than their PDC for their diabetes medications. In contrast, those subjects
receiving antihypertensives showed slightly higher adherence rates when compared to their
diabetes medications. Higher adherence rates for antihypertensives, although small, persisted
even in subjects receiving four medications: SU, TZD, anti-hyperlipidemic medications agents,
and antihypertensives. Interestingly, adherence rates to nitrates were lower substantially.
Additionally, adherence rates in the last two quarters showed an increasing trend regardless of
the nature of disease.
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Table 4.5: PDC Estimates for Subjects on Medications for Multiple Chronic
Disorders
Model

SU+TZD+
LIP

SU+TZD+
AHT

SU+TZD+
LIP+AHT

Param

Qtr 1 Qtr 2 Qtr 3 Qtr 4 Qtr 5 Qtr 6 Qtr 7 Qtr 8

Mean
(SU)

85.20

77.31

76.38

75.44

74.46

72.36

72.49

74.17

Std. Dev

23.76

31.92

33.17

34.53

35.28

37.16

37.79

38.74

Mean
(TZD)

86.22

79.02

77.21

75.53

73.07

72.38

72.98

74.99

Std. Dev

22.76

31.20

33.61

34.91

36.90

38.48

38.43

38.54

Mean
(LIP)

84.05

74.02

72.01

69.98

68.79

67.36

70.09

71.46

Std. Dev

24.42

34.05

36.27

37.89

38.65

40.47

39.22

39.59

N

2360

2360

2360

2360

2357

2234

1748

1233

Mean
(SU)

84.47

75.76

74.87

73.92

72.23

70.58

70.32

73.55

Std. Dev

23.85

32.36

33.42

34.46

35.59

37.50

37.97

37.80

Mean
(TZD)

85.26

76.76

74.66

73.67

71.57

70.84

70.82

71.99

Std. Dev

23.26

32.99

34.77

35.91

37.34

38.44

38.96

39.79

Mean
(AHT)

86.07

78.72

77.56

76.71

75.45

74.82

76.31

77.58

Std. Dev

22.71

31.34

32.40

34.06

35.12

36.21

35.05

35.70

N

2212

2212

2212

2212

2212

2145

1734

1276

Mean
(SU)

85.46

78.02

76.87

75.74

74.56

72.48

72.65

75.09

Std. Dev

24.01

31.94

33.14

34.74

35.30

37.22

37.65

38.61

Mean
(TZD)

85.88

79.50

78.05

77.32

74.90

73.88

74.74

76.38

Std. Dev

22.71

31.34

33.24

33.79

35.80

37.79

37.63

38.23

Mean
(LIP)

82.78

74.90

72.66

72.11

68.68

67.25

71.09

71.56

Std. Dev

25.23

33.73

35.99

36.70

38.00

40.42

38.83

39.92

Mean
(AHT)

86.40

81.75

80.42

79.50

78.03

77.79

79.89

80.19
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SU+TZD+
ANG

Std. Dev

23.27

29.29

31.04

33.23

33.74

35.22

33.64

34.82

N

830

830

830

830

830

775

593

408

Mean
(SU)

79.84

75.53

75.41

73.37

72.13

69.57

69.36

77.01

Std. Dev

28.94

34.27

34.89

36.34

37.38

40.27

39.47

36.87

Mean
(TZD)

80.90

71.09

69.57

70.12

68.09

69.00

69.87

71.45

Std. Dev

29.18

37.28

38.96

38.86

39.93

40.97

40.32

42.07

Mean
(ANG)

37.99

25.76

25.73

24.69

24.43

25.38

31.41

36.05

Std. Dev

37.07

40.48

40.12

38.38

39.10

39.50

42.38

44.80

N

300

300

300

300

299

253

166
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Param: Parameters; Qtr: Quarter;
Subjects may have incomplete quarters from quarter 5 onward and PDC denominator for
any incomplete quarters was based on available days of observation
SU: Sulfonylureas; TZD: Thiazolidinediones; LIP: anti-hyperlipidemic medications;
AHT: hypertension medications; ANG: Anti-anginal medications

Table 4.6: Number of Subjects for Inter-disease Multiple Medication Adherence
Quarter
1
2
3
4
5
6
7
8

Number of subjects with medications for multiple chronic diseases
SU+TZD+LIP SU+TZD+AHT SU+TZD+LIP+AHT SU+TZD+ANG
2360
2212
830
300
2360
2212
830
300
2360
2212
830
300
2360
2212
830
300
2235
2145
776
253
1752
1736
594
167
1240
1284
410
88
92
87
19
6

SU: Sulfonylureas; TZD: Thiazolidinediones; LIP: anti-hyperlipidemic medications;
AHT: hypertension medications; ANG: Anti-anginal medications
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Examination of Hypotheses: Inter-disease Multiple Medication Adherence
Multi-level modeling analyses were used to examine Hypotheses 3a through 3c.
Specifically, multivariate unconditional random intercept models were analyzed in which
quarter-specific PDC estimates for each medication were analyzed. Consistent with the
approach used to examine intra-disease multiple medication adherence hypotheses, a subject was
included in a quarter only if he had a full quarter of observation. Random effects were modeled
from data using the unstructured option in SAS and subject-specific random error was modeled
using the variance component option in SAS. It is noted that number of subjects in the following
analyses continued to decrease after the fourth quarter. The numbers of subjects available for
each analysis in each quarter appear in Table 4.6.

Table 4.7: Multilevel Model Analysis – Inter-disease Multiple Medication Adherence
Model
1

Unc. Mns
Unc. Mns 1
Unc. Mns 1
Unc. Mns 2
Unc. Mns2
Unc. Mns2
Unc. Mns 3
Unc. Mns 3
Unc. Mns 3
Unc. Mns 3
Unc. Mns 3
Unc. Mns 3
Unc. Mns 4
Unc. Mns 4

Parameter

Covariance

Correlation

Int-SU/Int-TZD
Int-SU/Int-LIP
Int-LIP/Int-TZD
Int-SU/Int-TZD
Int-SU/Int-AHT
Int-AHT/Int-TZD
Int-SU/Int-TZD
Int-SU/Int-LIP
Int-LIP/Int-TZD
Int-SU/Int-AHT
Int-AHT/Int-TZD
Int-LIP/Int-AHT
Int-SU/Int-TZD
Int-SU/Int-ANG

Estimate Std. error Z value
P
379.31
17.4716
21.71 <.0001
376.26
18.3807
20.47 <.0001
467.59
19.5534
23.91 <.0001
402.97
19.0566
21.15 <.0001
371.98
17.8122
20.88 <.0001
452.80
19.4428
23.29 <.0001
371.46
29.1893
12.73 <.0001
318.59
27.1611
11.73 <.0001
410.15
28.6394
14.32 <.0001
348.81
30.5863
11.40 <.0001
457.90
32.3164
14.17 <.0001
439.85
30.7196
14.32 <.0001
341.21
59.4130
5.74 <.0001
78.2794
63.7770
1.23 0.2197

0.5524
0.6239
0.5136
0.5524
0.5436
0.6208
0.5428
0.4909
0.6293
0.4753
0.6213
0.6294
0.3837
0.0753
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Unc. Mns 4

Int-ANG/Int-TZD

164.53

68.0516

2.42

0.0156

0.1498

Unc. Mns: Unconditional means model; Int: Random intercept;
1: PDCs for SU, TZD, LIP; 2: PDCs for SU, TZD, AHT; 3: PDCs for SU, TZD, LIP, AHT;
4: PDCs for SU, TZD, ANG
SU: Sulfonylureas; TZD: Thiazolidinediones; LIP: anti-hyperlipidemic medications; AHT:
hypertension medications; ANG: Anti-anginal medications

A total of 2360 subjects were available for analysis initially (i.e., until the fourth quarter)
and the number reduced to 1240 at the seventh quarter and only 92 in the eighth quarter. The
results of these analyses are summarized in Table 4.7. Covariation of random intercepts between
SU and anti-hyperlipidemic medications and that of TZD and anti-hyperlipidemic medications
were significant (p<0.001). Thus, H3a was supported. The correlation between random
intercepts for diabetes medications was 0.55. The correlation between random intercepts for SU
and that of anti-hyperlipidemic medications was 0.62 and that of TZD and anti-hyperlipidemic
medications was 0.51.
The above analysis was repeated to examine H3a1 in which subjects were on
antihypertensive medications instead of anti-hyperlipidemic medications. Initially, 2212 persons
were available. Covariation of random intercepts between SU and antihypertensives and that of
TZD and antihypertensive medications were significant (p<0.001). Thus, H3a1 was supported.
The correlation between random intercepts for SU and that of antihypertensive medications was
estimated at 0.54 (Table 4.7) and that of TZD and antihypertensives was 0.62.
To examine H3b, multivariate multilevel analysis was performed on subjects receiving
antihypertensive medications and anti-hyperlipidemic medications in addition to two diabetes
medications. Unlike the subjects in the aforementioned analyses, the subjects in the present
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analysis were on at least one additional medication. All covariations between cross-disease
medications were examined. Covariation of random intercepts between SU and
antihypertensives and that of TZD and antihypertensive medications were significant (p<0.001).
Covariation of random intercepts between SU and anti-hyperlipidemic medications and that of
TZD and anti-hyperlipidemic medications were significant (p<0.001). Finally, covariation of
random intercepts between anti-hyperlipidemic medications and hypertension medications were
significant (p<0.001). Thus, H3b was supported. The correlations of random intercepts for SU
and hypertension medication, for SU and cholesterol medication, for TZD and cholesterol
medication, for TZD and hypertension medication, and for hypertension and cholesterol
medication were estimated at 0.48, 0.49, 0.63, 0.62, and 0.63, respectively.
For the examination of H3c, in which subjects were on anti-anginal medications in
addition to diabetes medications, 300 persons were available initially. The covariation of
random intercepts between SU and angina medications was not significant (p=0.075) whereas
that of TZD and angina medications was significant (p=0.016). Thus, H3c was partially
supported. However, the correlation between random intercepts for SU and TZD was estimated
at 0.38 (Table 4.7) and significant (p<0.001).

Table 4.8: Associations of Evolutions for Inter-disease Multiple Medication
Adherence
Model

Parameter

Correlation

P

Con. Grt 1
Con. Grt 1
Con. Grt 1
Con. Grt 2

Slp-SU Slp -TZD
Slp -SU/ Slp -LIP
Slp -LIP/ Slp-TZD
Slp -SU/ Slp -TZD

0.6437
0.6084
0.6897
0.6390

<0.0001
<0.0001
<0.0001
<0.0001
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Con. Grt2
Con. Grt2
Con. Grt 3
Con. Grt 3
Con. Grt 3
Con. Grt 3
Con. Grt 3
Con. Grt 3
Con. Grt 4
Con. Grt 4
Con. Grt 4

0.7086
0.6881
0.7283
0.7215
0.7131
0.6280
0.7699
0.7123
0.5913
0.1472
0.2093

Slp -SU/ Slp -AHT
Slp -AHT/ Slp -TZD
Slp -SU/ Slp -TZD
Slp -SU/ Slp -LIP
Slp -LIP/ Slp -TZD
Slp -SU/ Slp -AHT
Slp -AHT/ Slp -TZD
Slp -LIP/ Slp -AHT
Slp -SU/ Slp -TZD
Slp -SU/ Slp -ANG
Slp -ANG/ Slp -TZD

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.1233
0.0406

Con. Grt.: conditional growth model with mean centered age and gender as covariates
1: PDCs for SU, TZD, LIP; 2: PDCs for SU, TZD, AHT; 3: PDCs for SU, TZD, LIP,
AHT; 4: PDCs for SU, TZD, ANG
SU: Sulfonylureas; TZD: Thiazolidinediones; LIP: anti-hyperlipidemic medications;
AHT: hypertension medications; ANG: Anti-anginal medications

Following the intra-disease multiple medication adherence analysis, additional analyses
were undertaken to examine the relationship between random growth patterns of inter-disease
medication adherence over time. Specifically, the relationships between random slopes for
adherence to two medications (i.e., associations of evolutions) were examined. The results of the
analyses are presented in Table 4.8. In general, associations of evolutions are strong and
significant at the level of 0.001. After controlling for the effects of age and gender, such
associations ranged from 0.61 to 0.76 for people who are on either anti-hyperlipidemic
medications or antihypertensive medications or both in addition to two diabetes medications.
However, the association of evolutions between SU and anti-anginal medications was poor and
not significant (p>0.1) whereas that of TZD and anti-anginal medications were week (0.21) but
significant (p<0.05). The association of evolutions of SU and TZD measured in patients taking
angina medications was estimated at 0.59 and significant (p<0.001).
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MEASUREMENT OF INTRA-DISEASE MULTIPLE MEDICATION ADHERENCE
PDC Estimates
It is known that single estimates of PDC for multiple medications can be computed using
different algorithms. Table 4.9 provides quarter specific and cumulative PDC estimates as
calculated by the continuous measure-based approaches. Cumulative PDC estimates were
calculated by proportion of days on medications out of all days until the end of quarter or
observation. Thus, subjects may or may not have a complete last quarter. Individual or
population estimates of PDC varied widely depending on types of measures used. For example,
population PDC estimates for the fifth quarter in which all had a 90-day observation period were
82.78%, 59.22%, and 71% based on maximum (i.e., availability of any medications on a day),
minimum (i.e., availability of all medications on a day), and average approaches, respectively.
Similarly, cumulative PDC estimates differed; cumulative PDC estimates for the eighth quarter
with subject-specific variable observation period were 87.40%, 67.29%, 71.47% when PDC was
calculated by maximum, minimum, and average based approaches, respectively. Variations in
estimates based on the minimum measurement were generally more than those of the other two
approaches.
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Table 4.9: PDC estimates by Different Continuous Measures
Approach

Maximum

Minimum

Average

Quarter

N

1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8

6043
6043
6043
6043
6043
6043
4979
3752
6043
6043
6043
6043
6043
6043
4979
3752
6043
6043
6043
6043
6043
6043
4979
3752

Quarter–specific
Mean
Std Dev

Cumulative
Mean
Std Dev

93.30
86.73
85.45
84.39
82.78
81.40
81.63
83.05
76.54
64.06
62.34
61.03
59.22
57.40
57.74
59.90
84.92
75.40
73.90
72.71
71.00
69.40
69.68
71.47

93.30
90.02
88.49
87.47
86.53
85.76
86.47
87.40
76.54
70.30
67.65
65.99
64.64
63.52
64.89
67.29
84.92
75.40
73.90
72.71
71.00
69.40
69.68
71.47

14.88
24.86
26.79
28.51
30.26
32.19
32.32
32.19
28.28
37.26
38.31
39.48
40.21
41.54
41.99
42.75
19.33
27.96
29.36
30.66
31.88
33.38
33.55
33.72

14.88
18.07
19.52
20.62
21.46
22.09
21.26
20.49
28.28
29.88
30.62
31.15
31.52
31.80
31.04
29.97
19.33
27.96
29.36
30.66
31.88
33.38
33.55
33.72

Single measures of multiple medication adherence were computed based on a
dichotomous scale where a cut-point of 80% was used to classify patients as adherent. There
was considerable variability in estimates measured by the ‘at least one’ (i.e., whether or not 80%
days on at least one medication), ‘both’ (i.e., whether or not 80% days on both medications), and
‘all’ (i.e., whether or not 80% days on each medication measured separately) approaches. PDC
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estimates varied from 88% at quarter 1 to 78% at quarter 8 when measured by the ‘at least 1’
approach. Similar estimates for ‘both’ were from 61% to 51%, and for ‘all’ 63% to 52%. A
detailed description of all estimates has been provided in Appendix. Thus, the both approach
consistently provided lowest estimates. The all-based estimates were slightly smaller but
closely followed the estimates measured by the both approach.

Table 4.10: Measure of Discrepancy
Quarter
1
2
3
4
5
6
7
8

Quarter-specific
N
1630
1778
1815
1769
1735
1697
1366
1011

%
30.6
36.71
38.21
37.74
37.9
37.71
36.47
34.55

Number of subjects who were rated adherent by one or two dichotomous measures
but not by all three approaches.

Using dichotomous measures of adherence, a subject can be classified as adherent or
nonadherent. Thus, a person can be classified as adherent by only one composite dichotomous
measure, two measures, or all three. An analysis was performed to examine the discrepancy in
classification provided by different dichotomy-based approaches. The analysis was run on
quarter-specific PDC for subjects who were rated adherent by at least one of the approaches.
Table 4.10 describes the rate of discrepancy across different quarters. It was found that at least
100

30% subjects were differentially classified. In other words, about one third population will be
rated as adherent based on an approach but nonadherent based on another approach.
Interestingly, the rates of such differential classification were even higher (35-38%) in later
quarters.

Figure 4.1: Persistency Estimates as Measured by Different Categorical Single Measures

2

1

3

Kaplan-Meier analysis (Figure 4.1) was performed to compare how different categorical
composite measures classified population persistence estimates. PDC was measured
cumulatively until last full quarter of observation and patients were followed until they became
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nonadherent (i.e., cumulative adherence <80%) for the first time or censored at the end of last
full quarter. As can be understood, ‘at least one’ identified more subjects as persistent and
showed a much slower decline than did the all or both approaches both of which closely
followed each other. In addition, the gap widened over time. The log-rank test (adjusted)
revealed that statistics produced by all three approaches were significantly (p<0.005) different
from one another. Thus, choice of measurement approach does matter.

EFFECTIVENESS OF MEASURES OF MULTIPLE MEDICATION ADHERENCE
PDC estimates for multiple medications based on different approaches varied. Apart
from six measures as above, a weighted-average measure of multiple medication adherence was
conceived as part of the objectives of the study. The analyses that follow address the selection of
the most effective measurement paradigm. Specifically, the analysis aims are to compare
different measures and offer an optimal cut point for adherence classification.
Different outcome measures may be used for answering the substantive issue described
above. Among them are emergency room (ER) visits, inpatient stays, and a combined indicator
of any ER or inpatient hospitalization, whichever occurring first. Additionally, outcomes may be
any cause, primarily diabetes related, or any diabetes-related utilization. Thus, it was possible to
choose from nine different outcome measures. The sample of study population demonstrated
high rates of censoring. It was more so for some types of events (e.g., primarily diabetes related
utilization). Thus, it was necessary to pay attention to focus on the selection of an outcome that
would be theoretically and practically meaningful and yet had a reasonable number of events for
survival analysis to run successfully.
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Table 4.11: Event Distribution Across Quarters

Quarter
2
3
4
5
6
7
8
Total*

AC_ER

Diab_ER

AC_cmb

Diab_cmb

N (%)

N (%)

N (%)

N (%)

313 (22.06)
279 (19.66)
299 (21.07)
235 (16.56)
169 (11.91)
107 (7.54)
17 (1.2)

55 (16.92)
49 (15.08)
51 (15.69)
69 (21.23)
58 (17.85)
37 (11.38)
6 (1.85)
325

379 (22.47)
338 (20.04)
355 (21.04)
268 (15.89)
193 (11.44)
133 (7.88)
21 (1.24)
1687

107 (16.77)
100 (15.67)
118 (18.5)
141 (22.1)
95 (14.89)
66 (10.34)
11 (1.72)
638

1419

AC_ER: all cause emergency room (ER) visits; Diab_ER: any diabetes related
ER; AC_cmb: all cause ER or inpatient hospitalization (IP), whichever
occurring first; Diab_cmb: any diabetes related ER or IP, whichever occurring
first
* Events occurring only in any fully observed quarters included

Event Distribution Analysis
A total of 1419 subjects had an all cause ER event. It is noted here that there were a few
more events when all observations were considered regardless of whether or not events occurred
in any fully observed period. Thus, an event that occurred during a subject’s last quarter, which
was shorter than 90 days, was not counted as the person was followed only until the last full
quarter, which preceded the occurrence of event. Such events were not concentrated in any
quarter and rather spread across quarters (Table 4.11). However, few events were observed
during quarter 8. There are other event types that can be utilized to examine the issue of
measurement effectiveness. Some have been presented in Table 4.11. Any diabetes related
103

utilization was considered conceptually meaningful and proximal to the causal relationship
between event and medication use. Similarly, any diabetes related ER or inpatient
hospitalization events (i.e., Diab_cmb in Table 4.11) capture those with which diabetes has been
explicitly associated. These outcomes not only appear theoretically appealing but also hold
practical implications. A total of 325 and 638 events were observed, respectively. However,
only the former category was used in this study for unbiased and consistent analysis because the
latter category may include planned inpatient admissions (e.g., surgical procedures such as
CABG) for which medication adherence may not be directly related. For this study, any diabetes
related ER utilization was considered in addition to any cause ER.

Measurement of PDC for Survival Analysis
For all PDC calculations associated with this dissertation study a duration of 90 days (i.e.,
90-day quarter) was used. However, several issues arose that needed additional consideration
with regard to the measurement of PDC. A large number of participants had an incomplete
observation period in their last quarter. In the examination of multiple medication adherence,
these incomplete observations (i.e., incomplete quarters) were ignored. However, the adoption
of a similar strategy for survival analysis may not be appropriate. A total of 1240 subjects had a
last quarter with 30 days or less and about 5500 had fewer than 90 days of observation.
Moreover, events may have occurred in some of these incomplete reporting periods. As such,
ignoring all incomplete 90-day quarters will result in a loss of events and, in turn, an increase in
censoring, the rate of which is already somewhat high. Because of excessive censoring, the
survival analysis may become underpowered. As such, it was believed that shortening of
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measurement period to 30-day periods might alleviate the problem of losing events and would
allow the inclusion of full-length observations. In addition, it was thought that shortening the
length of measurement period of PDC would bring closer the period of event measurement,
which was measured as day, to the PDC measurement period. If these periods are closer to each
other then there will be less error associated with any probable overestimation of PDC,
especially for PDC measured over the post-event period or any increase in post-event PDC.
Another consideration is that the primary outcome measure (i.e., all cause ER) chosen for this
analysis may require a short measurement period in order for capturing the effect of
nonadherence. Episodes of nonadherence within a short period may lead to hyperglycemia,
which may represent an underlying contributing factor for an acute event such as all cause ER.
In contrast to the above period-specific temporal measurement approach, the disease progression
paradigm posits that a patient’s adherence behavior over a period of time would represent his
propensity of having an event. Thus, the analyses for this part of the project will present the
results for 30-day and 90-day PDC period-specific measures as well as cumulative monthly and
cumulative quarter-specific measures. Only observations that represented a complete reporting
period were included. Subjects were censored at the of their last full observation period or after
an event, whichever occurred earlier.
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Weighted Average Adherence Measure
Survival analysis was performed to estimate drug-specific weights (Ws) required to
estimate weighted average adherence measure. By definition, the composite measure reflects the
benefits of individual medications based on partial adherence, if any.

Adhcom =

W1 . A1 + W2 . A2
W1 + W2

Table 4.12:Hazard Estimates for Predictors of Adverse Events
Parameter

DF

Parameter
Estimate

Standard
Error

ChiSquare

Pr >
ChiSq

Hazard
Ratio

Age
Gender
(male)
CCI
PDC (SU)
PDC (TZD)

1
1

-0.00160
-0.28755

0.00405
0.05328

0.1550
29.1282

0.6938
<0.0001

0.998
0.750

1
1
1

0.35141
-0.00095
-0.00215

0.04240
0.00085
0.00082

68.7027
1.2507
6.9825

<0.0001
0.2634
0.0082

1.421
0.999
0.998

Outcome: all cause ER; PDC is measured at each quarter

Weights were to be represented by medication-specific hazard estimates. Survival
analysis was performed with all cause ER visits as the outcome. Several models were run with
different PDC estimates based on the period lengths. Adherence estimates were calculated as
PDC measured over a period of 30 days and 90 days for each quarter and PDC measured
cumulatively at each quarter. When 90-day quarter-specific PDC was used, only PDC for TZD
was significant at the level of 0.05 (Table 4.12). However, when 90-day cumulative PDC
estimates were used, none of them were significant at a level of 0.05. In this instance, PDC for
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SU was significant at the level of 0.01 (Table 4.13). A similar trend was observed when PDC
measurement period was changed to 30 days. In other words, period-specific PDC for TZD was
significant (p=0.008) (Table 4.14), but cumulative PDC for SU was significant (p=0.028) (Table
4.15).
There was no difference between parameter estimates of individual 90-day quarterspecific PDCs (Chi square 0.725, p=0.39). A similar result (p=0.97) was observed when
cumulative 90-day PDCs were entered into the survival analysis. Results did not differ for
PDCs, both period-specific and cumulative, measured over a 30 period. Although all individual
hazard estimates were in the right direction and some were significant, there were no differences
in the hazard ratios. Under this situation, weights could not be estimated that were nontrivial and
different from each other. Thus, it was not possible to calculate a weighted average measure of
PDC.

Table 4.13:Hazard Estimates for Predictors of Adverse Events
Parameter
Age
Gender (male)
CCI
PDC (SU)
PDC (TZD)

DF
1
1
1
1
1

Parameter
Estimate

Standard
Error

ChiSquare

Pr >
ChiSq

Hazard
Ratio

-0.00166
-0.28968
0.35082
-0.00183
-0.00175

0.00407
0.05331
0.04243
0.00110
0.00109

0.1668
29.5281
68.3703
2.7725
2.5576

0.6829
<0.0001
<0.0001
0.0959
0.1098

0.998
0.749
1.420
0.998
0.998

Outcome: all cause ER; PDC is measured cumulatively over quarters
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Table 4.14:Hazard Estimates for Predictors of Adverse Events
Parameter

DF

Parameter
Estimate

Standard
Error

ChiSquare

Pr >
ChiSq

Hazard
Ratio

Age
Gender
(male)
CCI
PDC (SU)
PDC (TZD)

1
1

-0.00070
-0.27109

0.00397
0.05204

0.0315
27.1320

0.8592
<0.0001

0.999
0.763

1
1
1

0.34317
-0.00093
-0.00190

0.04279
0.00073
0.00072

64.3337
1.5925
6.9829

<0.0001
0.2070
0.0082

1.409
0.999
0.998

Outcome: all cause ER; PDC is measured at each 30-day period

Table 4.15:Hazard Estimates for Predictors of Adverse Events
Parameter
Age
Gender
(male)
CCI
PDC (SU)
PDC
(TZD)

DF

Parameter
Estimate

Standard
Error

ChiSquare

Pr >
ChiSq

Hazard
Ratio

1
1

-0.00042
-0.27231

0.00399
0.05209

0.0111
27.3289

0.9160
<0.0001

1.000
0.762

1
1
1

0.34038
-0.00236
-0.00150

0.04288
0.00107
0.00108

63.0147
4.8133
1.9347

<0.0001
0.0282
0.1642

1.405
0.998
0.998

Outcome: all cause ER; PDC is measured cumulatively over 30-day periods
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Comparison of the Adherence Measures: Predictive Power
As a weighted average-based composite model could not be computed, multiple survival
analyses were performed with the six different PDC estimates as described before. Analyses
were run using both a univariable and a multivariable framework. The results from survival
analysis with the six different PDC measures are presented in Table 4.16. Medication adherence
was significantly (p<0.001) associated with the adverse outcomes of interest. Indeed,
nonadherence to diabetes medications as measured by all different single estimates predicted
hazards of adverse events. However, hazard estimates as given by different single measures of
adherence widely varied. Hazard ratios for adherence, measured temporally over a 30-day
period, varied from 0.784 to 0.997. Although some hazards estimates were nearly 1.0, all were
statistically significant (p<0.005). Hazard estimates were slightly lower under the univariable
analysis for adherence measured over each 30-day period by the all, at least one, and both
approaches. Such differences were not observed when continuous measures of PDC were used.
As proposed, the analyses were rerun with PDC estimated at each quarter (i.e., 90 days).
Adherence was associated significantly with lower hazards of all-cause ER visits. For example,
the hazard of having any all-cause ER visit was 0.787 when adherence was measured over each
quarter following the both approach. Measures using dichotomous approaches provided slightly
lower hazard ratios when only PDC was used as the independent variable. The hazard estimates
for at least one-based PDC measured over 90 days were 0.785 and 0.807 in a univariable and
multivariable setting, respectively (Table 4.16). Mostly, the at least one approach among all
different measures appeared to provide lower hazard estimates regardless of measurement
period.
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Table 4.16: Hazard Estimates for Different PDC Measurements
Measurement
Parameter
Model Approach
Period
estimate
All
-0.2536
Atlst1
-0.2437
Avg
-0.0033
Uni
Both
-0.2538
Max
-0.0027
Min
-0.0025
30 days
All
-0.2189
Atlst1
-0.2205
Avg
-0.0028
Mul
Both
-0.2186
Max
-0.0024
Min
-0.0021
All
-0.2129
Atlst1
-0.2421
Avg
-0.0038
Uni
Both
-0.2392
Max
-0.0031
Min
-0.003
90 days
All
-0.1689
Atlst1
-0.2147
Avg
-0.0031
Mul
Both
-0.1965
Max
-0.0027
Min
-0.0024

Std. Err

P

0.05192
0.06193
0.00075
0.05192
0.00078
0.0006
0.05253
0.06296
0.00077
0.05254
0.0008
0.0006
0.05321
0.06114
0.00084
0.0534
0.00088
0.00067
0.05399
0.06233
0.00086
0.05417
0.0009
0.00068

<.0001
0.0001
<.0001
<.0001
0.0007
<.0001
<.0001
0.0005
0.0002
<.0001
0.0202
0.0005
<.0001
0.0001
<.0001
<.0001
0.0006
<.0001
0.0018
0.0006
0.0003
0.0003
0.0033
0.0005

Hazard
Ratio
0.776
0.784
0.997
0.776
0.997
0.997
0.803
0.802
0.997
0.804
0.998
0.998
0.808
0.785
0.996
0.787
0.997
0.997
0.845
0.807
0.997
0.822
0.997
0.998

Outcome: all cause ER; Uni: univariable; Mul: Multivariable; PDC measured for each
period
Atlst1: At least one approach; Avg: Average approach; Max: Maximum approach; Min:
Minimum approach
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Table 4.17: Hazard Estimates for Different Cumulative PDC Measurements
Measurement
Parameter
Model Approach
Period
estimate
All
-0.2279
Atlst1
-0.1918
Avg
-0.0033
Uni
Both
-0.2098
Max
-0.0041
Min
-0.0036
30 days
All
-0.1897
Atlst1
-0.1638
Avg
-0.0028
Mul
Both
-0.169
Max
-0.0036
Min
-0.0028
All
-0.2279
Atlst1
-0.1988
Avg
-0.0038
Uni
Both
-0.2185
Max
-0.0039
Min
-0.0035
90 days
All
-0.1857
Atlst1
-0.1658
Avg
-0.0031
Mul
Both
-0.1725
Max
-0.0033
Min
-0.0027

Std. Err

P

0.05198
0.06376
0.00075
0.05221
0.00123
0.00083
0.05276
0.06511
0.00077
0.05302
0.00126
0.00084
0.05321
0.0646
0.00084
0.05351
0.00124
0.00084
0.05401
0.06602
0.00086
0.05438
0.00128
0.00086

<.0001
0.0032
<.0001
<.0001
0.0011
<.0001
0.0003
0.0119
0.0002
0.0014
0.0045
0.0009
<.0001
0.0025
<.0001
<.0001
0.0022
<.0001
0.0006
0.012
0.0003
0.0015
0.011
0.0021

Hazard
Ratio
0.796
0.825
0.997
0.811
0.996
0.996
0.827
0.849
0.997
0.845
0.996
0.997
0.796
0.82
0.996
0.804
0.996
0.996
0.83
0.847
0.997
0.842
0.997
0.997

Outcome: all cause ER; Uni: univariable; Mul: Multivariable; PDC measured
cumulatively up to a period
Atlst1: At least one approach; Avg: Average approach; Max: Maximum approach; Min:
Minimum approach
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In general, medication adherence is measured over a period of 6 months or greater.
Cumulative PDC measurements are thought to capture patient behavior over a longer period of
time than do by period-specific measures. Adherence was measured cumulatively at each 30 day
period or 90-day quarter. Hazard of having an all cause event was significantly (p <0.05)
associated with medication adherence. Hazards estimates (Table 4.17) ranged from a low of
0.796 to almost 1 (0.997) for dichotomous measures and continuous PDC estimated cumulatively
over a 30-day period or 90-day period, respectively. The all approach revealed consistently
lowest hazards of having an all cause ER event regardless of whether a univariable model or
multivariable model was used or a measurement period of 30 or 90 days was used.
A subset of all cause events is any diabetes related event. Analyses were repeated with
diabetes-related ER as the outcome for adherence measured at each temporal period and
cumulatively at each period. The hazard estimates (Appendix) for PDC measured over each 30day period varied from 0.66 to 0.75 for the at least one, all, both approaches while continuous
measures indicated a hazard slightly less, although statistically significant, than one. The
corresponding results for dichotomous measures were between 0.54 and 0.71 when PDC
measurement period was 90 days. The at least one approach provided the lowest hazard
estimates that ranged from 0.54 to 0.69. When PDC was measured cumulatively, the hazard
estimates for the three said categorical approaches ranged for 0.56 to 0.68.
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Comparison of the Adherence Measures: Discriminatory Power
Nonadherence was found to be a consistent predictor of events of interest regardless of
measurement approach used or measurement period considered. However, the extent of
predictive power differed depending on the approach used. Analyses were performed to examine
how different measurement approaches discriminated subjects having events from those not
experiencing an event. Concordance statistics were computed with each PDC measurement
approach. Analyses were run in both a univariable and a multivariable framework. All the
approaches resulted in concordance statistics that lay very close to one another (Table 4.18). The
average based approach resulted in the highest mean value of 0.5391 under the univariable
setting. The mean value of other continuous measures were 0.5380 (min) and 0.5360 (max).
Dichotomous approaches resulted in slightly lower c-statistics than for analyses using continuous
adherence measures. Among dichotomy-based measures, the at least one approach showed the
lowest mean of 0.5228. Table 4.18 reports the values and confidence intervals of all
concordance statistics. Under the multivariable analysis, the mean values of all concordance
statistics improved from their respective univariable estimate. Among all, the average approach
showed the highest values of 0.5648 and at least one the lowest value of 0.5584. Although
indicating poor discrimination, all these concordance statistics were greater than 0.50 (p<0.05).
In addition, confidence intervals from all concordance statistics overlapped one another
indicating a lack of statistical significance.
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Table 4.18: Concordance Statistics for Different Adherence Measurement Approaches
Measurement
Period

All cause ER
Model Approach

Uni
30 days

Mul

Uni

90 days

Mul

All
Atlst1
Avg
Both
Max
Min
All
Atlst1
Avg
Both
Max
Min
All
Atlst1
Avg
Both
Max
Min
All
Atlst1
Avg
Both
Max
Min

Cstatistic
0.5330
0.5224
0.5426
0.5329
0.5355
0.5394
0.5606
0.5564
0.5645
0.5602
0.5622
0.5627
0.5290
0.5228
0.5391
0.5324
0.5360
0.5380
0.5612
0.5584
0.5648
0.5628
0.5621
0.5636

CI
0.5201-0.5460
0.5115-0.5333
0.5282-0.5570
0.5199-0.5458
0.5225-0.5485
0.5252-0.5535
0.5453-0.5759
0.5411-0.5718
0.5494-0.5796
0.5449-0.5755
0.5470-0.5774
0.5476-0.5779
0.5158-0.5422
0.5114-0.5342
0.5240-0.5542
0.5192-0.5455
0.5216-0.5504
0.5230-0.5531
0.5456-0.5768
0.5428-0.5739
0.5493-0.5804
0.5472-0.5783
0.5465-0.5777
0.5481-0.5792

Diabetes ER
Cstatistic
0.5404
0.5385
0.5637
0.5410
0.5483
0.5572
0.5643
0.5664
0.5698
0.5639
0.5659
0.5649
0.5484
0.5614
0.5597
0.5475
0.5599
0.5530
0.5687
0.5820
0.5725
0.5679
0.5759
0.5663

CI
0.5137-0.5672
0.5146-0.5624
0.5340-0.5933
0.5142-0.5677
0.5208-0.5757
0.5284-0.5860
0.5328-0.5958
0.5349-0.5979
0.5386-0.6009
0.5322-0.5955
0.5350-0.5968
0.5340-0.5959
0.5212-0.5757
0.5353-0.5876
0.5270-0.5923
0.5204-0.5746
0.5288-0.5910
0.5209-0.5850
0.5360-0.6014
0.5494-0.6146
0.5395-0.6054
0.5351-0.6006
0.5436-0.6082
0.5334-0.5991

C-statistic: Concordance statistic (CT from Kremers); CI: confidence interval of C-statistic;
Uni: univariable; Mul: Multivariable; PDC measured at each quarter
Atlst1: At least one approach; Avg: Average approach; Max: Maximum approach; Min:
Minimum approach

114

Table 4.19: Concordance Statistics for Different Cumulative Adherence Measurement
Approaches
Measurement
Period

All cause ER
Model

Uni
30 days

Mul

Uni

90 days

Mul

Approach
All
Atlst1
Avg
Both
Max
Min
All
Atlst1
Avg
Both
Max
Min
All
Atlst1
Avg
Both
Max
Min
All
Atlst1
Avg
Both
Max
Min

Cstatistic
0.5276
0.5157
0.5426
0.5253
0.5216
0.5338
0.5582
0.5535
0.5645
0.5572
0.5569
0.5599
0.5290
0.5169
0.5391
0.5281
0.5258
0.5358
0.5612
0.5570
0.5648
0.5607
0.5593
0.5626

CI
0.5146-0.5406
0.5053-0.5261
0.5282-0.5570
0.5124-0.5382
0.5068-0.5364
0.5188-0.5487
0.5429-0.5734
0.5383-0.5687
0.5494-0.5796
0.5419-0.5725
0.5416-0.5722
0.5446-0.5751
0.5157-0.5422
0.5061-0.5277
0.5240-0.5542
0.5149-0.5413
0.5107-0.5410
0.5206-0.5510
0.5456-0.5767
0.5415-0.5725
0.5493-0.5804
0.5451-0.5763
0.5437-0.5749
0.5470-0.5782

Diabetes ER
Cstatistic
0.5515
0.5531
0.5637
0.5529
0.5475
0.5587
0.5690
0.5728
0.5698
0.5710
0.5646
0.5665
0.5460
0.5457
0.5597
0.5489
0.5493
0.5542
0.5660
0.5672
0.5725
0.5683
0.5670
0.5648

CI
0.5249-0.5780
0.5288-0.5775
0.5340-0.5933
0.5268-0.5789
0.5153-0.5798
0.5278-0.5896
0.5371-0.6008
0.5410-0.6045
0.5386-0.6009
0.5395-0.6025
0.5328-0.5963
0.5349-0.5982
0.5186-0.5733
0.5208-0.5706
0.5270-0.5923
0.5221-0.5758
0.5161-0.5825
0.5223-0.5861
0.5330-0.5989
0.5344-0.6000
0.5395-0.6054
0.5356-0.6011
0.5341-0.5998
0.5320-0.5975

C-statistic: Concordance statistic (CT from Kremers); CI: confidence interval of C-statistic;
Uni: univariable; Mul: Multivariable; PDC measured cumulatively at each quarter
Atlst1: At least one approach; Avg: Average approach; Max: Maximum approach; Min:
Minimum approach
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The concordance statistics for different measurement approaches were computed for PDC
estimated over 30-day periods. The concordance statistics measured in the univariable setting
ranged from 0.5426 to 0.5224 (Table 4.18) with statistic for ‘average’ being the largest among
all. Like statistics for PDC measured over 90 days, multivariable concordance statistics for
adherence estimated in each 30-day period were higher than their univariable counterpart.
Again, the at least one approach resulted in lowest mean concordance statistics in both
multivariable and univariable analyses. Most of 30-day mean values are slightly higher than
their corresponding 90-day values.
Additional analyses were performed using the cumulative PDC measurement approach.
That is, adherence measured cumulatively at a specific period (i.e., 30 or 90 days) was entered in
survival analysis. For the 30-day based cumulative measures, the average and minimum
approaches showed two highest concordance statistics. The univariable and multivariable mean
values for the average approach were 0.5426 and 0.5645, respectively (Table 4.19) and for the
minimum-based approach, the corresponding statistics were 0.5338 and 0.5599, respectively.
When the 90-day measurement period was used, the estimates closely followed that of 30-day
cumulative analysis. For example, concordance statistics were 0.5391 and 0.5648 in the
univariable and multivariable analysis, respectively. Interestingly, the lower bounds of the at
least one based approach and its continuous version (i.e., maximum) lay barely above 0.5 in the
univariable analyses regardless of cumulative measurement period.
Analyses were repeated using any diabetes-related event as the outcome measure for
adherence measured at each period and cumulatively at each period. Table 4.18 and Table 4.19
present the results. Concordance estimates for PDC measured over each 30-day period varied
from 0.5385 (at least one) to 0. 5637 (average) under the univariable analysis and remained
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literally constant in the multivariable models for all approaches (Table 4.18). When period of
measurement was 90 days, concordance estimates ranged from 0.5475 (both) to 0.5646 (average)
in univariable models (Table 4.18). In the multivariable analysis, the at least one had the highest
estimate of 0.5820 and its continuous counterpart (minimum) has the lowest estimate of 0.5663.
When cumulative measures were used, the mean concordance varied from 0.5457 to 0.5728
(Table 4.19). The average approach resulted in the highest estimate in all analyses except for the
30-day multivariable model in which the at least one approach had the highest mean concordance
statistic of 0.5728 (Table 4.19). Confidence intervals of all concordance statistics were above
0.5.

Examination of Optimal Cut-points of Measures of Multiple Medication Adherence
There are three single measures of multiple medication adherence that measure adherence
on a continuous scale. These are based on the average, maximum, and minimum algorithms and
can be converted into categorical measures. Cut point analyses were performed on these
continuous PDC measures and results from both multivariable and univariable survival analysis
are presented in Table 4.20. In the case of multivariable analysis, likelihood difference
contributed by PDC was considered. That is, the differences in log likelihood of a survival
analysis model containing all variables (age, gender, CCI, and PDC) and that of a model with all
variables except PDC were computed. Additional dichotomous PDC variables were created
from the respective continuous measures by applying different cut points for dichotomization.
Five cut points were chosen for dichotomization: 65, 70, 75, 80, and 85. Maximum Chi square
statistics that were significant at p=0.05/15 (Bonferroni adjusted) were identified. Any values
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that were above 8.6154 were considered significant at a level of p=0.05/15 (approximately,
0.003). As above, analyses were performed using cumulative and period-specific PDC measured
over 90 days or 30 days.

Table 4.20: Optimality of Cut Point Analysis with Different Adherence Measures
Measurement
Cumulative
90-day
Quarter

Model
Mul

Uni

Mul
90-day
Quarter
Uni

Approach

PDC 65

PDC-70

PDC-75

PDC-80

PDC-85

Average
Maximum
Minimum
Average
Maximum
Minimum
Average
Maximum
Minimum
Average
Maximum
Minimum

7.0462
5.0143
9.4119
12.487
7.1239
15.524
8.7781
5.9385
9.5463
13.974
8.0635
15.399

3.9441
3.8126
8.4991
8.3871
6.0205
14.799
8.468
10.912
9.4438
13.938
14.232
15.904

6.4148
6.7254
14.401
11.314
9.5342
22.259
8.048
12.115
12.106
13.278
15.73
19.018

9.3322
6.125
10.107
14.915
9.1097
16.789
9.9933
11.465
13.223
16.268
15.037
20.18

11.227
2.7552
11.284
18.259
5.1445
17.904
12.409
10.812
11.887
19.359
14.893
18.44

Outcome variable: all cause ER visits; Uni: univariable; Mul: Multivariable; bold cells are
maximum chi square values among respective row values and are significant at p=0.05/15.
Numbers were obtained from chi square statistics from the Survival analysis

First, survival analyses were performed on all cause ER visits as outcome measure.
When PDC was measured cumulatively over 90 days, maximal Chi square statistics were
identified when dichotomization occurred at 85% in both multivariable and univariable analysis
(Table 4.20). Thus, statistics for average-based dichotomization analyses were significant. In
case of maximum and minimum algorithms, similar analyses showed that maximization occurred
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at 75%. However, statistic for maximum in the multivariable model was not significant at p =
0.003. When the PDC measure was based on each quarter, the maximization of average-based
dichotomization occurred at 85% in both univariable and multivariable models in which chi
square statistics were significant (p<0.003). For the maximum based approach, maximum values
were found at 75% and were significant (p<0.003). For minimum-based dichotomization,
maximizations occurred at 80% in both multivariable and univariable models.

Table 4.21: Optimality of Cut Point Analysis with Different Adherence Measures
Measurement

Model
Mul

Cumulative
30-day Period
Uni

Mul
30-day Period
Uni

Approach
Average
Maximum
Minimum
Average
Maximum
Minimum
Average
Maximum
Minimum
Average
Maximum
Minimum

PDC 65 PDC-70 PDC-75 PDC-80 PDC-85
5.2231
6.8647
7.6926
9.7486
13.277
6.4368
6.2179
6.1458
4.0449
8.6639
9.7597
11.011
10.196
9.7981
16.019
9.6211
11.914
12.568
15.195
19.98
8.6173
8.5361
8.7115
6.4434
11.381
15.754
17.486
16.23
15.484
23.36
7.4047
8.8584
9.2459
8.0082
14.139
8.6901
9.8615
9.5206
11.803
21.378
11.919
11.323
15.285
17.281
23.137
11.925
13.673
14.375
12.927
20.274
11.286
12.559
12.184
14.786
25.587
17.648
16.832
21.398
23.857
30.723

Outcome variable: all cause ER visits; Uni: univariable; Mul: Multivariable; colored cells are
maximum chi square values among respective row values and bold ones are significant at
p=0.05/15.
Numbers were obtained from chi square statistics from the Survival analysis

Above analyses on all cause ER visit were repeated with PDC measured over a 30-day
period. Table 4.21 presents the results of the analyses. When PDC was measured cumulatively
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or at each period over 30 days, the maximization of the average approach based dichotomization
occurred at 85% in both univariable and multivariable models. Similarly, maximizations were
noted for the maximum and minimum based approaches at 85% when PDC was measured at
each 30-day period in multivariable or univariable analysis. In contrast, dichotomization
analysis on these two approaches demonstrated that the maximized values were found to occur at
75% when PDC was measured cumulatively.

Table 4.22: Cut Point Analysis with Different Adherence Measures
Measurement
Cumulative
90-day
Quarter

Model
Mul

Uni

Mul
90-day
Quarter
Uni

Approach

PDC 65

PDC-70

Average
Maximum
Minimum
Average
Maximum
Minimum
Average
Maximum
Minimum
Average
Maximum
Minimum

7.070
3.455
8.885
10.080
9.395
8.990
9.698
5.114
11.613
12.826
11.806
11.475

8.521
7.464
8.712
10.906
11.023
8.185
11.381
9.860
11.419
13.768
13.786
10.640

PDC-75

PDC-80

PDC-85

11.783
12.105
13.235
14.400
18.319
9.596
14.956
15.038
16.386
17.57
21.716
12.207

13.766
12.094
11.048
15.521
22.031
9.3371
17.135
15.21
13.879
18.809
25.721
11.887

11.221
9.549
9.641
12.066
19.952
9.184
14.345
12.52
12.268
15.045
23.724
11.704

Outcome variable: any diabetes ER visits; bold cells are maximum chi square values among
respective row values and significant at p=0.05/15.
Numbers were obtained from chi square statistics from the Survival analysis

Next, optimal dichotomization analyses were performed using any diabetes related ER
visits as outcome measure. When PDC was measured cumulatively over 90-day quarters,
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maximal partial likelihood statistics occurred for dichotomization at 80% in both multivariable
and univariable analysis (Table 4.22). Similar results were observed for PDC measured at each
quarter. In case of minimum based algorithms, maximizations of partial likelihood statistics
occurred when PDC was dichotomized at 75% and these results held true for both multivariable
and univariable analysis. When analyses were run on the maximum based approaches,
maximization of statistic occurred for PDC dichotomized at 80% except for the case of
multivariable analysis with PDC measured cumulatively. In the latter case, the maximum value
was found at 75%. Statistics for all the above analyses were significant (p< 0.003).

Table 4.23: Optimality of Cut Point Analysis with Different Adherence Measures
Measurement
Cumulative
30-day
Period

Model Approach
Mul

Uni

Mul
30-day
Period
Uni

Average
Maximum
Minimum
Average
Maximum
Minimum
Average
Maximum
Minimum
Average
Maximum
Minimum

PDC 65
9.4571
4.3559
12.223
12.705
6.4359
15.591
5.4106
4.4476
6.2205
7.5734
6.4519
8.4399

PDC-70 PDC-75 PDC-80 PDC-85
12.758
6.4868
13.581
16.438
9.0358
17.101
4.7225
5.7976
6.8583
6.7659
8.0648
9.1793

14.643
11.369
17
18.483
14.642
20.746
4.9703
7.1672
5.5575
7.0906
9.6847
7.6826

15.281
18.242
14.18
19.145
22.376
17.619
6.9607
8.4171
7.0427
9.3951
11.136
9.4027

12.669
11.067
10.945
16.237
14.582
13.956
8.245
8.383
10.764
10.884
11.188
13.586

Outcome variable: any diabetes ER visits; bold cells are maximum chi square values
among respective row values and significant at p=0.05/15.
Numbers were obtained from chi square statistics from the Survival analysis
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The above analyses on any diabetes related ER visit were repeated with PDC measured
over a 30-day period. Table 4.23 presents the results of the analyses. For PDC measured
cumulatively over 30 days, the maximization of statistic for the average approach based
dichotomization occurred at 80% in both univariable and multivariable models. Similarly,
maximizations were observed at 80% for the maximum based approach when PDC was
measured cumulatively over a 30-day period in multivariable or univariable analysis. In
contrast, dichotomization analysis on the minimum approach showed the maximization at 75%
in both multivariable and univariable models. When analysis was performed on PDC measured
at each 30-day period, the maximization occurred at 85% in all cases except for the maximumbased multivariable analysis in which the statistic was maximized at 80% but not significant.
The above discussions on dichotomization have so far focused on the maximization of
partial likelihood statistic. However, in true sense, maximization was not found to occur for
some multivariable analysis. For example, in case of PDC measured cumulatively at 30-day
periods, partial likelihood statistic for average based dichotomization increased monotonously
(5.2231, 6.8647, 7.6926, 9.7486, and 13.277) before being maximized at 85%. Similarly, for the
PDC measure based on average at every 30 days, the partial statistics increased almost
monotonously (7.4047, 8.8584, 9.2459, 8.0082, and 14.139) before showing the highest value at
85%. In the latter case, all values except the first one (i.e., 65%) lie above 8.615, which is the
chi square value of the Bonferroni adjusted p value of 0.05. In other cases, maximization
occurred in true sense but statistics on either sides of the maximized one were significant. For
example, the results from analysis on diabetes-related ER based on average-based dichotomized
PDC measured cumulatively over 30 days demonstrated maximization at 75% (17) and values
around 75% (12.223, 13.581, 14.18, 10.945) were significant (p<0.0033) as well.
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Concordance Analysis between Results of Concordance Statistics and Maximization
Statistics
While computing concordance statistics, analyses were run with PDC measurement
approaches such as at least one and both. These two approaches had some equivalent formats in
the maximization analysis. These equivalent formats occurred when corresponding continuous
PDC was dichotomized at 80% (i.e., dichotomization performed on maximum and minimum
based estimates). Comparisons were made between statistics obtained from concordance
statistics analysis and maximization analysis. The results from analysis on all-cause ER visits
were presented in Table 4.24 in which C-stat represents concordance statistic for at least one or
both-based PDC and partial likelihood statistic contributed by maximum and minimum based
PDC dichotomized at 80%. Perfect correspondence was noted between concordance statistic and
partial likelihood statistic regardless of measurement period and multivariable or univariable
analysis. In other words, when C-statistic increased, so did partial likelihood. For example,
when PDC was measured cumulatively over quarters both concordance statistic and partial
likelihood statistic were lower for ‘at least one’ than those were for the both-based approach.
Because maximization analysis was performed on 5 cut points (65% through 85% at 5%
intervals), for each row (i.e., PDC measurement) in Table 4.24 contained a respective maximum
statistic that could range from 75% through 85%. The maximization column in Table 4.24
reports the maximum values associated with analysis performed on all-cause ER visit. The
concordance column reports whether maximum values are 80% or not. Of the 16 different ways
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in which PDC were measured in the study, maximization occurred at 80% only in 2 (12.5%)
cases.
Table 4.24: Concordance Analysis on Optimality of Cut-off Points
Measurement

Model

Approach

C-stat/ PL80

Max

Concordance

Multivar

At least one/
max 80

0.557/6.125

75%*

no

Both/min 80

0.5607/10.107

75%

no

At least
one/max 80

0.5169/9.1097

75%

no

Both/min 80

0.5281/16.789

75%

no

At least one/
max 80

0.5228/11.465

75%

no

Both/min 80

0.5324/15.037

80%

yes

At least one/
max 80

0.5584/13.223

75%

no

Both/min 80

0.5628/20.18

80%

yes

At least one
/max 80

0.5535/6.1458

75%

no

Both/min 80

0.5572/10.196

75%

no

At least one/
max 80

0.5157/8.7115

75%

no

Both/min 80

0.5253/16.23

75%

no

At least one/
max 80

0.5224/11.803

85%

no

Both/min 80

0.5329/17.281

85%

no

At least one/
max 80

0.5564/14.786

85%

no

Both/min 80

0.5602/23.857

85%

no

Cumulative
90 day
Univar

Multivar
90 day
Univar

Multivar
Cumulative
30 day
Univar

Multivar
30 day
Univar

Max: Maximization cut point; Outcome variable: All-cause ER; C-stat: Concordance
statistics (CT from Kremers); PL80: partial likelihood statistic of PDC dichotomized at
80%; Multivar: multivariable model; Univar: univariable model; Max 80: dichotomization
of maximum approach at 80%; Min 80: dichotomization of minimum approach at 80%
* statistic not significant at p=0.0033
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Concordance analysis was performed on any diabetes related event as outcome variable.
A total of six of eight of maximum-based PDC dichotomized at 80% yielded highest values
among all respective maximum-based PDC measure dichotomized at different cut points
(Appendix). The two that were not maximized at 80% were the ones when PDC was measured
cumulatively over 90 days in a multivariable model and when PDC was measured at every 30
days in a univariable model. Thus, the at least one based approach showed high concordance
with the maximization of partial likelihood statistic-based approach when analysis was run on
any diabetes related event. All of both-based PDC – alternatively, minimum-based PDC
dichotomized at 80% – were maximized either at 75% or at 85%.

125

CHAPTER 5
DISCUSSION
Using the MarketScan 2002-2003 commercial claims database, this dissertation examined
intra-disease and inter-disease multiple medication adherence and issues associated with intradisease multiple medication adherence. A number of inclusion and exclusion criteria were
imposed for the selection of study subjects; such methods resulted in a smaller pool of subjects
receiving two oral diabetes medications (SU and TZD) but they were thought to ensure
consistency in measurement and unbiased results. On average, this pool of older adults
demonstrated good levels of adherence for both SU and TZD over time although rates continued
to decline over time; these findings were consistent with past research.

Intra-disease Multiple Medication Adherence
A total of 6043 subjects were available initially for examining intra-disease multiple
medication adherence; however, the number of subjects declined to 4996, 3772, and 447 in the
6th, 7th, and 8th quarter, respectively. A series of multivariate multilevel random intercept and
growth models with and without covariates were undertaken to examine multiple medication
adherence. It was expected that a positive covariation between adherence behaviors related to
two medications taken concurrently for the same chronic disease would exist; consequently, a
significant correlation of 0.57 between the random components of adherence to the two
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medications was observed. The strength of the relationship persisted after controlling for age
and gender. To an extent, these results can be anticipated from the patterns of population
adherence estimates (Table 4.2) of the two diabetes medications under investigation. Thus, even
if there were variations in adherence at different times to individual medications prescribed for a
disease, the relationship between means measured at the individual level appear to be related.
More precisely, factors that are affecting the overall medication adherence behaviors for two
medications appear to have strong relationship. Many reasons can be speculated in support of
such results, including synchronization and scheduling (Choudhry et al., 2011); however, a
conceptually plausible reason may include the patient’s overall disease beliefs as a driver of
adherence behavior as supported by studies based on psychosocial factors affecting adherence
(Stack et al., 2011). The latter may be further supported by the subgroup analysis, which
included community pharmacy patrons only, that demonstrated a strong correlation between the
random effects (Appendix). In general, medications obtained from community pharmacies are
not refilled automatically; thus, community patrons generally make conscious decisions about
getting their prescriptions filled and continuing them over time.
Multivariate growth models were run to examine the relationships between changes in an
individual’s adherence behaviors to two medications taken concurrently for a chronic disease. In
other words, relationships between the random slopes for each medication adherence were
analyzed. The correlations (i.e., the association of evolutions) between random slope for SU and
that of TZD were greater than 0.62 regardless of whether or not the effects of age and gender
were controlled for. Thus, it appears that factors that affect adherence behaviors for multiple
medications over time are strongly related. Subgroup analysis on community patrons also
replicated strong relationships as described above. It is interesting to note that correlations of
127

random slopes from the growth model analyses were stronger than correlations from means (i.e.,
random intercept) model analyses. Among a host of potential reasons, one is that underlying
factors driving the growth of individual medication adherence behaviors change in a more
closely coordinated manner than do those representing overall behaviors.
To a patient receiving treatment, medications may have a symbolic meaning for disease
state. It is possible that when a patient is put on an additional medication for the treatment of a
disease, he will start perceiving the disease more seriously. Thus, disease beliefs may be driving
the state of adherence for each medication for that disease at every point in time and ensure
similarities in the pattern of consumption variations. In contrast, mean model correlation
estimations may be affected by differential initial states of adherence as prescriptions are likely
to be not initiated simultaneously more often than not. However, the effect of statistical
modeling (i.e., use of random intercept vs. growth model) cannot be ruled out when a variable
such chronic medication adherence is truly time-dependent.

Inter-disease Multiple Medication Adherence
Because so many patients suffer from multiple chronic diseases, this study explored the
adherence behaviors of diabetes patients for medications prescribed for other diseases in addition
to adherence to two diabetes medications. In order to investigate inter-disease multiple
medication adherence, diabetes patients who were prescribed two oral diabetes medications were
evaluated as to their use of medications to treat hypertension, hyperlipidemia, or angina. Over
2300 patients were taking medications for either hypertension or cholesterol, 860 were on
prescriptions for both hypertension and cholesterol. Additionally, many were prescribed anti128

anginal medications. It should be noted here that these numbers are not estimates of percent of
diabetes patients suffering from the aforementioned chronic diseases; it is very likely that the
number of diabetes patients suffering from other chronic diseases has been underestimated
because of the selective medication filling-based selection criterion used in the study. The
subjects for the analyses of inter-disease multiple medication adherence were observed, on
average, for over one and a half years and slightly dominated by male.
As such, there were four sets of patients on which analyses related to inter-disease
multiple medication adherence were performed. While the statistical modeling strategy was the
same as that of the intra-disease multiple medication adherence analysis, the number response
variables was 3 or 4; thus, the number of random effect correlations were always 3 or greater.
Adherence rates for individual medications for all four subgroups of patients were estimated
(Table 4.5) for each quarter. Adherence rates for diabetes medications of these groups of
patients as presented in Table 4.5 were slightly different from actual adherence estimates of the
same because different index dates for intra-disease and inter-disease medication adherence
might have been used for some patients.
Diabetes Patients with One Additional Asymptomatic Chronic Disease
Chronic diseases may be related to one another based on disease patho-physiologic
profile leading to concordance or lack of that with another chronic disease. There were two
groups of diabetes patients who were suffering from concordant diseases and prescribed
medications (hypertension or hyperlipidemia). The average quarter-specific PDC estimates for
concordant disease medications trailed the corresponding PDC estimates for SU and TZD except
for that of hypertension medications, which were slightly above their respective diabetes
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medications estimates. However, the results for hypertension medications may have occurred
because of a liberal methodology adopted for estimation (i.e., possession of any medications on a
day) of PDC for hypertension medications. The average population adherence estimates for
cholesterol medications were about 70% in all quarters and that for hypertension were slightly
greater than 70% in all quarters.
Similar to intra-disease multiple medication adherence analyses, the multivariate multilevel models for inter-disease multiple medications adherence were run on quarter-specific PDC
estimates for each medication on those subjects that had a full quarter of observation and the
strategy led to decline in number of subjects in later quarters. The results of unconditional
random intercept models analyses revealed strong correlations (greater than 0.5) among all
medications, including those for cholesterol and hypertension. Thus, when patients suffered
from multiple concordant chronic diseases, significant correlations were observed with regard to
within-patient adherence to medications taken concurrently for an index chronic disease (i.e.,
diabetes) and another asymptomatic chronic disease regardless of disease state (i.e., hypertension
or hypercholesterolemia). Interestingly, correlation estimates of inter-disease multiple
medication adherence (i.e., between SU and anti-hyperlipidemic medications and between
hypertension medications and TZD) were stronger than that for intra-disease correlation. It is
difficult to explain such findings definitively. However, a few reasons can be speculated to have
caused such results including simultaneous initiation or synchronization of refills of those
specific medications. Alternatively, patients demonstrated selective medication adherence (e.g.,
Wogen et al. (2003) noted adherence to specific medication class; McHorney and Gadkari (2010)
found differential beliefs to medications patients chose to persist compared to ones patients did
not) that are tied to one medication for each disease. Additional analyses using conditional
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growth models showed that there were significant correlations between random slopes of
medication-specific adherence over time. Thus, it appears that a patient’s changes in adherence
behavior over time related to each chronic disease medication are strongly related even after
controlling for age and gender. Interestingly, the results of means model analyses are replicated
qualitatively in growth model analyses in that some inter-disease association of evolutions
estimates were higher than their intra-disease counterparts although association of evolutions
estimates were much greater than estimates of association of means. In sum, consistency and
strength in relationships that were observed for inter-disease multiple medication adherence is
interesting; indeed, it may provide evidence of a higher order construct affecting patients’ health
behavior decisions, specifically as it relates to medication consumption. This is consistent with a
recent work that found that a pharmacist-provided counseling program improved adherence to
target and nontarget chronic medications (Taitel et al., 2012).
Diabetes Patients with More than One Additional Asymptomatic Chronic Disease
Many diabetes patients suffer from more than one chronic disease (e.g., hypertension and
hypercholesterolemia). This study found that for these patients the average adherence estimates
in all quarters were consistently highest for hypertension medications and lowest for cholesterol
medications. The average adherence rates for hypertension medications were about 80% in all
quarters whereas other rates were suboptimal (based on the ≥80% criterion). The unconditional
random intercept models were run to examine six correlations: five for cross-disease medications
and one for within-disease medications. All random intercept correlations were significant and
were above 0.5 except for two between SU and anti-hyperlipidemic medications (0.49) and SU
and hypertension medications (0.47). Thus, when patients suffered from multiple concordant
chronic diseases, significant correlations were observed with regard to within-patient adherence
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to medications taken concurrently for an index chronic disease (i.e., diabetes in this case) and
another asymptomatic chronic disease even when number of chronic diseases increased.
Conditional growth model analyses in which age and gender were controlled for showed that
there were significant correlations between random slopes of medication-specific adherence over
time with the correlation between TZD and hypertension medications and that of TZD and SU
being the highest (0.77) and lowest (0.6), respectively. Although these patients are a subset of
the group with one asymptomatic chronic disease and not different from the later concerning
their demographic profile and mean adherence estimates, such high correlations in random
slopes appear interesting and need further investigation. At the present time, it can be suggested
that factors affecting their adherence that may include disease or medication beliefs are strong
and consistent. Alternatively, it is likely that these subjects are very health conscious and
maintain healthy behaviors. It should be noted here that there were very few subjects left in the
last quarter in the analysis reported above. However, the result did not differ when the 1st or 8th
quarter was dropped from the analysis (Appendix).
Diabetes Patients with an Additional Symptomatic Chronic Disease
Chronic diseases may be symptomatic or asymptomatic in addition to being concordant
with another chronic disease. Angina is symptomatic and considered concordant with diabetes.
Angina patient selection was limited to those filling only tablet or capsule forms of nitroglycerin.
Although necessary, this inclusion criterion resulted in about 300 subjects being available for
analysis and this number declined sharply in the last two quarters. The average population
adherence estimates for nitrates were substantially lower in all quarters in comparison with
corresponding rates for diabetes medications although it showed small improvement in the last
two quarters with smaller numbers of patients. Given that this group was not very different in
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the overall follow up time and demographic profile from those with only asymptomatic diseases,
such low rates are hard to explain and may lie in methodological artifacts (e.g., SOS
prescriptions). Alternatively, low adherence may reflect by patients’ decision that they can find
a rescue medication (e.g., sublingual nitrates) to treat the disease when needed. The correlations
of random intercepts between SU and TZD and between TZD and nitrates were statistically
significant (p<0.05) while that for SU and nitrates was not. Thus, the relationship between
adherence to concordant chronic symptomatic and asymptomatic disease medications was not
clear. It is interesting to note that the correlation estimate (0.38) between random intercepts of
SU and TZD is much lower than the corresponding ones observed in intra-disease or other interdisease analyses. Similarly, there was a poor correlation (0.15; p=0.016) between TZD and
nitrates. Like other analyses, the association of evolutions estimates were higher than random
intercepts model estimates; however, the association of evolutions of SU and nitrates were not
significant while that of TZD and nitrates was poor but significant (0.21; p<0.05) and that of SU
and TZD was strong (0.59; p<0.001). When the models were rerun excluding the last 2 and 3
quarters, no significant changes in results were observed. Although the analyses may be
constrained by smaller sample size especially in the last few quarters, it is encouraging to note
that the intra-disease random intercepts and growth model correlation estimates were consistent
with the results from all other analyses. Contrary to popular beliefs about higher adherence to
symptomatic disease, lower adherence to angina medications was little surprising.

Measurement of Intra-disease Multiple Medication Adherence
Based on existing methods that were identified from the literature, a single composite
estimate of adherence for multiple medications for a disease can be computed using six different
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methods: three each for continuous and categorical measures. The means of (single) continuous
PDC estimates of multiple medication adherence varied widely depending on the type of
measurement used. Both average and minimum-based approaches yielded suboptimal (per
≥80% criterion) adherence rates. These differences were present when PDCs were calculated at
each quarter or estimated cumulatively up to each quarter. It can be expected that variations in
estimates of PDC based on a restrictive methodology (e.g., requiring patients to take both
medications or minimum approach) became large and would continue to grow in populations in
which overall adherence rates are lower than the population used in the study or in instances
where a patient is followed for a longer time (i.e., >8 quarters).
When single measures of multiple medication adherence based on a dichotomy (i.e.,
adherent vs. nonadherent) with a cut-point of 80% PDC were used, similar to the results for
continuous measure-based estimates, there was a considerable variability in estimates based on
the approach used and adherence estimates can be considered suboptimal based on measurement
method selected. The all-based estimates were slightly smaller but closely followed the
estimates measured by the both approach, which provided the lowest estimates. Thus, it is
understood that not every composite dichotomous measure will classify patients consistently as
adherent or nonadherent unless a patient shows high adherence rates. Interestingly, it was found
that the extent of discrepancy in classification of patients who were rated adherent at least by one
approach could be as high as 38%. Thus, this can be concluded that such discrepancy, which is
indeed high in the study population, will become more apparent if overall population adherence
rates become poor or when a longer observation period is considered.
Different composite measures of PDC estimates for multiple medications were compared.
In addition, a weighted average-based composite measure was conceptualized and proposed to
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be compared against other composite measures. All-cause and any diabetes related ER visits
were chosen to derive weights and compare the performance of measurement approaches. The
decisions to choose outcome measures were based on theoretically and practically meaningful
and statistical modeling rationales. In analyses related to measurement, an additional time unit
(i.e., 30-day periods) of measurement was considered. This decision was partly driven by the
fact that episodes of nonadherence within a short period might lead to hyperglycemia that might
lead to an acute ER event. In addition, shorter measurement unit may prevent excluding subjects
due to incomplete reporting periods and thus, to some extent, might alleviate the problem of high
censoring rate or fewer events. Although small, the number of events was not particularly
concentrated on any specific quarters except that the last quarter had the fewest events.
In order for deriving weights for the proposed weighted average-based composite
measure, survival analysis was performed. Although individual hazard estimates were in the
right direction, hazard estimates for both SU and TZD were not significant simultaneously. In
some analyses, hazard estimates for SU were significant but not that of TZD or vice versa. Such
results were repeated regardless of whether PDC was measured using 30-day periods or 90-day
periods or cumulatively over those periods. As strong relationships between adherence to SU
and TZD were noted consistently in the multiple medication adherence analyses, it is believed
that strong multicolinearity may have caused such results. Thus, any outcome-based weights and
weighted average-based composite measure of intra-disease multiple medication adherence
could not be computed. Most studies in adherence do not differentiate specific medications with
regard to their impact of health outcome. In the light of evidence gained in this study, the
assumption that all medications have the same health impact cannot be ruled out. Indeed, this
study provides evidence for averaging out adherence values for multiple medications.
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Comparisons of Measures of Multiple Medication Adherence: Predictive power
A series of survival analyses were performed to compare the six different composite
measures of intra-disease multiple medication adherence. All composite measures of adherence
to diabetes medications significantly predicted hazards of all-cause adverse events; however,
hazard estimates yielded by different composite measures varied depending on whether
continuous or dichotomous measures were used. Hazards estimates of all continuous measures
approached one regardless of whether or not PDC was measured at 30-day or 90-day periods or
cumulatively, all were statistically significant (p<0.005). As such, findings that even a small
improvement in adherence will result in lower hazards of adverse events are encouraging for
healthcare providers for whom adherence improvement is a focus of their patient care activities.
The hazard ratios of dichotomous composite measures differed on the basis of the method used
to compute adherence estimate; while the at least one method showed slightly superior (i.e.,
lower) hazards when adherence was computed over 90-day periods, the all measure consistently
revealed the lowest hazards regardless of adherence being computed cumulatively over 30-day
periods or 90-day periods. Interestingly, the hazard ratios in multivariable models were slightly
higher than those in the corresponding univariable models for all dichotomous measures. As age
and comorbidity are strong and consistent predictors of health outcomes, the effect of adherence
is less pronounced in the multivariable models.
When analysis was performed on any diabetes related ER events, a clear trend emerged.
Similar to the results from all-cause analysis, hazard estimates on any diabetes-related ER visits
were significant (p<0.05) but nearly one for all continuous composite PDC measured over 30day periods or 90-day periods or cumulatively. In cases of dichotomous composite measures, the
at least one measure consistently demonstrated the lowest estimates regardless of period specific
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or cumulative PDC or the length of PDC measurement period used; hazards estimates were
slightly wide apart and 90-day based measures yielded lower hazards whereas 30-day based
cumulative measures showed lower hazards. Thus, the results appear to suggest that 30-day
based measures show enough power if considered cumulatively whereas 90-day based measures
is strong enough to predict an event in a period when patients are nonadherent. Compared to allcause hazard ratios as estimated by composite PDC measures, all of the respective diabetesrelated hazard estimates were much lower. This is intuitive in that diabetes medication
adherence should be a better predictor of diabetes-related ER events than it would be for allcause ER events. In sum, consistent with other studies (Balkrishnan et al., 2003; Sokol et al.,
2005), nonadherence measured by any composite measure was a consistent predictor of adverse
healthcare events regardless of adherence measurement approach or period. However,
significant relationships do not state anything about a model’s overall prognostic or explanatory
power.

Comparison of the Adherence Measures: Discriminatory Power
One attribute of a good measure is its ability to discriminate well between groups that are
different on outcome potential. In other words, a measure should have the ability of classifying
subjects into appropriate groups to which they actually belong. A concordance statistic was
computed for each adherence measurement approach to determine how well each method
classifies subjects into groups of those having events and those having none. All the approaches
resulted in statistically significant concordance statistics. With regard to all-cause analyses, the
average based approach consistently demonstrated highest concordance statistics regardless of
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30-day or 90-day measurement periods or cumulative period measurement. Among categorical
composite measures ‘all’ (especially, when measured cumulatively) or ‘both’ showed slightly
higher values than did ‘at least one’. When diabetes-related outcomes were analyzed, no clear
trends emerged; the average and at least one approaches appeared to perform better than others.
Regardless of outcome selected, the multivariable models resulted in improved concordance
statistics compared to their respective univariable model-based values. Although some
performance-related trends were observed, concordance statistics generated by the different
measurement methods were not statistically different from one another as reflected by their
overlapping confidence intervals. In addition, the value of concordance statistics were slightly
greater than 0.5 implying poor discriminatory power. However, comparable values of
discriminatory index (i.e., c-statistics) were observed in a previous study of comparison of
measures of adherence to a single medication or medications for a disease (Karve et al., 2009).

Examination of Optimal Cut-points of Measures of Multiple Medication Adherence
Apart from the average approach, the two other continuous composite approaches
evaluated were the maximum and minimum algorithms. These two showed comparable
estimates of concordance statistics while the average-based estimates were slightly better than
those estimated by the minimum and maximum approach. Cut point analysis was performed on
these continuous composite PDC measures. Five cut points were chosen for dichotomization:
65, 70, 75, 80, and 85. The dichotomization point that resulted in an adjusted significant
maximization of likelihood statistics was examined. Analysis on all-cause ER revealed that if
the average measure is dichotomized at 85% with PDC being measured at each period or
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cumulatively over 90 days, the likelihood statistics maximized. For the more restrictive
minimum approach, such results were observed at 75% or 80%, while it is interesting to note that
the more liberal minimum approach indicated maximization at 75%. More clear trends emerged
when PDC was measured over 30 days such that almost all maximization occurred at 85%.
When the analyses were repeated on diabetes-related outcomes with measurement period being
at 90 days or cumulative 90 days, maximization occurred at 80% for average, 75% for minimum,
and 80% or 75% for maximum. When the measurement period was cumulative 30 days, above
results were replicated. However, when the measurement was done at every 30 days, higher
value (85%) of optimal adherence was observed. Thus, based on the study findings it can be
suggested that, in general, the 80% cut-point paradigm holds in the context of multiple
medication adherence; however, providers should encourage their patients to bring their
adherence level slightly higher for more effective disease management and for avoiding
unnecessary health events.
Several points deserve attention in light of the above discussion. In a true sense, it may
not be appropriate to describe some phenomena as maximization if it had occurred at 85% as no
higher values were examined. That said, as the other maximum points also lie below 85% and
conventional wisdom advocating 80%, it can be suggested that increment in benefit of improving
adherence will be declining sharply above 85% or maximum occurs at 85% even if higher values
are examined. It was apparent that from a measurement standpoint, the optimality of cut point
was related to what methods were used to measure multiple medication adherence. This makes
sense because some measurements are more restrictive than others in their rationale on disease
management and control process. Another interesting observation can be made from the results
such that when diabetes medication adherence is used for its ability to predict global events the
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bar that indicates that adverse events are unlikely should be raised. Similarly, if there is an
imminent chance of event, higher standard of medication consumption behavior may be required
considering that the maximization values were 85% in most 30-day period analyses. Finally, the
maximization analysis provided a valuable insight. The at least one, all, and both approaches
were operationalized with a cut point at 80%, which may not always be appropriate as
maximization did not occur at that level for most cases. Those measurement algorithms may still
be useful, but the issue of cut point may need to be revisited to generate more clear insight.

Limitations
The study has several limitations, which should be considered while the results of the
study are interpreted. The study was conducted in a population that is enrolled in employer
provided insurance programs. This population has several attributes that might have affected
study results. For example, this population consists of relatively younger adults and, on average,
is 10 years younger than the Medicare population. Age is a well-known risk factor for disease
outcomes. Indeed, in this study, age has been found to be a significant predictor in all analyses.
The results of this study (i.e., associations of evolutions or cut-point estimates) may or may not
hold in other populations that differ with respect to age. Similarly, this population may be
different from general population with regard to other socio-economic variables (e.g., income,
life style, dietary habits, etc.) that may play a role in disease progression, health outcomes, and
health behavior including medication adherence.
Chronic disease management, by definition, is a long term process. In this study, the
mean observation time was little over one and a half years. Although not short, the observation
period may not reflect long-term patient behavior or capture health outcomes that are likely to
140

occur as a result of poor medication adherence for a longer period of time. In fact, some patients
were available for observation for less than a year for survival analysis or just a little over a year
for the analysis of multiple medication adherence association. The results may not be
appropriate when the goal is to study or predict long term behavior or events.
This study primarily focused on diabetes patients who were on two medications. If
adherence behavior is rooted in specific medications then the study results may not be
generalizable to other medications. For many patients, different medication formulations are
currently prescribed concurrently for the treatment of diabetes. As both of the study medications
were tablets, findings based on tablet formulation may not be applicable to other formulation
types or a combination of different formulation types. Similarly, it may not be generalizable to
situations where primary disease state is not diabetes. Existing evidence (Cramer et al., 2008)
suggests that adherence rates may be different in difference diseases and failure to adhere to
prescribed regimen may result in adverse outcomes that might occur at different times dependent
on disease. If such underlying dynamics are at play, it would limit the findings of this study.
For analyzing the optimality of cut point for dichotomization of medication adherence,
patient comorbidity (i.e., CCI) was calculated based on only two quarters. While it was
consistent for all subjects, comorbidity may not have measured optimally by the method
followed in the study. For example, if a patient does not visit a physician in six months under
consideration for CCI calculation, CCI will be underestimated for the patient. Similarly, if a
patient does not have any in-patient hospitalizations during the period under consideration his
CCI score may likely to be underestimated compared to one having a hospitalization (e.g.,
increased options for reporting ICD-9 codes that may result in higher likelihood of reporting
multiple diagnoses compared to ones that may occur in an outpatient setting). It is not known
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what the impact would be on the study findings had CCI been measured over a year or longer.
As CCI has been consistently found as a significant predictor in all analyses related to
measurement issues, it is speculated that appropriate measurement of CCI would likely improve
concordance statistics.
This study was able to include only a relatively small number of subjects. The inclusion
and exclusion criteria that led to small sample size were based on the objective of deriving an
unbiased result. In general, studies that use claims data methodology include a larger number of
subjects compared to the number of subjects included in this study. However, precedence also
exists in which a small sample size was used including studies on medication adherence (e.g.,
Balkrishnan et al., 2003). That said, a relatively smaller sample size should be recognized as a
limitation, especially when it is known that millions of subjects in the US suffer from diabetes or
other chronic diseases.
The outcome events that were analyzed in this study deserve a note. Two types of events
were analyzed: all-cause ER visits and any diabetes-related ER visits. Other types of outcome
events that are analyzed in claim-based studies include in-patient hospitalization or primarycause events. Naturally, extending the results of measures being able to predict outcomes beyond
the ones used in the study or comparing measures in any contexts of outcomes beyond these ones
are limited. In addition, patients were not followed once they had an event. Thus, results cannot
be extended to situations in which the goal is to identify patients susceptible to readmission or
repeated adverse events.
The methodology adopted to estimate adherence could limit the results of the study.
Many patients included in the study had an incomplete period of observation. Such patients (i.e.,
those having less than 30 days for 30-day periods or less than 90 days for 90-day quarters) were
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not included while calculating period-specific adherence rates for multi-level model or survival
analyses. Thus, adherence estimates or association between adherence estimates could have
been different had these people been included. This problem may be further aggravated for
inter-disease multiple medication adherence estimates as the number of observation periods
further declined. Furthermore, if there was any significant nonlinearity in patient adherence
behavior, associations of evolutions estimated in this study will not represent true estimates. As
many of the subjects were not included in later time-periods, number of subjects continued to
decline in later periods that may have affected the results related to survival analysis in several
ways including reducing statistical power or introducing some biases.
Finally, the results should be interpreted with caution because of the statistical techniques
that were used in the study. Several approaches have been proposed in the statistical literature
for computing discriminatory index (i.e., concordance statistic) for a survival analysis model;
however, there is a limited guidance in the literature as to which approach performs better. In
addition, this question becomes further complicated for analyzing a time dependent variable and
in presence of a high rate of censoring. Similar issues exist for choosing a method for
determining an optimal cut point. As the method adopted in this study was based on an
unpublished scholastic work and failed to demonstrate a consistent and meaningful trend in some
analyses (e.g., for ‘at least one’), such limitations should be recognized while interpreting the
results.
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Future Research
This study opens up several opportunities for future investigation. First, although the
hypothesized multiple medication adherence relationships were founded upon the Common
Sense Model it was not possible to conclude about association of actual beliefs. Future research
should focus on the collection of information on actual beliefs about two or more different
medications and how these beliefs evolve over a period of time. Actual measures of theorybased adherence beliefs will help us further understand multiple medication adherence behavior.
Second, it is important to understand the multiple medication adherence construct. If beliefs
drive adherence behavior, it will be insightful to understand how beliefs are structured or nested.
For example, intra-disease multiple medication adherence may be driven by beliefs in individual
medications or it may be subsumed under disease beliefs. From the results of the study it can be
speculated that there may be a higher order construct in which part of individual medication
beliefs are nested as reflected by high correlation. In other words, disease beliefs may influence
individual medication beliefs and adherence. If so, how distinct are individual medications
beliefs from disease beliefs? Are there any contextual effects where one might be more
important than the other? Are there different antecedents to each of these belief types? Third, as
the current literature on medication adherence provides no conceptualization of multiple
medication adherence, understanding of the theoretical structure of multiple medication
adherence begs further attention. In the future, studies should be undertaken to understand
whether or not multiple medication adherence is a complex construct and is distinct from single
therapy adherence. In particular, its complexity increases further for inter-disease multiple
medication adherence. Presently, it leaves us with no understanding of what roles are played by
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disease beliefs and individual medication beliefs within the context of inter-disease multiple
medication adherence.
Medication adherence is a complex behavior. A multitude of factors are thought to affect
medication adherence. Previous studies of medication adherence have found that disease state
(Briesacher et al., 2008), severity (DiMatteo, Haskard, and Williams, 2007), cormorbid
conditions (Rozenfeld et al., 2008; Wogen et al., 2003), cost (Briesacher, Gurwitz, and
Soumerai, 2005), and medication burden (Benner et al., 2009; Ren et al., 2002) affect medication
adherence (i.e., adherence to a single medication). While comorbidity was controlled for when
analyzing measurement issues, it was not included in the analyses related to intra- and interdisease multiple medication adherence. Additional analysis (Appendix), consistent with past
work (Ho et al., 2006b), shows that patients behave differently after an adverse event that affects
disease state. Fourth, in the future, the effects of variables found to have significant relationships
with adherence, including disease state, comorbidity, cost, and number of medications need to be
investigated in the context of multiple medication adherence.
Multiple prescriptions are likely to occur more naturally in elderly than others. Fifth, in
future studies of multiple medication adherence the Medicare population should be included.
Especially, in light of emphasis on outcome-based reimbursement by the Centers for Medicare
and Medicaid Services (CMS), as reflected by higher weight on medication adherence based
measures, multiple medication adherence in the Medicare population assumes increased
relevance.
Sixth, future studies should be designed such that a large number of patients can be
observed for a longer duration. A few past studies of adherence have followed patients over a
couple of years (e.g., Nichol et al. (2009) followed patients for 6 years), and found adherence
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rates generally declining, thus, it will be interesting to know how associations of evolutions
evolve over years. While increasing sample size and duration of observation will certainly
increase power and have the potential to provide better concordance statistic estimates and
stronger evidence of maximization (as opposed to trends that were observed for some cut-point
analyses in the study), yet empirical evidence is required before any conclusion can be made.
Seventh, it may be useful to validate the results in different disease states. Past research
on optimality of cut point for medication adherence has been replicated in different disease states
(e.g., Karve et al., 2009); however, disease state was not related to cut-point estimates. A similar
analysis related to multiple medication adherence will be useful for at least two reasons: 1) it
may make results more generalizable in terms of identifying the measure demonstrating
consistent and superior predictive and discriminatory power and 2) it will improve the strength of
evidence. In addition, it will be enlightening to know if any clarity of and differences in cutpoints emerge in such studies.
Finally, this study proposed a novel (weighted) composite measure of multiple
medication adherence. Although the measure was theoretically appealing, it was not possible to
test the measure empirically because of multicollinearity. Future studies should employ an
appropriate methodology (e.g., analysis on split sample, matched sample analysis with one
medication) such that the weighted composite measure can be compared against other
measurement approaches discussed in this dissertation.
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Contribution
This dissertation makes several contributions to the literature and enriches the existing
knowledge base. First, this study generates baseline information on multiple medication
adherence. Unlike prior studies that either looked at a single medication or did not differentiate
medications for a disease, this research provides temporal adherence (population) estimates for
individual medications when patients are advised two medications simultaneously for a disease.
Similarly, it provides temporal adherence estimates for patients who are on multiple medications
for different chronic disorders. Although adherence estimates are high for some medications,
they are not at an acceptable level of appropriate adherence target and may be utilized for
intervention decisions.
Second, recently efforts have been made to understand medication adherence for two
distinct diseases (e.g., Chapman et al., 2005). This study is the first to extend the work by
focusing on diseases that have different types of relationships. This work identifies the fact that
many patients may be suffering from two or more chronic concordant symptomatic and
asymptomatic diseases and attempts to estimate adherence rates for the subgroup of patients who
are on multiple medications for different chronic diseases.
Third, this study extends the generalizability of past work that focused on other
population (e.g., Nichol et al., 2009) examined multiple medication adherence for two diseases in
the Medicaid population. Although the commercially-insured older adult population may be
perceived to be adherent because of higher ability to afford costs or better access to healthcare,
empirical evidence shows they may not reflect an ideal behavior.
Fourth, multiple medication adherence has strong futuristic implications given the way
the science of drug development and medical treatment are evolving. This is the first study that
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draws an explicit attention to intra-disease multiple medication adherence. Indeed, it strives to
differentiate multiple medication adherence into distinct phenomena: intra-disease multiple
medication adherence and inter-disease multiple medication adherence by comparing and
contrasting these two types of adherence behaviors.
Fifth, measurement of adherence is the first step before any intervention decisions can be
made. This research highlights how the selection of a measurement paradigm can result in
inconsistency in classification of a patient’s adherence status; it provides an estimation of
inconsistency in patient classification that occurred based on the different measurement
paradigms chosen. It is noted that the issue of inconsistency may become more important when
the population average PDC estimates are not as high as was observed in this study.
Finally, the academic community has always wrestled over the issue of choosing an
appropriate adherence measure. Past work has compared and contrasted different measurement
approaches for measuring adherence (e.g., Hess et al., 2006). This work complements the
previous work by generating evidence regarding the selection of an appropriate measure of intradisease multiple medication adherence and toward formalizing an operational definition of
multiple medication adherence. A categorical measure of adherence is very frequently employed
by researchers. To serve the need in the context of multiple medication adherence, this work
attempted to derive an optimal cut-point that was not based on the concept of adherence to a
single medication.
This study has two primary methodological contributions to the field. First, many
individual-level factors (e.g., attitude, intentions, self-efficacy) may not be temporally stable and
time-dependent values of these factors may affect outcomes. Medication adherence is
potentially one of such variables because of the possibility that changes in factors that may affect
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adherence. These factors may be manifested as within-patient random variables. This research
utilized the multilevel modeling technique to explicitly model intra-patient variation or random
effects modeling. There are other approaches that can be utilized for multiple medication
adherence. For example, latent growth curve modeling is a powerful and flexible technique to
analyze the interrelationships among multiple dependent variables such as nested longitudinal
adherence measures (Appendix). However, multilevel modeling offers advantages when there
are incomplete observations that may have little influence on mixed models (Gao et al., 2009;
Littell et al., 1996). In addition, it adopted the concept of association of evolutions from the
statistics literature to introduce in the adherence research.
Second, adherence has traditionally been treated as a non-time varying variable in the
literature. This research treated adherence as a time-dependent variable and thus, it emphasizes
examining not only events but also the proximity of event or time to event. Such a consideration
is more meaningful practically and similar to an operationalization followed in a recent
published study of relationship between adherence and health outcomes (Yu, Yu, and Nichol,
2010). This dissertation work has operationalized adherence in its true sense such that values
that change over time are captured adequately while examining the measurement of adherence
itself.

Implications
The importance of medication adherence cannot be overstated. Any work that improves
adherence or deepens the understanding of adherence holds strong implications. This study
focused on patient behavior under a specific treatment pattern (i.e., use of multiple medications
for better management). Within such a disease management context, it brings insight about how
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medication adherence behavior evolves for patients who are advised to consume multiple
prescriptions. As the practice is likely to grow in the future because of advancement in
knowledge and technology, findings of the study appear to have strong implications for future
disease management practice. Furthermore, these results will become more valuable because of
the declining age of onset of chronic disease and increasing life expectancy both of which affect
cost and management strategies.
Interventions are made to improve patient adherence. Many factors may affect the
effectiveness of intervention or adherence. Although much is not known about their potential
effect on multiple medication adherence, the study results suggest that there may be some higher
order constructs (e.g., disease belief or trait) that may drive the joint behavior. If interventions
are designed effectively around such factors, there may be a spillover effect of any success in
one disease into others with respect to medication consumption. Period-specific changes in
adherence demonstrated a stronger relationship in patient adherence behavior than overall mean
associations. Thus, it can be suggested that interventions focused on factors that may change
periodically may be more effective. Similarly, intervention decisions should be tailored to the
goal of achieving a desired outcome or preventing outcome of interest. This is implied by the
variability in cut-points in predicting health outcomes or predicting outcomes that may occur at
differential temporal points.
Measurement of adherence to multiple medications is an important issue. This study
brought to light several issues including the potential chance of misclassification and the utility
of existing measurement approaches. The study results may help toward formulating a
consistent operational definition of multiple medication adherence and serve to identify an
appropriate and effective measurement algorithm.
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Conclusion
Medication adherence is critical to managing a rising burden of chronic diseases. This
research investigated medication adherence that would occur in a particular segment of patients
due to the pressing need to manage the disease process more effectively or aggressively. Intradisease multiple medication adherence and inter-disease multiple medication adherence were
clearly discussed, distinguished, and defined and examined in the working older adult population
that might be increasingly inflicted given onset age decreasing and life span increasing.
Although this population demonstrated good adherence, the adherence rates cannot be termed
optimal by a much-accepted norm of 80% based on the single medication adherence. Applying
the concepts from the biostatistics literature, it was observed that there were significant
relationships in the growth pattern in intra-patient adherence behavior to multiple medications
intended to treat a single chronic disease or multiple chronic diseases that are related to one
another with regard to the patho-physiology of disease or disease management. Consistent with
existing knowledge (Steiner et al., 2009), this study found that demographic variables alone may
not explain adherence well as reflected in the fact that random effect correlations remained
strong after controlling for covariates. Additional analyses in a subset of patients (i.e.,
community patrons) supported the theoretical justifications and interpretation of results.
Compared to the association of overall means, a stronger relationship between period-specific
changes in adherence implies that factors that may change periodically may be stronger
determinants of long-term adherence to multiple medications.
This dissertation assembled different approaches from the literature that can be applied to
measure intra-disease multiple medication adherence and compared and contrasted the
measurement approaches in the context. This is consistent with past scholastic work on the issue
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of choosing an appropriate adherence measure. In spite of statistical power issues and
methodological constraints, the study found that all measurement approaches significantly
predicted outcomes and discriminated subjects. However, there were no clear trends in
superiority in predictive and discriminatory power of one approach over others. That said, the
average (continuous) and all (dichotomous) approaches appear to have edge over others due to
some empirical support observed in the study or merely for the ease of measurement. The
efficacy of a measure may also be tied to outcome of interest as differences in predictive or
discriminatory power or the optimality of cut points were observed depending on outcome event
(i.e., diabetes vs. all-cause ER) analyzed. Diabetes outcomes may have theoretical justification
because of diabetes medication adherence being measured and more proximity to underlying
causes leading to adverse events; however, it may also suffer from the lack of measurement
validity because of the way a physician chooses ICD-9 codes or due to limited options of coding
in the outpatient setting. In addition, other issues of substantive interest include whether or not
the objective is to prevent any undue adverse events or design interventions to prevent any
versus diabetes-specific events. Study findings should be interpreted and utilized with these
issues in mind.
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Table D: List of Medications Used in the Study
Disease
Diabetes

Medication Class
Sulfonylurea (SU)

Thiazolidinediones (TZD)
Hypertension Angiotensin Receptor Blockers
(ARB)
Angiotensin-Converting Enzyme
(ACE) inhibitors

Calcium Channel Blockers(CCB)

β-blockers

Diuretics

Dislipidemia

Statins

Angina

Fibrates
Nitrates (oral)

Medication (Brand)
Acetohexamide, chlorpropamide,
glimepiride, glipizide, glyburide,
tolazamide, tolbutamide
Pioglitazone, rosiglitazone
Candesartan, eprosartan,
irbesartan, losartan, olmesartan,
telmisartan, valsartan
Benazepril, captopril, enalapril,
fosinopril, lisinopril, moexipril,
perindopril, quinapril, ramipril,
trandolapril
Amlodipine, diltiazem, felodipine,
isradipine, nicardipine, nifedipine ,
nisoldipine, verapamil
Acebutolol, atenolol, betaxolol,
bisoprolol, carvedilol, labetolol,
metoprolol, nadolol, pindolol,
propranolol, sotalol
Hydroclorothiazide, chlorthiazide,
indapamide, methyclothiazide,
metolazone, bumetanide,
ethacrinic acid, furosemide,
torsemide, amiloride,
spironolactone, triamterene
Atorvastatin, fluvastatin,
lovastatin, pravastatin, simvastatin,
rosuvastatin
Gemfibrozil, fenofibrate
Isosorbide dinitrate, isosorbide-5mononitrate, nitroglycerin

Adapted from Parker and Parker, 1998; Wang, 2006
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Table A1: PDC Estimates by Different Dichotomous Measures
Approach Qtr

At least
one

Both

All

1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8

N
6043
6043
6043
6043
6043
6043
4979
3752
6043
6043
6043
6043
6043
6043
4979
3752
6043
6043
6043
6043
6043
6043
4979
3752

Quarter –specific
Nonadh
Adh
716 (11.85) 5327 (88.15)
1199 (19.84) 4844 (80.16)
1293 (21.4)
4750 (78.6)
1356 (22.44) 4687 (77.56)
1465 (24.24) 4578 (75.76)
1543 (25.53) 4500 (74.47)
1233 (24.76) 3746 (75.24)
826 (22.01)
2926 (77.99)
2346 (38.82) 3697 (61.18)
2977 (49.26) 3066 (50.74)
3108 (51.43) 2935 (48.57)
3125 (51.71) 2918 (48.29)
3200 (52.95) 2843 (47.05)
3240 (53.62) 2803 (46.38)
2599 (52.2)
2380 (47.8)
1837 (48.96) 1915 (51.04)
2241 (37.08) 3802 (62.92)
2868 (47.46) 3175 (52.54)
3004 (49.71) 3039 (50.29)
3029 (50.12) 3014 (49.88)
3112 (51.5)
2931 (48.5)
3161 (52.31) 2882 (47.69)
2549 (51.2)
2430 (48.8)
1805 (48.11) 1947 (51.89)

Cumulative
Nonadh
Adh
716 (11.85)
5327 (88.15)
967 (16)
5076 (84)
1156 (19.13) 4887 (80.87)
1209 (20.01) 4834 (79.99)
1275 (21.1)
4768 (78.9)
1393 (23.05) 4650 (76.95)
1091 (21.91) 3888 (78.09)
777 (20.71)
2975 (79.29)
2346 (38.82) 3697 (61.18)
2868 (47.46) 3175 (42.54)
3132 (51.83) 2911 (48.17)
3253 (53.83) 2790 (46.17)
3345 (55.35) 2698 (44.65)
3423 (56.64) 2620 (43.36)
2766 (55.55) 2213 (44.45)
1999 (53.28) 1753 (46.72)
2241 (37.08) 3802 (62.92)
2681 (44.37) 3362 (55.63)
2952 (48.85) 3091 (51.15)
3037 (50.26) 3006 (49.74)
3085 (51.05) 2958 (48.95)
3201 (52.97) 2842 (47.03)
2579 (51.8)
2400 (48.2)
1847 (49.23) 1905 (50.77)

Qtr: Quarter; Nonadh: Nonadherent; Adh: Adherent (based on the 80% rule)
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Table A2: Intra-disease Multiple Medication Adherence: Fixed Effects for
Unconditional Growth Models
Effect

Med

Estimate

Standard Error

DF

med
med

SU

80.3023

0.3425

5988

234.46 <0.0001

TZ

81.6592

0.3389

5976

240.98 <0.0001

-2.8469

0.0853

5537

-33.36 <0.0001
6.45 <0.0001

qtr_cont
qtr_cont*med

SU

0.5825

0.0903

5310

qtr_cont*med

TZ

0

.

.

t Value

Pr > |t|

.

.

Table A3: Intra-disease Multiple Medication Adherence: Fixed Effects for Conditional
Growth Models
Effect

med

Estimate

Standard Error

DF

t Value

Pr > |t|

med

SU

80.2982

0.3391

5985

236.78

<0.0001

med

TZ

81.6541

0.3351

5972

243.64

<0.0001

qtr_cont

-2.8435

0.0853

5537

-33.32

<0.0001

age_mc

0.6348

0.0495

6029

12.82

<0.0001

qtr_cont*med

SU

0.5818

0.0903

5310

6.44

<0.0001

qtr_cont*med

TZ

0

.

.

.

.

age_mc*med

SU

-0.0199

0.0511

6036

-0.39

0.6975

age_mc*med

TZ

0

.

.

.
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Table A4: Intra-disease Multiple Medication Adherence: Fixed Effects for Conditional
Growth Models
Gender
of Patient

Effect

med

med

SU

79.0280

0.5036 6236

156.92 <.0001

med

TZ

79.5628

0.5034 6092

158.04 <.0001

-2.8463

0.08534 5537

-33.35 <.0001

0.6713 6019

5.62 <.0001

qtr_cont

Estimate

SEX

1

3.7732

SEX

2

0

Standard Error

.

qtr_cont*med

SU

0.5824

qtr_cont*med

TZ

0

med*SEX

SU

1

-1.4798

med*SEX

SU

2

0

.

med*SEX

TZ

1

0

med*SEX

TZ

2

0
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DF t Value Pr > |t|

.

0.09031 5310
.

.

.

6.45 <.0001

.

.

.

0.6861 6035

-2.16

0.0310

.

.

.

.

.

.

.

.

.

.

.

Table A5: Intra-disease Multiple Medication Adherence: Fixed Effects for Conditional
Growth Models
Effect

med

Gender
of Patient

Estimate Standard Error

DF

t Value

Pr > |t|

med

SU

79.1823

0.4982

6251

158.93

<0.0001

med

TZ

79.7204

0.4977

6104

160.18

<0.0001

qtr_cont

-2.8430

0.0853

5537

-33.31

<0.0001

age_mc

0.6257

0.0494

6028

12.66

<0.0001

SEX

1

3.4805

0.6633

6020

5.25

<0.0001

SEX

2

0

.

.

.

.

qtr_cont*med SU

0.5817

0.0903

5310

6.44

<0.0001

qtr_cont*med TZ

0

.

.

.

.

age_mc*med SU

-0.0160

0.0512

6035

-0.31

0.7541

age_mc*med TZ

0

.

.

.

.

med*SEX

SU

1

-1.4721

0.6866

6034

-2.14

0.0321

med*SEX

SU

2

0

.

.

.

.

med*SEX

TZ

1

0

.

.

.

.

med*SEX

TZ

2

0

.

.

.
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Table A6: Inter-disease Multiple Medication Adherence: Fixed Effects for Conditional
Growth Models
Effect

med

med

Gender

Estimate

Std Error

DF

t Value

Pr > |t|

LP

77.3629

0.8466

2389

91.39 <0.0001

med

SU

81.1535

0.8028

2438

101.09 <0.0001

med

TZ

81.6540

0.7947

2392

102.75 <0.0001

qtr_cont

-2.6842

0.1411

2124

-19.03 <0.0001

age_mc

0.5144

0.0840

2347

6.12 <0.0001

SEX

1

3.5604

1.0270

2345

3.47

0.0005

SEX

2

0

.

.

.

.

qtr_cont*med LP

-0.1847

0.1469

1923

-1.26

0.2087

qtr_cont*med SU

0.5191

0.1478

2056

3.51

0.0005

qtr_cont*med TZ

0

.

.

.

.

age_mc*med

LP

0.1696

0.0871

2353

1.95

0.0516

age_mc*med

SU

0.09593

0.0896

2354

1.07

0.2842

age_mc*med

TZ

0

.

.

.

.

med*SEX

LP

1

0.5763

1.0653

2353

0.54

0.5886

med*SEX

LP

2

0

.

.

.

.

med*SEX

SU

1

-1.8462

1.0951

2354

-1.69

0.0919

med*SEX

SU

2

0

.

.

.

.

med*SEX

TZ

1

0

.

.

.

.

med*SEX

TZ

2

0

.

.

.
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Table A7: Inter-disease Multiple Medication Adherence: Fixed Effects for Conditional
Growth Models
Effect

med

Gender

Estimate Standard Error

DF

t Value

Pr > |t|

med

AH

82.6801

0.7647

2243

108.13

<0.0001

med

SU

80.2791

0.7904

2300

101.57

<0.0001

med

TZ

80.4139

0.8061

2222

99.75

<0.0001

qtr_cont

-2.7314

0.1385

1985

-19.72

<0.0001

age_mc

0.5930

0.0858

2205

6.91

<0.0001

SEX

1

3.0248

1.0988

2200

2.75

0.0060

SEX

2

0

.

.

.

.

qtr_cont*med

AH

0.7580

0.1383

1878

5.48

<0.0001

qtr_cont*med

SU

0.3826

0.1485

1951

2.58

0.0100

qtr_cont*med

TZ

0

.

.

.

.

age_mc*med

AH

-0.0653

0.0830

2207

-0.79

0.4312

age_mc*med

SU

0.00234

0.0898

2208

0.03

0.9792

age_mc*med

TZ

0

.

.

.

.

med*SEX

AH

1

-2.3466

1.0629

2205

-2.21

0.0274

med*SEX

AH

2

0

.

.

.

.

med*SEX

SU

1

-1.4841

1.1504

2206

-1.29

0.1971

med*SEX

SU

2

0

.

.

.

.

med*SEX

TZ

1

0

.

.

.

.

med*SEX

TZ

2

0

.

.

.
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Table A8: Inter-disease Multiple Medication Adherence: Fixed Effects for Conditional
Growth Models
Effect

med

med

AH

med

Gender

Estimate Standard Error

DF

t Value

Pr > |t|

76.7130

1.4053 847

54.59

<0.0001

LP

85.1435

1.2428 850

68.51

<0.0001

med

SU

82.3388

1.3236 852

62.21

<0.0001

med

TZ

82.3879

1.2834 840

64.20

<0.0001

qtr_cont

-2.3323

0.2326 741

-10.03

<0.0001

age_mc

0.5198

0.1384 823

3.75

0.0002

1.7063 822

1.49

0.1354

.

.

.

SEX

1

2.5503

SEX

2

0

.

qtr_cont*med

AH

-0.3392

0.2315 619

-1.47

0.1434

qtr_cont*med

LP

0.7163

0.2276 686

3.15

0.0017

qtr_cont*med

SU

0.0291

0.2334 705

0.12

0.9009

qtr_cont*med

TZ

0

.

.

.

age_mc*med

AH

0.0232

0.1469 824

0.16

0.8745

age_mc*med

LP

-0.0261

0.1347 825

-0.19

0.8463

age_mc*med

SU

0.0501

0.1515 825

0.33

0.7411

age_mc*med

TZ

0

.

.

.

med*SEX

AH

1

2.9325

1.8106 824

1.62

0.1057

med*SEX

AH

2

0

.

.

.

med*SEX

LP

1

-3.5545

1.6601 825

-2.14

0.0326

med*SEX

LP

2

0

.

.

.

med*SEX

SU

1

-1.7493

1.8680 826

-0.94

0.3493

med*SEX

SU

2

0

.

.

.

.

med*SEX

TZ

1

0

.

.

.

.

med*SEX

TZ

2

0

.

.

.

.

184

.

.
.
.

Table A9: Inter-disease Multiple Medication Adherence: Fixed Effects for Conditional
Growth Models
Effect

med

Gender

Estimate

med

AG

36.4003

3.5094 305

10.37 <0.0001

med

SU

74.9576

2.7807 311

26.96 <0.0001

med

TZ

73.8889

2.9722 306

24.86 <0.0001

qtr_cont

-2.3166

0.4521 258

-5.12 <0.0001

age_mc

0.1489

0.3842 297

0.39

0.6987

3.7399 297

1.27

0.2039

.

.

.

SEX

1

4.7621

SEX

2

0

Standard DF
t
Error
Value

.

Pr > |t|

qtr_cont*med

AG

-0.1099

0.5178 243

-0.21

0.8321

qtr_cont*med

SU

0.4843

0.4927 256

0.98

0.3265

qtr_cont*med

TZ

0

.

.

.

age_mc*med

AG

0.4364

0.5464 297

0.80

0.4251

age_mc*med

SU

0.1908

0.4262 297

0.45

0.6547

age_mc*med

TZ

0

.

.

.

med*SEX

AG

1

-10.5834

5.3200 297

-1.99

0.0476

med*SEX

AG

2

0

.

.

.

med*SEX

SU

1

1.5000

4.1498 297

0.36

0.7180

med*SEX

SU

2

0

.

.

.

.

med*SEX

TZ

1

0

.

.

.

.

med*SEX

TZ

2

0

.

.

.

.
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Table A10: Additional Analysis on Groups of Subjects or Specific Quarters
Model

Patrons

Conditional means model:
random intercepts
Conditional growth model: ae
(SU and TZ)
Conditional means model:
random intercepts
Conditional growth model: ae
(SU and TZ)

First five5 Q

Five Q from 2nd
onward
0.5383

All

0.5466

All

0.6581

0.6347

Community

0.5520

0.5491

Community

0.5949

0.5842

Conditional: covariates sex and age included in the model; Q: quarter; ae: association of
evolutions; SU: Sulfonylurea; TZD: thiazolidinediones

Table A11: Survival Analysis (Analysis of Maximum Likelihood Estimates)
Parameter

DF

Parameter
Estimate

Standard
Error

Chi-Square

Pr > ChiSq

Hazard
Ratio

1

-0.01009

0.00813

1.5419

0.2143

0.990

1

-0.02412

0.11178

0.0466

0.8292

0.976

cci

1

0.19789

0.09127

4.7008

0.0301

1.219

pdcs

1

0.0008417

0.00174

0.2344

0.6283

1.001

pdct

1

-0.00648

0.00159

16.5827

<.0001

0.994

AGE
SEX

1

Difference in PDC test statistic: 6.5447 (p=0.0105); Outcome variable: Diabetes ER; pdcs:
PDC for sulfonylurea; pdct: PDC for thiazolidinediones
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Table A12: Survival Analysis (Analysis of Maximum Likelihood Estimates)
Parameter

DF

Parameter
Estimate

Standard
Error

Chi-Square

Pr > ChiSq

Hazard
Ratio

1

-0.01016

0.00815

1.5511

0.2130

0.990

1

-0.02674

0.11183

0.0572

0.8110

0.974

cci

1

0.20215

0.09158

4.8722

0.0273

1.224

pdcs_c

1

0.0005078

0.00232

0.0478

0.8269

1.001

pdct_c

1

-0.00710

0.00215

10.9314

0.0009

0.993

AGE
SEX

1

Difference in cumulative PDC test statistic: 3.8774 (p=0.0489); Outcome variable: Diabetes
ER pdcs_c: cumulative PDC for sulfonylurea; pdct_c: cumulative PDC for thiazolidinediones
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Table A13: Survival Analysis Hazard Estimates
Measurement
Parameter
Model Approach
Period
estimate
All
-0.3257
Atlst1
-0.4188
Avg
-0.0053
Uni
Both
-0.3318
Max
-0.0045
Min
-0.004
30 days
All
-0.2851
Atlst1
-0.3688
Avg
-0.0046
Mul
Both
-0.2911
Max
-0.0038
Min
-0.0035
All
-0.3969
Atlst1
-0.6151
Avg
-0.0066
Uni
Both
-0.387
Max
-0.0058
Min
-0.005
90 days
All
-0.3588
Atlst1
-0.5796
Avg
-0.0059
Mul
Both
-0.3487
Max
-0.0051
Min
-0.0045

Std. Err

P

0.10831
0.12117
0.00149
0.10845
0.0015
0.00122
0.10979
0.12367
0.00153
0.10993
0.00153
0.00124
0.11286
0.1168
0.00165
0.11342
0.00166
0.00136
0.11458
0.1195
0.00169
0.11511
0.00171
0.00138

0.0026
0.0008
0.0005
0.0022
0.004
0.0011
0.0094
0.0029
0.0024
0.0081
0.0125
0.0043
0.0004
<0.0001
0.0001
0.0006
0.0009
0.0002
0.0017
<0.0001
0.0005
0.0025
0.0027
0.0011

Hazard
Ratio
0.722
0.658
0.995
0.718
0.996
0.996
0.752
0.692
0.995
0.747
0.996
0.996
0.672
0.541
0.993
0.679
0.994
0.995
0.699
0.56
0.994
0.706
0.995
0.995

Outcome: any diabetes related ER; Uni: univariable; Mul: Multivariable; PDC measured
for each period
Atlst1: At least one approach; Avg: Average approach; Max: Maximum approach; Min:
Minimum approach
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Table A14: Survival Analysis Hazard Estimates
Measurement
Parameter
Model Approach
Period
estimate
All
-0.4485
Atlst1
-0.5847
Avg
-0.0053
Uni
Both
-0.4632
Max
-0.0077
Min
-0.0064
30 days
All
-0.4081
Atlst1
-0.5386
Avg
-0.0046
Mul
Both
-0.423
Max
-0.0066
Min
-0.0057
All
-0.3993
Atlst1
-0.4999
Avg
-0.0066
Uni
Both
-0.4214
Max
-0.0074
Min
-0.0058
90 days
All
-0.3601
Atlst1
-0.4547
Avg
-0.0059
Mul
Both
-0.3828
Max
-0.0064
Min
-0.005

Std. Err

P

0.11012
0.11832
0.00149
0.11217
0.00229
0.00167
0.11191
0.12158
0.00153
0.11391
0.00238
0.00171
0.11268
0.12328
0.00165
0.11471
0.00234
0.00172
0.11456
0.12659
0.00169
0.11654
0.00243
0.00176

<.0001
<.0001
0.0005
<.0001
0.0015
0.0002
0.0003
<.0001
0.0024
0.0002
0.0056
0.001
0.0004
<.0001
0.0001
0.0002
0.0026
0.001
0.0017
0.0003
0.0005
0.001
0.0083
0.0042

Hazard
Ratio
0.639
0.557
0.995
0.629
0.992
0.994
0.665
0.584
0.995
0.655
0.993
0.994
0.671
0.607
0.993
0.656
0.993
0.994
0.698
0.635
0.994
0.682
0.994
0.995

Outcome: any diabetes related ER; Uni: univariable; Mul: Multivariable; PDC measured
cumulatively up to a period
Atlst1: At least one approach; Avg: Average approach; Max: Maximum approach; Min:
Minimum approach
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Table A15: Concordance Analysis on Optimal Cut-off
Measurement

Cumulative 90
day

Model

Approach

C-stat/ PL80

Maximization

Concordance

Multivar

At least one/
max 80

0.5672/12.094

75%

no

Both/min 80

0.5683/11.048

75%

no

At least
one/max 80

0.5457/22.031

80%

yes

Both/min 80

0.5489/9.3371

75%

no

At least one/
max 80

0.582/15.2100

80%

yes

75%

no

80%

yes

75%

no

Univar

Multivar

Both/min 80
90 day
Univar

At least one/
max 80
Both/min 80

Multivar
Cumulative 30
day
Univar

Multivar
30 day
Univar

0.5679/13.879
0
0.5614/25.721
0
0.5475/11.887
0

At least one
/max 80

0.5728/18.242

80%

yes

Both/min 80

0.571/14.18

75%

no

At least one/
max 80

0.5531/22.376

80%

yes

Both/min 80

0.5529/17.619

75%

no

At least one/
max 80

0.5664/8.4171

80%

yes

Both/min 80

0.5639/7.0427

85%

no

At least one/
max 80

0.5385/11.136

85%

no

Both/min 80

0.541/9.4027

85%

no

Outcome variable: Any diabetes ER; C-stat: Concordance statistics (CT from Kremers);
PL80: partial likelihood statistic of PDC dichotomized at 80%; Multivar: multivariable
model; Univar: univariable model; Max 80: dichotomization of maximum approach at 80%;
Min 80: dichotomization of minimum approach at 80%
* statistic not significant at p=0.0033
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Table A16: Comparison Pre-ER and Post-ER Adherence
Variable
pdcs_e1
pdcs_e2
pdcs_e3
pdcs_e4
pdcs_e5
pdcs_e6
pdct_e1
pdct_e2
pdct_e3
pdct_e4
pdct_e5
pdct_e6
pdcs_b
pdcs_a
pdct_b
pdct_a

N*
525
801
801
801
801
546
525
801
801
801
801
546
801
801
801
801

Mean
76.08
74.27
73.09
71.80
68.66
69.75
78.37
75.84
71.39
70.01
67.13
66.28
76.68
68.40
77.39
65.77

Std Dev
30.56
32.26
34.35
34.25
36.49
36.47
30.79
32.61
35.96
36.68
38.95
39.45
26.48
33.75
26.98
35.71

Minimum
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Maximum
100
100
100
100
100
100
100
100
100
100
100
100
100
99.81
100
99.81

Pdcs_ex: PDC for SU at quarter x; Pdct_ex: PDC for TZD at quarter x; Pre-ER and
post-ER quarters are 1 through 3 and 4 through 6, respectively;
Pdcx_b: Average PDC for SU/TZD estimated on all available days before ER
Pdcx_a: Average PDC for SU/TZD estimated on all available days after ER
*Subjects were available for observation for at least 180 days preceding and
following an all-cause ER event.

Table A17: Paired t-test Between Pre-ER and Post-ER Adherence
Medication
SU
TZD

N*
801
801

Mean**
-8.28
-11.6205

Std Dev
24.20
24.98

95% CI
-9.96, -6.60
-13.35, -9.89

t-statistic
-9.68
-13.1

p-value
<0.0001
<0.0001

**Difference between average pre-ER and post-ER PDC for SU/TZD estimated on all
available days before ER
*Subjects were available for observation for at least 180 days preceding and following
an all-cause ER event.
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Table A18: Latent Growth Curve Modeling Analysis of Multiple Medication
Adherence

Model

N*

Parameter

Correlation

P-value

Uncon. Grt 1

3772

Int-SU Int -TZD
Slp -SU/ Slp -TZD

0.6099
0.5975

<0.0001
<0.0001

Uncon. Grt.: unconditional growth model with mean centered age and gender as
covariates
Int: Intercept; Slp: Slope
SU: Sulfonylureas; TZD: Thiazolidinediones;
*Subjects were available for 7 quarters of observation and all 7 quarters were included
in the analysis.
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APPENDIX: ADDITIONAL FIGURES
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Figure A1: Quarter-wise Analysis on All-cause ER Visit
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Y-axis: Partial likelihood estimate; X-axis: PDC dichotomization points at 65%, 70%, 75%,
80%, and 85%
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Figure A2: Quarter-wise Analysis on Any Diabetes ER Visit
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Figure A3: Month-wise Analysis on All-cause ER Visit
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Figure A4: Month-wise Analysis on Any Diabetes ER Visit
24
22
20
18
16
14
12
10
8
6
4
PDC 65
Av_Ml_cumM
Mx_Ml_cumM
Mn_Ml_cumM

PDC-70

PDC-75

Av_Ml_M
Mx_Ml_M
Mn_Ml_M

PDC-80
Av_Un_cumM
Mx_Un_cumM
Mn_Un_cumM

Y-axis: Partial likelihood estimate; X-axis: PDC dichotomization points
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